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Bacterial vaginosis (BV) describes a dysbiotic state of the vaginal mucosa, during which 
the dominance by beneficial lactobacilli species is lost, the vaginal pH increases, and the flora 
comprising the vaginal microbiome becomes more diverse. Bacterial taxa associated with this 
dysbiotic state interact to form a dense polymicrobial biofilm on the surface of the vaginal 
epithelium. This shift in the vaginal microflora is clinically important, even when symptoms are 
not noted, as women with BV are at increased risk for acquisition of other sexually transmitted 
infections, including HIV, and are more than two times as likely to experience preterm birth. 
Moreover, BV has been associated with numerous other adverse outcomes, including pelvic 
inflammatory disease, recurring urinary tract infections, chorioamnionitis, postpartum 
endometritis, infertility, and adverse neonatal outcomes, even among full term infants. The 
prevalence of BV, in the United States alone, is approximately 30% for women of reproductive 
age, and is significantly increased in Hispanic and African American women. Standard 
metronidazole treatment carries a recurrence rate of 52% within 12 months of treatment and recent 
reports indicate that BV recurrence can, at least in part, be attributed to the inability to reestablish 
the beneficial lactobacilli population after antibiotic treatment. Thus, it is clear that more targeted 
approaches to BV treatment are needed. 
 
While the last few decades of research have given us a better understanding of the 
organisms that comprise the vaginal microbiome, there are still a lot of gaps in our understanding 
of what they are doing and how they are interacting with the host and each other, both in the context 
of health and disease. This is due to inadequacies of animal models and difficulty in culturing and 
genetically manipulating vaginally relevant microorganisms. The overarching aim of this 
 xvi 
dissertation research was to characterize the factors that contribute to the establishment and 
maintenance of vaginal dysbiosis, focusing on the role(s) of one organism, Gardnerella vaginalis.  
Various tools were developed to further characterize putative virulence determinants produced by 
Gardnerella to better understand how the bacterium interacts with the human host, with emphasis 
on the cholesterol-dependent toxin, vaginolysin (VLY), and an opacity phenotype presumptively 
driven by differential pilus production. Through the development of a human vaginal epithelial 
model of Gardnerella infection, in which Gardnerella spp. grow to in vivo densities, we uncovered 
a previously undescribed influence of tissue polarity on VLY activity. This influence was mediated 
by differential expression of the proposed VLY co-receptor, CD59. Further investigation of VLY 
in different Gardnerella strains revealed conserved amino acid differences within regions of the 
toxin known to interact with host cells, allowing for the characterization of distinct VLY types. 
Two predominant VLY types exhibited differential interaction with vaginal epithelial cells, 
putatively related to CD59 availability. Bioinformatic analyses showed that certain VLY types are 
restricted to select Gardnerella species and the dominant VLY type in vaginal samples has 
implications for overall Gardnerella abundance and symptom frequency during BV. We then 
characterized a colony opacity phenotype potentially susceptible to phase variation. Both opaque 
and translucent variants were detected in all tested Gardnerella isolates, representing six different 
species. Opaque variants exhibited increased bacterial aggregation in suspension as well as 
increased surface biofilm formation, to suggest that opacity may promote resistance to host 
defenses. Finally, we report the development of the first method for performing site-specific 
mutagenesis in Gardnerella spp. After optimization, this oligonucleotide-based protocol yielded 
transformants at an efficiency similar to that observed in other bacterial species. Using these 
optimized methods, we were able to transform 3 strains of Gardnerella representing 3 different 
 xvii 
species. While this represents a significant advance in the field, continued optimization is 
necessary to further improve transformation efficiency in order to increase the practicality of using 
this tool to generate non-selectable transformants. In sum, continuing to build upon the knowledge 
gleaned from this work will allow us to develop more targeted therapies for BV and ultimately 





































The healthy vaginal microbiome 
The human microbiome project has shown us that humans are intimately associated with 
and dependent upon microbes for survival. Different body sites are characterized by different host 
pathogen interactions that, when disrupted, can promote disease1–4. Within the niche of the vaginal 
mucosa, a complex interplay between commensal lactobacilli species and the stratified epithelium, 
immune cells, and secretions comprising this environment must be maintained to promote the 
overall health of each woman as well as her progeny5–7. These lactobacilli, through numerous 
functions, ultimately serve to create an environment that is exclusionary to invading organisms 
that threaten this eubiosis8.  
 
Specifically, lactobacilli directly compete with other organisms by adhering to the surface 
of the epithelium to prevent their binding9,10. Lactobacilli acidify vaginal secretions through the 
production of D- and L- lactic acid, which not only directly inhibit the growth of pathogenic 
organisms, but also promote and inhibit the production of anti- and pro-inflammatory cytokines, 
respectively11–14. In addition, by facilitating DNA repair through the inhibition of histone 
deacetylase activity, lactic acid also enhances the survival of vaginal epithelial cells to maintain 
barrier integrity15. Other inhibitory products secreted by vaginal lactobacilli include hydrogen 
peroxide and bacteriocins, which may also suppress the growth of urogenital pathogens16–20.   
Because of these important functions, and the abundance of these organisms in the vaginal 
microflora of clinically healthy women, a healthy human vaginal microbiome is typically 
described as one dominated by select lactobacilli species6,21,22. It is important to note, however, 
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that “health” is a relative term than can vary depending on ethnicity or age, among other factors23–
25.  
It is also worth mentioning that this lactobacilli dominance in the vagina is unique to 
humans. While lactobacilli typically comprise over 70% of the bacteria in the healthy human 
vagina, the microbiomes of other mammals are made up of less than 1% of lactobacilli26. This may 
be due to physiological differences among species. The human vaginal mucosa in reproductive 
aged women is described as a thick, multilayer squamous epithelium overlaying the lamina propria 
and coated in secretions produced via mucin-secreting cervical glands and the Bartholin’s glands 
in the vaginal wall, among other sources27–29. Keratinocyte cells originating from the basolateral 
side, mature, differentiate, and flatten over time, through a process called cornification. During 
this process, cells that were once actively replicating, become anucleated and devoid of organelles, 
and build large cytoplasmic stores of glycogen. Cornified vaginal epithelial cells in some animals 
are also keratinized; in humans they are not30. As these terminally differentiated apical epithelial 
cells slough off, the deeper layers become progressively closer to the lumenal face. These sloughed 
off cells are thought to contribute to the available pool of glycogen in vaginal secretions31. Alpha 
amylase, also abundant in human vaginal mucus, contributes to glycogen break down so that it can 
be further catabolized by lactobacilli to ultimately produce the lactic acid that maintains the low 
vaginal pH32,33. Compared to other mammals, the levels of glycogen in the tissues and vaginal 
fluid in humans are significantly higher 26.  Likewise, humans also have a more acidic vaginal pH 
relative to other mammals. In a comparison of 26 mammalian species, humans exhibited the lowest 
vaginal pH at 4.5, whereas the median vaginal pH across the non-human mammals was 6.826. 
While there are several interesting hypotheses to explain this human uniqueness and its 
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evolutionary consequences34, there is one immediate implication: non-human animal models 
developed to study host-pathogen interplay within the vaginal microbiome are inherently limited.  
 
Bacterial vaginosis 
Many well-characterized urogenital and sexually transmitted infections (i.e. chlamydia, 
gonorrhea, and yeast infections) are mediated by a singular pathogen. Bacterial vaginosis, on the 
other hand, is better described as a polymicrobial infection35–38. During BV, the lactobacilli 
dominance is lost, the vaginal pH increases, and the flora comprising the vaginal microbiome 
becomes more diverse16,17,39–41.  Bacterial taxa associated with this dysbiotic state interact to form 
a dense polymicrobial biofilm on the surface of the vaginal epithelium38,42,43. When sloughed off, 
these biofilm-coated clue cells can be used to diagnose BV44. Women with BV may present as 
symptomatic or asymptomatic, with symptoms including a malodorous vaginal discharge and 
vaginal discomfort44.  
 
While these symptoms of BV are generally mild and frequently not reported, this shift in 
the vaginal microflora is clinically important, even when symptoms are not noted45. This is likely 
due to the finding that both the cervicovaginal mucus and the cervicovaginal epithelium of BV 
positive women are compromised in their protective barrier functions46,47. In addition, women 
dominated by a diverse, anaerobic flora exhibit an increase in Th17-associated cervicovaginal 
cytokines as well as increased numbers of genital HIV target cell numbers48. Accordingly, women 
with BV are at increased risk for acquisition of other sexually transmitted infections, including 
HIV, wherein a BV positive status increases susceptibility to HIV by an estimated 60%49–51.  
Women who experience BV during pregnancy are more than two times as likely to experience 
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preterm birth, potentially due to ascending infection from the vagina/cervix into the uterus or 
premature cervical remodeling induced by dysbiotic cervicovaginal flora 52–55. Moreover, BV has 
been associated with numerous other adverse outcomes, including pelvic inflammatory disease, 
recurring urinary tract infections, chorioamnionitis, postpartum endometritis, infertility, and 
adverse neonatal outcomes, even among full term infants 56–62. The prevalence of BV, in the United 
States alone, is approximately 30% for women of reproductive age, and is significantly increased 
in Hispanic and African American women63,64.  Standard metronidazole treatment carries a 
recurrence rate of 52% within 12 months of treatment63–67 and recent reports indicate that BV 
recurrence can, at least in part, be attributed to the inability to reestablish the beneficial lactobacilli 
population after antibiotic treatment68,69. Thus, it is clear that more targeted approaches to BV 
treatment are needed.  
 
Great progress has been made in the last 20 years with respect to understanding the risk 
factors and adverse sequelae associated with the disorder as well as improving and validating 
diagnostic methods70–75. However, there are still many gaps in the mechanistic understanding of 
the progression of BV, with particular regard to the in vivo roles of specific taxa, virulence factors, 
and host-pathogen interactions that promote this shift from lactobacilli dominance and that 
contribute to its immunopathology. These gaps have limited the development of novel treatments 
and have ultimately perpetuated BV’s significant public health burden. The overarching aim of 
this dissertation research is to characterize the factors that contribute to the establishment and 




Evidence that Gardnerella plays a role bacterial vaginosis  
BV is ultimately a polymicrobial disorder. The abundance of several bacterial species 
concomitantly increases with the characteristic decrease in lactobacilli. However, the most 
common bacterial species to predominate during BV is Gardnerella vaginalis39,70,76–80 . While G. 
vaginalis is frequently detected in women without BV, its abundance is high in 95-99% of BV 
positive subjects; it is the most abundant organism comprising the in vivo biofilm; and its mean 
relative abundance increases just days prior to the onset of incident BV81. Multiple studies suggest 
that distinct commensal and BV-associated strains may exist, potentially explaining why G. 
vaginalis presence within the vaginal epithelium is less BV-specific compared to other BV-
associated organisms82–85. Moreover, BV positive and negative women harboring G. vaginalis can 
be distinguished by differences in their in vivo concentrations of the bacterium. G. vaginalis is 
documented at 102-104 CFU/mL for healthy women but reach 105-108 CFU/mL during BV86–88.  
 
In addition, the vast repertoire of putative virulence factors produced by G. vaginalis is 
suggestive of its high virulence potential: 
 
Iron acquisition 
Multiple Gardnerella strains were shown to utilize iron salts and host iron compounds as 
the sole source of iron for growth89. Human lactoferrin (120 kDa) and hemoglobin (124 kDa) 
binding proteins were identified and associated with the Gardnerella cell surface90,91. The amount 
of lactoferrin binding protein was increased under iron deplete conditions and may be specific for 
human lactoferrin, as binding of bovine lactoferrin was not detected. The human specificity of 
lactoferrin binding could potentially explain Gardnerella host restriction.  Furthermore, a study of 
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siderophore production showed that all 8 tested strains exhibited siderophore activity. These 
mechanisms for iron acquisition may help the bacterium overcome nutritional immunity in vivo, 
but this has yet to be studied.   
 
Sialidase 
A sialidase enzyme with a pH optimum of 5.5 was first isolated from G. vaginalis in 198492. 
Later studies showed that sialidase activity was significantly increased in the vaginal secretions of 
BV-positive women relative to BV-negative women93,94. A correlation between high sialidase 
activity in vaginal secretions and increased degradation of anti-Gardnerella hemolysin IgA and 
IgM as well as an inverse correlation with IL-8 levels were reported, suggesting that sialidases 
present during BV diminish the immune response to the Gardnerella hemolysin95–97. It was also 
found that pregnant BV-positive women with high sialidase activity were at an increased risk for 
preterm birth and low birth weight98,99. Interestingly, not all Gardnerella strains make a functional 
sialidase100–102. However, sialidase positive G. vaginalis strains were able to both catabolize and 
consume sialoglycans from IgA and mucin in vitro103. This sialoglycan foraging was also observed 
ex vivo in human vaginal secretions and in vivo in a murine infection model. These results 
suggested that Gardnerella sialidase may contribute to mucus barrier degradation in addition to 
immune suppression. More recent reports clarify the genetic basis of sialidase activity in 
Gardnerella strains104. Three sialidase genes, nanH1, nanH2, and nanH3, were differentially 
distributed among Gardnerella isolates, but nanH1 and nanH2 seemed to be the primary sources 






Fifteen years ago, Swidsinski et. al reported the presence of a dense biofilm coving 50% 
or more of the epithelial surface of vaginal biopsies from BV-positive subjects43. Using 
oligonucleotide probes and fluorescence in situ hybridization (FISH), they showed that 
Gardnerella spp. made up a majority of the biofilm mass. This biofilm was implicated in the sexual 
transmission of Gardnerella between partners as all tested BV positive patients (20/20) and their 
partners (10/10) exhibited the cohesive Gardnerella aggregates on desquamated, urine voided 
epithelial cells and prepuce epithelial cells in seminal fluid42,105. The recalcitrance of the 
Gardnerella biofilm to treatment was highlighted in a study investigating the efficacy of 
intravaginal octenidine antiseptic treatment38. The 6-month cure rate was only 29.2% and 37.5% 
of patients exhibited complete resistance at the one-year follow-up time point. In vitro studies of 
the Gardnerella biofilm show that the biofilm phenotype enhances resistance to hydrogen peroxide 
and lactic acid by 4-fold and 8-fold, respectively, relative to planktonic cells106. Gardnerella 
strains  produce thicker biofilms compared to other BV-anaerobes and N-acetylglucosamine 
appears to be an important component of the biofilm matrix106,107.  
 
Bacterial antagonism 
A study of 11 G. vaginalis BV-isolates showed that all tested isolates reduced growth of at 
least one out of twenty-two other vaginally relevant bacterial species108. This antagonistic activity 
was partially characterized and attributed to a bacteriocin-like compound. In a different study, in 
vitro assays show that G. vaginalis was able to displace adherent lactobacilli from vaginal 
epithelial cells10. The mechanism behind this activity was not further characterized. In both studies, 
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the pH at which these activities were detected, ~7.0, was more characteristic of a Gardnerella-
dominated vaginal environment. Thus, whether or not these antagonistic activities are possible 
under lower pH conditions of a healthy vaginal microbiome is unknown.  
 
Pili 
In the 1980s, three publications showed evidence of pilus production in Gardnerella spp109–
111. These studies reported that the diameter of Gardnerella pili varied from 3 to 7.5 nm, with 
occasional aggregation into bundles. Pili were shown to interact with human erythrocytes to 
promote agglutination but the degree of piliation among strains was highly variable. Heavy 
piliation was observed more frequently on freshly isolated strains but declined upon repeated 
laboratory passage, which suggests that pili are important for survival in the human host. There 
was no mention of the genes suspected to be involved in Gardnerella pilus production. More recent 
studies show that G. vaginalis exhibits increased attachment to host cells relative to other BV-
associated bacteria; this could potentially be mediated by pili107.  
 
Cholesterol-dependent pore-forming cytotoxin 
In 1990, Rottini et. al noted zones of hemolysis on blood agar plates streaked with G. 
vaginalis112. With this, they hypothesized that the bacterium secreted a hemolytic cytotoxin and 
went on to purify a 61-63 kDa protein with cytolytic activity from Gardnerella culture 
supernatants. Secretion of the toxin paralleled bacterial growth during logarithmic and early 
stationary phases and plateaued during bacterial death phase. The hemolysin exhibited a species 
selectivity for human erythrocytes. Erythrocytes from other species either required a greater 
amount of toxin to achieve the same amount of lysis (rat erythrocytes) or were resistant to up to 
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100-fold the amount of toxin used on human erythrocytes (horse, rabbit, sheep, guinea pig 
erythrocytes).  Purified toxin also mediated injury to endothelial cells and leukocytes. Hemolytic 
activity was inhibited by temperatures below 20ºC, the addition of trypsin, and pre-incubation with 
phospholipids.  
 
The following year, a different group also purified and characterized a Gardnerella 
hemolysin with a similar molecular mass113. They observed that toxin activity exhibited a 
temperature optimum between 20-40 ºC and a pH optimum of 6.0. A loss in activity was observed 
following protease, trypsin, glucosidase, and cholesterol treatment. They found that human 
lymphocytes were 100-fold less susceptible to the hemolysin relative to human erythrocytes, and 
similar to the Rottini et al. study, that the toxin exhibited a species specificity for human cells. 
Results from binding and osmotic protection assays suggest that the hemolysin, rather than 
functioning as an enzyme, instead mediates lysis through pore formation. These pores on human 
erythrocytes were estimated to be approximately 1.4 to 2.1 nm in diameter.  
 
In 1993, yet a third group purified and characterized the toxin114. Results from their studies 
suggested that the protein required aggregation on the target membrane to form a functional lesion 
and estimated the pore radius to be 2.4 nm. They similarly observed activity inhibition by the 
addition of cholesterol, and more so when cholesterol was added alongside phospholipids, to 
suggest that the negative surface potential increased affinity of the toxin for the membrane. This 
group also reported for the first time the detection of Gardnerella hemolysin-specific IgA in the 
vaginal fluids of BV-positive women. In a separate paper published the same year, this group 
found that low ionic strength and divalent cations inhibited activity at a step subsequent to binding. 
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They observed toxin-mediated damage on cholesterol-containing lipid vesicles and, in contrast to 
other reports, a pH optimum at 5.0. Over the next 9 years, this group went on to generate several 
publications highlighting the relevance of the toxin to BV and adverse pregnancy outcomes94,99,115.  
These studies showed that 60% of women with overt BV and 18.5% of women with intermediate 
flora exhibited a specific IgA response to the hemolysin. This specific response correlated with 
increased IL-1ß levels and leukocyte counts in vaginal fluids. No woman with BV and a strong 
anti-hemolysin IgA response had an adverse pregnancy outcome (preterm delivery or low 
birthweight infant).  
 
The availability of G. vaginalis genetic information later enabled further, and more detailed 
characterization of the toxin. In 2008, Gelber et. al identified a 1.5 kb open reading frame in the 
G. vaginalis genome with homology to known cholesterol dependent cytolysins116. Because of this 
sequence similarity, they proposed the name “vaginolysin (VLY)” to maintain consistency with 
CDC nomenclature. They subsequently cloned and recombinantly purified the toxin and then 
demonstrated that it lysed erythrocytes in a species-specific manner. Pre-incubation of the toxin 
with cholesterol prevented erythrocyte lysis. Importantly, they provide evidence that the human 
complement receptor, CD59, contributed to the species specificity of lytic activity. When VLY 
was added to cervical epithelial cells, the p38 MAPK pathway was activated and IL-8 production 
was induced. A single amino acid substitution within the undecapeptide region (P480W) 
significantly reduced cytolytic activity. Subsequent studies by this group show that VLY is also 
cytotoxic towards human cervical epithelial (HeLa) and vaginal epithelial (VK2) cells117. Lower 
concentrations of the toxin induced membrane blebbing, rather than pore-driven lysis. It was 
hypothesized that epithelial cells respond to pore forming toxins in this way as a defense 
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mechanism to expel the toxin from the cell118. The response of erythrocytes to VLY, on the other 
hand, was shown to be rather distinct119. Co-incubation of VLY with erythrocytes induced lipid 
raft enlargement by increasing the amount of CD59, cholesterol, and other raft-associated factors 
in membrane fractions. Programmed cell death factors were also recruited to lipid rafts. This led 
VLY-treated erythrocytes down a programmed necrosis pathway, which enhanced G. vaginalis 
growth in vitro.  
 
In 2013, Budvytyte et. al successful reconstituted VLY into tethered bilayer membranes120. 
Using this tool, they were able to show that VLY damage of lipid membranes could occur in the 
absence of CD59, but was absolutely dependent upon adequate membrane cholesterol levels (> 10 
mol %). Despite CD59 being non-essential for pore formation, they suggest that in vivo it may 
potentiate cytotoxicity by promoting monomer binding to the cell surface. Subsequent reports 
provided evidence that VLY-mediated lysis can occur on cells via two separate pathways, one 
involving only cholesterol, the other both cholesterol and CD59, due to the ability of the 
undecapeptide region to adopt two distinct conformations121,122. Analysis of VLY pore formation 
on artificial membranes suggest a membrane cholesterol content requirement between 40-55 mol% 
and a neutral pH optimum, with weak to no activity at acidic pH123. Interestingly, VLY exerts 500-
fold less attracting force on CD59 relative to other CD59 dependent pore forming toxins 124.  
 
Despite all that has been gleaned by studies of VLY, the function of the toxin in vivo is still 
unknown. It could potentially help overcome nutritional immunity. Alternatively, it could protect 
G. vaginalis from innate immune cells, as it has been shown to induce cell death in neutrophils112. 
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In any case, evidence of evolution under strong constraint (purifying selection) suggests that VLY 
is important to the fitness of Gardnerella spp125.  
 
In sum, while the unfulfillment of classical Koch’s postulates initially cast doubt on the 
contribution of G. vaginalis to BV, its fulfillment of the more modernized molecular guidelines 
for establishing microbial disease causation proposed by Fredricks and Relman in 1996  clearly 
suggests that G. vaginalis plays an important, causative role126,127. In fact, many groups have 
hypothesized that a combination of G. vaginalis’s presence in healthy women, its inability to 
induce a strong host immune response, its virulence potential, and its ability to form a robust, 
resistant biofilm make this opportunistic pathogen an ideal candidate keystone species for the 
establishment of BV128. 
 
Obstacles in defining the role of Gardnerella spp. in bacterial vaginosis 
Many studies have sought to investigate how G. vaginalis and its virulence factors interact 
with the host to promote the development of BV. Unfortunately, many obstacles have impeded 
detailed characterization of Gardnerella spp. virulence determinants and their interaction with the 
host, making it difficult to definitively establish a role for G. vaginalis in BV. First, analyses of 
multiple strains reveal substantial genetic and phenotypic heterogeneity within the genus84,85,101,129. 
In an analysis of 17 different strains, the core genome made up only 51.6% of each strain’s genome. 
Furthermore, for each measure studied, G. vaginalis isolates had the highest degree of difference 
when compared to 23 other pathogenic bacterial species. Numerous studies of Gardnerella spp. 
strains also highlight the vast phenotypic differences within the genus. Comparisons between 
isolates in the production of certain biochemicals, resistance to antimicrobials and human serum, 
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and virulence factor production, among many other things, illustrate the diversity employed by 
this organism130–133. Because of this heterogeneity, studies prior to 2019 consistently supported the 
regrouping of the Gardnerella genus into multiple species102,129,134. This regrouping was officially 
proposed in a 2019 publication in the International Journal of Systematic and Evolutionary 
Microbiology135. Through whole genome sequencing of all 81 sequenced full genomes of 
Gardnerella spp., as well as phenotypic distinction using MALDI-TOF MS, Vaneechoutte et al. 
proposed to delineate the Gardnerella genus into 13 distinct species. The contribution of each of 
these newly defined species to BV, whether some or all are associated, as well as whether some 
are more or less pathogenic, is currently unknown. Although, a recent publication found that some 
species are more likely to co-occur while others are associated with various BV symptoms136.  
 
Next, animal models of BV poorly recapitulate in vivo phenomena137–140.  This may be due, 
in part, to the uniqueness of the human vaginal mucosa, as previously mentioned. But this may 
also be due to the human selectivity of key BV species, including G. vaginalis. Apart from 2 reports 
of isolation of G. vaginalis-like organisms from mares, it  has only been found in humans141,142. 
Initial hypotheses proposed that the human restriction of G. vaginalis was attributable to the CD59 
co-receptor for the vaginolysin toxin116. However, humanization of mice with human CD59 failed 
to promote growth in mouse models of G. vaginalis infection (personal communication, Dr. Adam 
Ratner, New York University). Thus, it is unclear what human-specific factors may be contributing 
to the human specificity of Gardnerella spp.  
 
Finally, the genetic intractability of Gardnerella has severely limited the characterization 
of potentially important virulence determinants. There are no reports of directed mutagenesis in 
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Gardnerella.  Up to this point, studies of putative virulence factors have depended on the use of 
purified or recombinantly-produced Gardnerella proteins or comparisons of non-isogenic 
variants89–91,104,112,116. The only published documentation of genetic manipulation of G. vaginalis 
involves selection of a spontaneous streptomycin resistant mutant on Gardnerella semi-selective 
media supplemented with streptomycin138,139. While random mutagenesis using mutagenic 
chemicals or UV-light is certainly possible, it often produces off-target effects and the process to 
generate truly isogenic mutants is laborious and time-consuming. As Gardnerella produces a 
variety of putative virulence factors that have the potential to mediate the development of BV, the 
ability to perform efficient, directed mutagenesis in Gardnerella would be a huge advance for the 
field and would be invaluable for future studies aiming to better understand the interplay between 
G. vaginalis, the host, and other urogenital microbes.  
 
Research objectives  
 
In conclusion, while we have a better understanding of the organisms that comprise the 
vaginal microbiome, there are still a lot of gaps in our understanding of what they are doing and 
how they are interacting with the host and each other, both the context of health and disease. This 
is due to inadequacies of animal models and difficulty in culturing and genetically manipulating 
vaginally relevant microorganisms. In the studies presented herein, various tools were developed 
to further characterize putative virulence determinants produced by Gardnerella to better 
understand how the bacterium interacts with the human host, focusing on the cholesterol-
dependent toxin, vaginolysin, and the phase variable opacity phenotype presumptively attributed 
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to differential pilus production. Continuing to build upon this understanding will allow us to 









Materials and Methods 
 
 
Strains and culture conditions 
Gardnerella strains (Table 3) were cultured anaerobically (90% N2, 5% H2, 5% CO2) at 37°C on 
sBHI (brain heart infusion broth [Oxoid] containing 1.0% [wt/vol] gelatin, 1.0% yeast extract, 
0.1% starch, and 0.1% dextrose) agar plates supplemented with 10% human blood or fetal bovine 
serum (FBS), or in sBHI broth with or without 5-10% human serum (Fisher Scientific) or FBS at 
37°C. Starch agar plates (0.75% [wt/vol] tryptone, 0.75% special peptone, 1.1% starch, 0.4% 
potassium phosphate dibasic, 0.1% potassium phosphate monobasic, 0.5% NaCl, 0.0012% 
bromocresol purple) were used to quantify Gardnerella growth on EpiVaginal tissues. sBHI plates 
with FBS were used to distinguish Gardnerella colony morphology variants.  E. coli was grown 
in Luria-Bertani (LB) broth or on 1.5% agar LB plates supplemented with antibiotics as 
appropriate (Table 4) at 37°C under atmospheric conditions. 
 
The human vaginal epithelial cell line VK2/E6E7 was cultured at 37°C with 5% CO2 in 
keratinocyte serum-free medium (Gibco) with 0.1 ng/mL human recombinant epidermal growth 
factor (EGF), 0.05 mg/mL bovine pituitary extract, 0.4 mM CaCl2, 50 U/mL penicillin, and 50 
µg/mL streptomycin. Partial thickness EpiVaginal tissues derived from primary human 
vaginal/ectocervical cells were purchased from MatTek. Upon arrival, the tissues were moved 
from semisolid transport medium into 2 mL of prewarmed serum-free VEC-100 medium (without 
antibiotics, pH 7.2). The tissues were maintained at the air-liquid interface at 37°C with 5.0% CO2. 
 17 
The HL-60 cell line was cultured in IMDM (Quality BiologicalTM) supplemented with 20% FBS, 
50 U/mL penicillin, and 50 µg/mL streptomycin.  
 
Agarose gels 
Gels for visualizing or purifying DNA were prepared with 1.5% (wt/vol.) low electroendosmosis 
agarose (Ambion) in 1X Tris-acetate-EDTA (TAE) buffer (Invitrogen). Ethidium bromide (Pierce) 
was added at 1 µg/mL to enable DNA visualization. After solidification, gels were submerged in 
1X TAE buffer, loaded with samples mixed with gel loading dye (BioLabs), and electrophoresed 
at 125 volts.  
 
Polyacrylamide gel electrophoresis (PAGE) 
Protein-containing samples were mixed with NuPAGE LDS Sample Buffer (ThermoFisher 
Scientific) and NuPAGE Sample Reducing Agent (ThermoFisher Scientific) at 1X concentrations 
and then heated at 70°C for 10 min before being added to NuPAGE 4-12% Bis-Tris protein gels 
(ThermoFisher Scientific). The gels were then submerged in MES SDS Running Buffer prepared 
at 1X concentration in ddH2O and electrophoresed with 125 volts applied. SDS gels were stained 




DNA was extracted from Gardnerella strains using the DNeasy Blood and Tissue kit (Qiagen), 
following the protocol for Gram-positive bacteria with the following modifications. Bacterial 
pellets were resuspended in 200 µl enzymatic lysis buffer (20 µl 10X TE buffer, 2.4 µl TritonX100, 
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177.6 µl ddH2O, 4mg lysozyme) and incubated at 37°C for 60 minutes. After adding proteinase K 
and Buffer AL, the solution was incubated at 56°C until clear (lysed; ~15 min). Elution of genomic 
DNA was achieved by adding 50 µl ultrapure ddH2O to the DNeasy membrane and collecting by 
centrifugation twice for a final elution volume of 100 µl. 
 
Plasmid extraction 
Plasmids (Table 7) were extracted from E. coli using the QIAprep Sping Miniprep Kit (Qiagen), 
according to manufacturer’s instructions (October 2011). Ultrapure ddH2O was used for elution.  
 
PCR/Digest product purification  
Following DNA amplification using the PCR parameters outlined in Table 5 or digestion (below), 
DNA products were purified using the QIAquick Gel Extraction Kit (Qiagen) as outlined on the 
kit insert (September 2010). Ultrapure ddH2O was used for elution.  
 
Digestion 
Double enzymatic digestion of plasmids (Table 7) and inserts (vly and λ bet) by BamHI and XhoI 
(NEB) was performed in buffer 3.1 (NEB) for 3 hours at 37°C. Digested DNA was purified as 
outlined above prior to ligation.  
 
Ligation  
Purified, digested plasmid (20-100ng) was mixed with a 3-fold molar excess of purified, digested 
insert and adjusted to a final volume of 5 µl with ddH2O. A volume of 5 µl Instant Sticky-end 
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Ligase Master Mix (NEB) was added and mixed by pipetting up and down 10 times. Reactions 
were either used immediately or stored at -20°C. 
 
Competent cell preparation 
Competent E. coli strains (Table 3) were purchased from New England BioLabs. For competent 
Gardnerella cells, a single colony of a given strain was used to inoculate 3 mL of sBHI. After 48 
hours of growth under anaerobic conditions, 1 mL of this culture was used to inoculate 25 mL of 
fresh sBHI. Following overnight growth, this culture was used to inoculate fresh sBHI and this 
subculture was grown anaerobically until the cells reached early log phase (OD600 = 0.35).  For G. 
vaginalis 14018, this took approximately 6 hours. For G. leopoldii AMD, cells were first allowed 
to reach an OD600 of 0.2, diluted 200-fold into fresh media, and then grown anaerobically for 16 
hours. After reaching early log phase, cultures were placed on ice for 10 minutes and then 
centrifuged at 4,000 rpm for 10 minutes at 4°C to collect cells. Translucent variant cells were 
washed three times with ice cold 10% glycerol in ddH2O and resuspended in a volume of 10% 
glycerol that is 100-fold less than the original culture volume. To prevent bacteria from sticking 
to tube walls and losing the pellet, opaque variant cells were washed once with 50 mL ice cold 
ddH2O, moved to 1.5mL Eppendorf tubes, and then washed 7 times in 1mL ice cold 10% glycerol, 
increasing the centrifugation speed to 10,000 rpm. Aliquots of 100-200 µl were frozen at -80°C 
until needed.  
 
Transformation of chemically competent cells  
NEB Stable competent cells were thawed on ice for 10 minutes and then 2ul of plasmid:insert was 
added. The tube was flicked 5 times to mix and then incubated on ice for 30 minutes. Following 
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incubation, cells were heat shocked for 30 seconds at 42°C and then placed on ice for 5 minutes. 
NEB 10-beta/Stable Outgrowth Medium (950 µl) was added and the cells incubated at 37°C with 
shaking for 60 minutes. Cells (50 µl) were added to pre-warmed plates with the appropriate 
antibiotic (Table 4) and incubated overnight at °C. For the transformation of BL21(DE3), cells 
were thawed on ice for 10 minutes and then 1 µl plasmid DNA was added. Cells were flicked to 
mix, placed on ice for 30 minutes, then heat shocked at 42°C for 10 seconds. After 5 minutes on 
ice, 950 µl of SOC medium was added and the cells were incubated at 37°C for 60 minutes with 
shaking. Aliquots of 25, 50, or 100 µl were added to prewarmed plates and incubated at 37°C 
overnight.  
 
Vaginolysin expression and purification  
The vly gene was amplified from Gardnerella strains using primers and PCR conditions outlined 
in Table 5. Purified PCR products were digested with BamHI and XhoI and then ligated to 
pET32XT. The vly-containing plasmid was transformed into E. coli strain NEB Stable. Single 
colonies growing on LB agar containing ampicillin were used to inoculate LB broth. After 
overnight growth at 37°C with shaking, plasmids were extracted and purified as described above 
and presence of the vly gene was confirmed with Sanger sequencing (Eurofins). The plasmid was 
then transformed into E. coli strain BL21(DE3) CodonPlus pRIPL (Agilent technologies) as 
described above. Single colonies were used to inoculate 3 mL LB broth and after overnight growth 
at 37°C with shaking, 1 mL of culture was used to inoculate 25 mL fresh LB broth. After overnight 
growth at 37°C with shaking, the 25 mL culture was added to 500 mL fresh LB broth and incubated 
at 37°C with shaking to exponential phase (OD600= 0.5). The expression of vly was induced by the 
addition of 1 mM IPTG for 2 hours and then the bacteria were collected by centrifugation. Bacteria 
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were then lysed in a French pressure cell in 25 mL B-PER™ (ThermoFisher Scientific) containing 
protease inhibitors (EDTA-free cOmplete™, Sigma) and the lysate was cleared by centrifugation 
and filtration. The protein was purified by cobalt affinity chromatography (His-Pur™, Thermo-
Fisher Scientific) according to manufacturer instructions, eluted in 0.25 M imidazole, and dialyzed 
against 1X phosphate buffered saline (PBS) overnight and then for two hours at 4°C. In some 
instances, the affinity tag was removed by thrombin digestion (1 unit/mL, Sigma-Aldrich). VLY 
in 1X PBS was then concentrated using a 3,000-molecular-weight(3K)-cutoff centrifugal filter 
(Millipore). Purified, concentrated protein was then sterile filtered (Pall), and aliquots were frozen 
at -80°C until needed. The empty vector control was similarly prepared. Protein purity was 
assessed by denaturing PAGE gel as described above.  
 
Protein quantification 
For quantification of VLY used for EpiVaginal studies, and preparations of phage λ beta, a 
NanoDropTM spectrophotometer was used. For more accurate quantification of VLY used in 
comparative studies of AMD and 14018 VLY, a bicinchoninic acid (BCA) assay (PierceTM) was 
used. This assay was performed according to the manufacturer’s instructions. In brief, absorbance 
values at 562nm of sequential BSA concentrations were used to generate a standard curve. 
Absorbance values of samples of diluted VLY were compared against the standard curve to 
generate a total protein concentration for the sample. Then, because calculated values were total 
protein and not just VLY concentrations, dilutions of each protein preparation were analyzed by 
denaturing PAGE. Dilutions that exhibited the same intensity of VLY protein on the gel were 
considered to have “similar” VLY concentrations and these dilutions were used for comparisons 
in subsequent assays.  
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Endotoxin quantification  
Endotoxin contamination of protein preparations was assessed using a ToxinSensorTM Gel Clot 
Endotoxin Assay Kit (GenScript). This Limulus Amebocyte Lysate-based test is a semi-
quantitative test for Gram-negative bacterial endotoxin. Endotoxin levels in negative samples are 
lower than 0.25 EU. The endotoxin concentration value in a sample can be determined by 
multiplying the dilution factor by 0.25. The assay was performed according to manufacturer’s 
instructions. We determined that <25 EU/mL were added to each tissue during EpiVaginal 
experiments and <2.5 EU/mL were added during cell monolayer experiments.  
 
EpiVaginal cytotoxicity 
One hundred µl of VLY (10 µg/mL) or G. leopoldii AMD (OD600 0.05 or ~105 CFU/mL) in PBS 
without magnesium or calcium chloride, was added to the apical or basolateral side of EpiVaginal 
tissue. Positive cytotoxicity controls (100 µl of 1.0% Triton X-100 or 100% methanol) were added 
apically to tissues for 2 hours. To the side opposite of inoculation, 100 µl of PBS was added.  After 
16 hours of anaerobic incubation with VLY, the fluid from the apical side was combined with the 
basolateral media and the tissue was removed. To the tissues incubated 16 hours with G. vaginalis, 
300µl of fresh media was added apically to collect apically released LDH. Basolateral media was 
decanted separately. The fluid was clarified by centrifugation (10,000 X g for 10 minutes), and 
100 µl was used for quantification of extracellular LDH using a Cytotoxicity Detection Kit 
(Roche). Spent media from the tissues and LDH substrate were incubated for 15 minutes at room 
temperature. A490 values were measured after addition of stop solution to determine relative LDH 
activity released from treated and untreated tissues. The % LDH release relative to controls was 
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calculated using the following formula: ((LDHsample-LDHno treatment)/LDHlysis reagent control-LDHno 
treatment )x100. The tissues were rinsed twice with 400 µl PBS and added to either 300 µl of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Calbiochem) (1mg/mL in 
DMEM) or submerged in 1 mL 1:1 PBS: 0.4% trypan blue (Sigma). For MTT assays, tissues were 
incubated with MTT for 3 hours at 37˚C and 5.0% CO2. Tissues were exposed to the trypan blue 
solution for 3 minutes at room temperature. Stained tissues were then rinsed and fixed in 10% 
formalin (~1.5mL) at 4˚C for 72 hours.  
 
EpiVaginal co-culture growth assay 
G. vaginalis was added to tissues apically or basolaterally as described above. After 16 hours of 
anaerobic incubation at 37˚C and 5.0% CO2, CFUs were quantified by plating 10 µl of each 10-
fold dilution of tissue or basolateral media onto starch agar plates via the drip plate method. Each 
dilution was sonicated for 10 seconds prior to plating to disperse bacterial aggregates. To quantify 
bacteria located on and within the tissue, inserts were first moved to 1mL PBS and then sonicated 
to homogenize the tissues using a Series 60 Sonic Dismembrator Model F60 set at the lowest 
possible setting (Fisher Scientific). Plates were incubated anaerobically at 37˚C for 72 hours and 
colonies counted from dilutions with 20-200 colonies. Bacteria in the basolateral media of tissues 
inoculated only apically were removed from subsequent analyses, as this indicated that the tissue 
integrity was compromised.  
 
EpiVaginal kill assay 
A log-phase culture of G. vaginalis was first diluted to an OD600 of 0.05 in sBHI and then 50µl 
was added to wells of a 96-well plate. Next, 50µl of spent EpiVaginal tissue media from the apical 
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or basolateral side or 50µl of sBHI (no treatment) was added to the wells. After 24 hours of 
anaerobic growth at 37˚C, bacterial cultures were diluted, sonicated, and plated to quantify 
CFU/mL.  
 
EpiVaginal cytokine analysis  
G. vaginalis or VLY was added to tissues apically or basolaterally as described in the 
“Cytotoxicity” section above. For VLY-treated tissues, after 16 hours of anaerobic incubation, the 
apical fluid was pooled with the basolateral media and the tissue was removed. For the G. 
vaginalis-treated tissues, 300µl of fresh media was added apically to collect apically secreted 
cytokines. Basolateral media was decanted separately. To compare cytokine secretion in response 
to VLY or empty vector control, 1 µg/mL protein prep was added to 24-well plates of VK2 cell 
monolayers and incubated anaerobically for 4 hours. Aliquots of clarified spent media were stored 
at -80˚C until analysis. Supernatants were analyzed for relative cytokine concentrations using both 
a Bio-Plex Pro Human 27-Plex Assay and a Quantikine HS ELISA Human IL-1β Immunoassay. 
Assays were performed according to manufacturers’ instructions and plates analyzed by the BIO-
RAD Bio-Plex MAGPIX Multiplex Reader. The Quantikine assay was used for IL-1β 
quantification instead of the Bio-Plex assay because of its increased sensitivity, which was 
important for detecting significant differences in our preliminary experiments. Cytokine 
concentrations were quantified by comparing sample values to a standard curve. The standard 
curve of each cytokine was fit with a 5-parameter logistic model. Some sample values from IL-
1ra were beyond the limits of this model. Consequently, standard curve values were fitted with a 
power model (y = 24.639x4.3196, R2=0.953) and sample values calculated using its equation. Four 
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cytokines, IL-10, IL-5, IL-13, and Basic FGF were excluded from subsequent analyses because 
their levels in spent media from the tissues were below the limit of detection. 
 
EpiVaginal RT-PCR 
Approximately 109 G. vaginalis AMD in PBS was added to the apical or basolateral face of 
EpiVaginal tissue, EpiVaginal tissue culture media alone, or to sBHI. After 4 hr, the bacteria were 
collected and resuspended in 500μl RNALater for 5 min. The bacteria were collected by 
centrifugation and resuspended in 500 μl buffer RLT (Qiagen). The suspension was transferred to 
Lysing Matrix B tubes (MP Biomedicals) and 500 μl of a 5:1 mixture of acid phenol: cholorform 
(ThermoFisher) was added. The cells were lysed using a FastPrep FP120 Instrument 
(ThermoFisher) with settings of power 6 and duration of 40 seconds. Samples were centrifuged 5 
minutes 20,817 rpm at 4°C, the upper layer was transferred to a new microfuge tube containing 
500 μL EtOH (500 μl), the samples were mixed by inversion, and the RNA purification was 
performed using the RNeasy kit (Qiagen) according to manufacturer's instructions, and the RNA 
was eluted in 90 μl of RNase-free water. DNA was removed using the Turbo DNA-free kit 
(Ambion). Synthesis of cDNA from 1 μg RNA was carried out using the iScript kit (BioRad). 
Resulting cDNA was diluted 1:10, and 2 μl of the diluted cDNA was used as a template for realtime 
RT-PCR in reactions that included 0.4 μM of each forward and reverse primer as well as iTaq 
Universal SYBR Green Supermix (BioRad). Primer sets are listed in Table 5. Control reactions 
lacked reverse transcriptase enzyme to ensure that DNA contamination was minimal. Reactions 
were performed on an IQ5 Multicolor Realtime PCR Detection System (Bio-Rad). Relative vly 
transcript levels were determined by normalization to 16S rRNA gene expression using the 
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equation 2^-(CTGOI- CT16S). Averages were obtained from technical replicates and standard 
deviation was determined.  
 
EpiVaginal histology 
Trypan blue and MTT stained tissues were rinsed with PBS, fixed in 10% formalin at 4°C for 72 
hours, and embedded in either paraffin or O.C.T Compound (Tissue-Tek®). Prior to tissue 
processing, tissues were cut in half to prevent folding during the embedding process. Paraffin-
embedded tissues were processed using the standard core protocol using an automatic processor 
under vacuum: 70% EtOH 30min; 2x 95% EtOH 45min each; 3x 100% EtOH 45min each; 2x 
clearing agent (CitriSolv) 45min each; 4x paraffin (Paraplast plus) 30min each at 60 ˚C. To 
visualize staining, 5 µM sections were cut, deparaffinized, and immediately cover-slipped with 
mounting media. O.C.T-embedded tissues were first bathed in 15% and then 30% sucrose in PBS 
for cryoprotection. To visualize staining, 5 µM cryosections were cut onto SUPERFROST® PLUS 
Gold Slides, rinsed in PBS, and cover-slipped with 90% glycerol.  Hematoxylin and eosin (H&E) 
staining was performed by the VCU Massey Cancer Center Cancer Mouse Model Core Laboratory 
(CMMCL). Digital images of tissue sections were captured on an EVOS® XL Core imaging 
system. Percent trypan blue-staining was calculated by counting the number of stained cells in the 
most apical or most basolateral layer of the tissue and dividing by the total number of cells in that 
layer. Four tissue sections were counted for each treatment.   
 
EpiVaginal immunohistochemistry 
Immunohistochemistry (IHC) to detect CD59 (1:100, Novus Biologicals) was performed in the 
CMMCL with the Leica Bond RX autostainer using heat-induced epitope retrieval buffer 2 (Leica, 
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EDTA pH 8.0). Stained slides were then imaged on the Vectra Polaris (PerkinElmer). The color 
deconvolution method was used to semi-quantitatively assess CD59 staining on apical vs 
basolateral sections of tissues143. 3,3′-Diaminobenzidine (DAB) and hematoxylin were digitally 
separated using the Fiji version of  ImageJ software (version 2.0.0-rc-69/1.52i, National Institutes 
of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/) and an ImageJ plugin for color 
deconvolution144,145. Following deconvolution, the minimum image threshold was set to 20 and he 
maximum to 200, using a black and white color scale. The number of pixels within apical or 
basolateral sections of deconvoluted, DAB-stained images was assessed using ImageJ software, 
and this value was divided by the cell number to give a value of Density/cell. Four total sections 
were quantified. 
 
Clade, species, and VLY type assignment to available Gardnerella genomes 
In order to extract the VLY sequences from all the Gardnerella genomes available on NCBI, we 
created a profile Hidden Markov Model using HMMER3 for the pfam PF01289 (Thiol_cytolysin 
protein). All proteins and CDS from complete and draft from 110 Gardnerella genomes available 
from NCBI were downloaded. Proteins were searched using HMMsearch to find hits to the PF0289 
HMM profile created above and the corresponding CDS was extracted from each of the genomes. 
The Gardnerella strains from which VLY sequences were extracted (84 strains) were 
automatically aligned using MUSCLE and the final alignment was manually inspected. The 
maximum-likelihood tree was inferred by PhyML using Phylogeny.fr tool using the gamma-
distributed heterogeneity rate categories with 1,000 bootstraps146,147.  Clade and species 
designations were assigned manually using schema outlined in Ahmed et. al 2012 and 
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Vaneechoutte et. al 2019, respectively129,135. VLY type was assigned based on the scheme 
described below (Fig. 13). 
 
VLY alignment 
Extracted undecapeptide and CD59 region sequences were aligned using Clustal Omega; Guide 
Tree; Cladogram and colored to highlight conserved and divergent sequences (Fig. 11)148.  
 
Distinction of VLY types  
Based on the similarities and differences observed in the sequence alignment, VLY types were 
first classified based on sequence differences in the CD59 region149,150. Type 1 VLY contained 
aspartate and serine in positions 4 and 6 of the CD59 region while type 2 VLY contained 
asparagine and threonine and type 3 VLY contained asparagine and serine. The toxin types were 
then sub-grouped based on sequence differences in the undecapeptide region. Since types 2 and 3 
were uniform in this region, there were no subgroups for these types. Type 1, on the other hand, 
had either double valine (1A), valine and alanine (1B), or glutamine and valine(1C) at positions -
1 and 6 of the undecapeptide region (Fig. 12).  
 
Comparison of VLY monolayer cytotoxicity 
Preparations of either VLYAMD or VLY14018 containing similar concentrations of the toxin, as 
determined by visualization of ~72 kDa band (57 kDa VLY plus 6xHis tag) on a NuPAGE 4 to 
12% Bis-Tris gel under denaturing conditions, were compared. Protein preparations were diluted 
to 1 or 5 µg/mL in VK2/E6E7 culture medium without antibiotics and then 100ul of diluted toxin 
or control medium was added to at least 3 individual wells of 96-well plates of VK2 monolayers. 
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After 30 minutes of co-incubation at 37°C, the media was removed and 100ul of a 1:1 solution of 
0.4% trypan blue and PBS was added to each well and incubated at 37°C for 1 minute. The trypan 
blue was removed, the wells rinsed with PBS, and 100ul of fresh medium was added. Monolayers 
were then imaged by light microscopy to assess the percent of cells staining with trypan blue. This 
was done on both “less mature” cells (4 days post-seeding), with and without anti-CD59 
pretreatment (1:1000, 30 minutes), and “more mature cells” (7 days post-seeding). Percent trypan 
blue staining was calculated by diving the number of blue stained cells in an image by the total 
number of cells and multiplying by 100.  
 
VK2/E6E7 monolayer cytokine analysis 
Five hundred microliters of preparations of either VLYAMD or VLY14018 in VK2 medium 
containing similar concentrations (less than 5ug/mL) of the toxin (predetermined to not lyse more 
than 50% of the cells in each well) were added to 24-well plates in triplicate and then incubated 
aerobically in 5% CO2 at 37°C. After 19 hours of co-incubation, media was decanted from wells, 
clarified, and frozen at -80°C until analysis. Supernatants were analyzed for relative cytokine 
concentrations using a Bio-Plex Pro Human 27-Plex Assay as outlined in the “EpiVaginal cytokine 
analysis” section above. As a default, the standard curve of each cytokine was fit with a 5-
parameter logistic model. When any sample value for a given cytokine was beyond the limits of 
this model, standard curve values were fitted with a different, appropriate model and all sample 
values for that cytokine were re-calculated using its equation. These equations are presented in a 
table below. While 27 cytokines were quantified, only those with different values between controls 








Table 1. Standard curve equations for VK2/E6E7 cytokines 
Cytokine Equation R² 
IL-1β y = 4E-05x2 + 0.0073x + 0.2404 0.999 
IL-1ra y = 0.0002x2 + 0.2825x + 48.306 0.9998 
IL-2 y = 0.9218x + 3.5371 0.9959 
IL-4 y = 0.1055x + 0.2119 0.9981 
IL-5 y = 6.2281x + 9.001 0.9978 
G-CSF y = 1.2522x + 8.0105 0.9983 
GM-CSF y = 6E-08x3 - 0.0001x2 + 0.1957x + 1.1629 1 
Eotaxin y = 0.0212x + 0.1187 0.9972 
MIP-1a y = -0.0001x2 + 0.0837x + 0.5733 1 





Cohort 1 VLY type metagenomic data analysis  
 
Participant recruitment: We analyzed 64 samples from our Vaginal Human Microbiome Project 
(VaHMP) cohort. In this study, we collected more than 40,000 vaginal, cervical, introital and 
buccal swab samples cross-sectionally from a racially diverse cohort of 3,815 women visiting 
VCU Medical Center women’s clinics. 
 
Sampling and sample processing: Samples were collected with BD BBL CultureSwab EZ swabs. 
Swabs were processed immediately using MoBio Powersoil kit as described by the manufacturer. 
DNA samples were stored at −80 °C.  
 
Whole shotgun metagenomic sequencing: DNA libraries were prepared using Illumina Truseq 
DNA library prep kit and sequenced on an Illumina HiSeq 2000 (2 × 100 b PE). Samples were 
sequenced individually in each lane and 5 × 108 paired-end reads per sample were obtained. 
 
Whole shotgun metagenomic data pre-processing: Raw sequence data were demultiplexed into 
sample-specific fastq files using bcl2fastq conversion software from Illumina. The pre-processing 
of raw paired-end sequence data was performed using Trimmomatic, by removing Illumina 
specific adapters from the reads and trimming the 5ʹ end for quality using a sliding-window 
approach (average Q20 over a window of 4 b). Reads shorter than 70 bases after trimming were 
discarded. This was followed by removal of contaminant reads of vector and human origin by 
aligning against the UniVec database (https://www.ncbi.nlm. nih.gov/tools/vecscreen/univec/) and 
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the hg19 build of the human genome using bwa. Two samples had fewer than 100,000 high-quality 
reads and were removed from further downstream analysis. 
 
Taxonomic classification: Taxonomic classification of the metagenomics sequence data was 
performed on high-quality non-human reads by alignment to a custom database of bacterial 
genomes using CLARK-S, a discriminative space k-mer-based approach. Bacterial genomes were 
downloaded from the NCBI Reference Sequence Database, accessed in March 2017, supplemented 
with our in-house genome assembly of Lachnospiraceae_BVAB1. Species abundances were 
estimated by normalizing the assigned read counts to species genome size. 
 
Gardnerella spp. cpn60 database: In order to create a comprehensive cpn60 database, we first 
created a profile Hidden Markov Model using HMMER3 for the pfam PF00118 protein family 
(TCP-1/cpn60 chaperonin family). This method uses a homology detection approach by 
comparing sequence reads to HMM profile. All proteins and CDS from complete and draft from 
105 Gardnerella genomes available from NCBI were downloaded. Proteins were searched using 
HMMsearch to find hits to the PF00118 model created above and the corresponding CDS was 
extracted from each of the genomes. This cpn60 database was used to taxonomically classify the 
Gardnerella reads from the metagenomic data to the species/strain levels.  
 
Grouping samples by VLY type: The number of vly reads of each type in a given sample were 
used to determine the “dominant” VLY type of the sample. The VLY type exhibiting a clear 
majority of the total vly reads for a sample (representing ≥ 50% of all vly reads) was designated as 
the dominant type. If two VLY types were equally represented and together made up a majority of 
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the total vly reads in a sample, this sample was said to be dominated by both types and placed into 
both VLY type groups.  
 
Cohort 2 data analysis  
 
Participant recruitment: We analyzed 733 of 762 samples from our Vaginal Human Microbiome 
Project (VaHMP) cohort. This sub cohort of the VaHMP study has 3 groups with the following 
characteristics: Group 01, 185 participants with current diagnosis of bacterial vaginosis (BV) but 
no history of recurrent BV; Group 02, 191 participants with history of BV but no current BV 
diagnosis and Group 03, 357 participants with no history nor current diagnosis of BV.  
 
Sampling and sample processing: Samples were processed, and DNA was extracted as described 
above. 
 
16S rRNA taxonomic surveys: DNA in each sample was amplified with barcoded primers 
targeting the V1–V3 region of the 16S rRNA Samples were amplified and sequenced on the 454 
Titanium Sequencer and analyzed as previously described23. Each high-quality amplicon sequence 
was taxonomically classified to the species level using STIRRUPS by alignment to a custom 
reference database of vaginally relevant species151. Samples were filtered based on the sequencing 




Resolution of Gardnerella spp. using cpn60: The cpn60 gene encodes the 60 kDa chaperonin, 
(also called groEL or hsp60). Similar to 16S rRNA gene heterogeneity, this gene is particularly 
useful since a phylogenetically informative fragment of the gene can be amplified with degenerate 
polymerase chain reaction (PCR) primers. The target region used in this study corresponds to 
nucleotides 274–828 of the Escherichia coli cpn60 sequence. Targeted deep sequencing of the 
cpn60 gene was performed using the tailed amplicon sequencing approach (a.k.a. Two-Step PCR 
Approach). The PCR approach was carried out in 2 steps: the first round of PCR uses primers 
containing a cpn60 locus-specific sequence (Table 5) and a common 5’ tail, and the second round 
of PCR is performed to introduce the indexes (barcodes) as well as the Illumina-specific 
sequencing adapters152. The first round of PCR was performed using High-Fidelity Polymerase, 
0.2 mM each dNTP, and 0.4 μM of each primer. The PCR thermocycler profile used is detailed in 
Table 5. Samples were purified using Agencourt® AMPure XP beads using DNA:beads ratio of 
1.2 to remove primer and unincorporated dNTPs. Next, the second round of PCR was performed 
using 1 μl of a 1/10 diluted first-round PCR product as template and Applied Biosystems 9700 
PCR System with 1 U Thermo Scientific Phusion Hot Start II High-Fidelity PCR Master Mix, and 
0.2 μM of each primer. The PCR thermocycler profile used is detailed in Table 5. Samples were 
submitted to a second PCR clean-up using Agencourt® AMPure XP beads using DNA:beads ratio 
of 1.12 to remove primer and unincorporated dNTPs. Libraries were quantified using fluorometric 
quantification and pooled equimolarly. Libraries were sequenced using Illumina MiSeq v3 600 
cycle kit. Samples were filtered based on the sequencing depth—samples having fewer than 1,000 
high-quality amplicons were removed from further analysis. Each high-quality amplicon sequence 
was taxonomically classified to Gardnerella strain level by alignment to the custom cpn60 
reference database detailed in the Cohort 1 section above. High-quality reads that aligned at ≥ 99% 
 35 
identity using the USEARCH v4.0 global alignment algorithm were assigned to the same strain-
level taxon. 
 
Grouping samples by VLY type: Since a given Gardnerella strain can be distinguished via its 
cpn60 sequence, and each strain produces a specific VLY type, VLY type abundance in each 
sample was extrapolated from cpn60 read data to classify the dominant VLY type of each sample. 
Similar to Cohort 1, If two VLY types were equally represented and together made up a majority 
of the total vly reads in a sample, this sample was said to be dominated by both types and placed 
into both VLY type groups. 
 
VLY type distribution among study participants  
For Cohort 1, the number of reads of a given VLY type across all samples was divided by the total 
number of vly reads across all samples and multiplied by 100 to give a percent value.  For Cohort 
2, after cpn60 reads were assigned to a specific VLY type, these reads were similarly divided by 
the total number of reads and multiplied by 100 to give a percent value.  
 
Frequency of vaginal symptoms in women with different VLY types 
After each sample was assigned a dominant VLY type, they were then grouped according to the 
symptoms reported. Samples with more than one reported symptom were placed in both symptom 
groups. Then, in each symptom group, each sample was counted as a “yes” or “no” for having 
each VLY type as the dominant VLY type. This answers the question, “Of women experiencing a 
certain symptom, what percent of those women had a given VLY type as the dominant type?” For 
Cohort 1, a Homogeneity test (appropriate for comparing proportions of 3 or more groups with 
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binary outcomes) was used to detect any significant differences in the proportions among the VLY 
types being compared for each symptom. For Cohort 2, a Chi-Square test (appropriate for 
comparing proportions of two groups with binary outcomes and with expected frequencies all 
greater than or equal to 5) was used.  
 
Relative bacterial abundance in women with different VLY types 
16S rRNA sequencing reads were used to determine the relative abundance of different bacterial 
species in each sample as described above. After sample grouping by VLY type, the median 
relative abundance of each bacterial species was calculated. As relative abundance data were not 
normally distributed, a non-parametric Wilcoxon test was used to test for statistically significant 
differences in the median relative abundance values between VLY type groups.  
 
Transmission electron microscopy 
One mL of an overnight culture of opaque variant bacteria grown in sBHI was spun down at 11,000 
x g for 2 minutes, and the supernatant decanted. The bacterial pellet was washed once in 1mL PBS 
and resuspended in 100ul of PBS. Bacteria were then fixed by adding 100ul of 0.2% 
glutaraldehyde in 0.1M cacodylate buffer and incubating at 4°C for 2 hours. A formvar-carbon 
coated mesh grid was first glow discharged and then floated on the surface of a drop of this 
bacterial suspension for 15 minutes. The grid was blotted, washed twice by being dipped onto a 
drop of distilled water, then transferred to a drop of 0.5% uranyl acetate for 60 seconds. The grids 
were blotted and allowed to dry overnight before visualization on a Jeol JEM-1400Plus electron 
microscope at 100 kV.  
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Identification of Tad locus homologues  
The tight adhesion (Tad) locus encodes the genes for the biogenesis of type IV pili in a wide variety 
of bacterial species. Amino acid sequences from the genes encoded in the predicted Tad locus of 
G. leopoldii AMD were used to perform a BLAST protein search on NCBI. Gardnerella strains 
encoding proteins with at least 50% amino acid identity across at least 80% of the coding region 
were noted. The appropriate operon organization of the respective genes (i.e. sequential, in the 
same region of the chromosome) was verified, apart from tadV, which commonly resides outside 
the operon in Gram-positive organisms.  
 
Sequencing Tad locus 
DNA for sequencing was extracted as outlined in the “gDNA extraction” section above. DNA was 
extracted from both bacteria grown as colonies and in liquid cultures. The amplification of various 
regions within and upstream of the Tad locus in G. leopoldii AMD was performed using the 
primers and PCR parameters detailed in Table 5. Sanger sequencing was performed by Eurofins 
Genomics.  
 
Tad locus RT-PCR 
Bacteria (both grown as colonies and in liquid cultures) were collected and resuspended in 500μl 
RNALater for 5 min. The bacteria were collected by centrifugation and resuspended in 500 μl 
buffer RLT (Qiagen). The suspension was transferred to Lysing Matrix B tubes (MP Biomedicals) 
and 500 μl of a 5:1 mixture of acid phenol: cholorform (ThermoFisher) was added. The cells were 
lysed using a FastPrep FP120 Instrument (ThermoFisher) with settings of power 6 and duration of 
40 seconds. Samples were centrifuged 5 minutes 20,817 rpm at 4°C, the upper layer was 
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transferred to a new microfuge tube containing 500 μL EtOH (500 μl), the samples were mixed by 
inversion, and the RNA purification was performed using the RNeasy kit (Qiagen) according to 
manufacturer's instructions, and the RNA was eluted in 90 μl of RNase-free water. DNA was 
removed using the Turbo DNA-free kit (Ambion). Synthesis of cDNA from 1 μg RNA was carried 
out using the iScript kit (BioRad). Resulting cDNA was diluted 1:10, and 2 μl of the diluted cDNA 
was used as a template for realtime RT-PCR in reactions that included 0.4 μM of each forward and 
reverse primer as well as iTaq Universal SYBR Green Supermix (BioRad). Primer sets are listed 
in Table 5. Control reactions lacked reverse transcriptase enzyme to ensure that DNA 
contamination was minimal. Reactions were performed on an IQ5 Multicolor Realtime PCR 
Detection System (Bio-Rad). Relative Tad locus transcript levels were determined by 
normalization to 16S rRNA gene expression using the equation 2^-(CTGOI- CT16S). Averages were 
obtained from technical replicates and standard deviation was determined.  
 
Biofilm assay  
Single colonies of either G. vaginalis 14018 or G. leopoldii AMD were used to inoculate sBHI 
and incubated anaerobically for 72 hours. Subcultures of 1:30 were prepared in fresh media and 
allowed to grow anaerobically overnight.  These overnight cultures were then adjusted to an OD600 
of 0.075 (AMD) or 0.01(14018) in fresh sBHI. Two hundred microliters were added to 9 wells in 
a 96-well CellBIND plate (Corning) and incubated anaerobically at 37°C for 24 hours. Six wells 
were used to quantify OD600 and biofilm. The other 3 wells were used to determine the % of each 
variant making up the cells in the medium and the adherent cells making up the biofilm. For biofilm 
quantification, the medium was removed from each well and wells were washed once with 200ul 
PBS. Wells were allowed to air dry for 1 hour. They were then stained with 200ul 100% safranin 
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for 60 seconds, rinsed once in PBS, and then air dried again for 1 hour. Stained biofilms were then 
solubilized by adding 200ul 33% acetic acid and then the A562 was quantified. Each biofilm A562 
value was normalized against the average growth (OD600 output- OD600 input) in 3 wells. For 
quantifying variants in the medium of each well (planktonic bacteria), 2.5 ul was taken off the top 
of the well, added to 1mL PBS, diluted 1:100, and then 25ul was plated onto sBHI plates with 10% 
FBS. For quantifying variants in the biofilm, all media was removed from each well, the biofilm 
was rinsed once in PBS, then 200ul fresh PBS was added. Each well was sonicated for 5 seconds 
and similarly diluted before plating.  
 
Scoring bacterial aggregation  
Overnight cultures of bacteria of each variant were grown in sBHI. Bacteria were collected by 
centrifugation, rinsed once in PBS, and then resuspended in PBS. Bacteria were then adjusted to 
1 x 107 cells/mL in IMDM or sBHI. Various substrates were added (final concentrations detailed 
below) to see whether aggregation was impacted. One hundred microliters of bacteria in media 
with different substrates were added to wells of a 96-well plate and incubated at room temperature 
for 90 minutes. Media in wells was dumped, and media remaining in each well was allowed to air 
dry overnight. Bacteria in wells were then fixed with 50 ul of methanol for 3 minutes and then 
wells were allowed to air dry. Wells were stained with 50ul of 10% Giemsa stain for 25 minutes, 
rinsed once in PBS, and air dried. Bacterial aggregates were then imaged using an inverted light 





Table 2. Concentrations of substrates used in Gardnerella aggregation experiments  
Compound Final concentration 
Fibronectin  0.01 mg/mL 
EDTA 0.5 mM 
Hyaluronic acid  0.01 mg/mL 
BSA 0.1 mg/mL 
Collagen VI 0.01 mg/mL 
Elastin 0.01 mg/mL 
Mucin 0.01 mg/mL 
Lactic acid 0.90% 
Streptomycin 1mg/mL 
Sodium citrate 12.5 mg/mL 
H2O2 0.30% 
Trypsin, EDTA 0.0005%, 0.0002% 
Proteinase K 0.2 mg/mL 
DNase 0.1 mg/mL 





Opacity variant growth during stressor exposure 
Cultures (48-72 hours old) of bacteria of each variant were grown in sBHI and 10 ul used to 
inoculate 200 ul of fresh media (3 wells each) in a 96 well plate. Bacteria were added to wells with 
and without stressors (lactic acid, hydrogen peroxide, metronidazole, streptomycin) at a range of 
concentrations. The plates were incubated anaerobically for 48 hours and optical density at 600nm 
measured. Percent optical density relative to untreated wells is presented for hydrogen peroxide. 
It was calculated by dividing the OD600 of treated wells by the OD600 of untreated wells and 
multiplying by 100. Average MIC50 is presented for the remaining stressors. It was calculated by 
generating a standard curve using the percent OD600 values calculated above and then plugging 
50% into the equation to give the appropriate concentration. 
 
HL-60 differentiation 
For cell differentiation, cells were treated with all-trans retinoic acid (ATRA) (Acros Organics) at 
a final concentration of 0.3 µg/mL for 4 days in IMDM supplemented with 20% heat inactivated 
FBS, 50 U/mL penicillin, and 50 µg/mL streptomycin.  
 
NBT assay 
A nitroblue tetrazolium (NBT) (Sigma) assay was used to confirm cell differentiation153. The 
production of superoxide anion in differentiated, stimulated cells acts to reduce yellow, water 
soluble NBT and promote the formation of water insoluble blue formazan deposits which can be 
quantified. A final concentration of 0.5 µg/mL NBT was added to HL-60 cells with or without the 
addition of the stimulant, phorbol 12-myristate 13-acetate (PMA, 600 ng/mL) (Abcam). Cells were 
incubated at 37°C for one hour, washed with warm PBS, washed with 100% methanol, and then 
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air dried for one hour. The formazan was solubilized by the addition of 2M KOH followed by 
DMSO and the absorbance at 620nm was determined. 
 
Opacity variant survival of phagocytosis  
HL-60 cells were collected by centrifugation and resuspended in IMDM containing 10% human 
serum. The cell density was adjusted to 2 x 106 cells/mL. Overnight cultures of G. vaginalis 14018 
or G. leopoldii AMD were grown in sBHI. Bacteria were collected, rinsed once in PBS, and then 
resuspended in PBS. Bacteria were then adjusted to 2 x 107 cells/mL in IMDM with 10% human 
serum. Bacteria were incubated in medium for 15 minutes with end over end rotation at 37°C to 
promote opsonization prior to the addition of HL-60 cells. Then, equal volumes of either medium 
alone or HL-60s in medium were added to bacteria and incubated for 75 minutes with end over 
end rotation at 37°C. Dilutions of bacteria were plated to determine the number of bacteria at input 
and after 90 minutes of total incubation. The percent survival is determined by dividing the number 
of bacteria in samples with HL-60s by the average of the number of bacteria in samples without 
HL-60s and multiplying by 100.  
 
Oligonucleotide recombineering  
A 100ul aliquot of electrocompetent cells was thawed on ice for 10 minutes. Then, 10ug of 
oligonucleotide in 1 uL volume was added to the 100ul aliquot of cells and incubated on ice for 
10 min. Eighty microliters of this was added to a pre-chilled 0.1cm cuvette and electroporated 
using the “Agr” protocol on the BIORAD MicroPulser. Immediately following electroporation, 
220 ul of sBHI (without any antibiotics) was added to the cuvette and then this was added to 4.7mL 
sBHI (without any antibiotics). Cells were incubated anaerobically overnight and then diluted and 
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plated onto sBHI plates with 10% FBS, with or without 100ug/mL streptomycin to determine the 
% of transformants.   
 
Phage λ beta cloning, expression, and purification 
Phage λ bet was amplified from pKD46 using the primers detailed in Table 5, designed to include 
BamHI and XhoI restriction sites. Purified PCR products were digested with BamHI and XhoI and 
then ligated to pET32XT. The bet-containing plasmid was transformed into E. coli strain NEB 
Stable. Single colonies growing on LB agar containing 100 μg ampicillin / mL were used to 
inoculate LB broth. After overnight growth at 37°C with shaking, plasmids were extracted and 
purified as described above and presence of the bet gene was confirmed with Sanger sequencing. 
The plasmid was then transformed into E. coli strain BL21(DE3) CodonPlus pRIPL (Agilent 
technologies) as described above. Single colonies were used to inoculate 3 mL LB broth and after 
overnight growth at 37°C with shaking, 1 mL of culture was used to inoculate 25 mL fresh LB 
broth. After overnight growth at 37°C with shaking, the 25 mL culture was added to 500 mL fresh 
LB broth and incubated at 37°C with shaking to exponential phase (OD600= 0.5). The expression 
of bet was induced by the addition of 1 mM IPTG for 2 hours and then the bacteria were collected 
by centrifugation. Bacteria were then lysed in a French pressure cell in 25 mL B-
PER™ (ThermoFisher Scientific) containing protease inhibitors (EDTA-free cOmplete™, Sigma) 
and the lysate was cleared by centrifugation and filtration. The protein was purified by cobalt 
affinity chromatography (His-Pur™, Thermo-Fisher Scientific) according to manufacturer’s 
instructions, and then eluted sequentially in 0.25 M and 0.5M imidazole. Five units of free bovine 
thrombin (Sigma-Aldrich) were added to 5mL eluate and this was dialyzed against 1X PBS at 4°C 
overnight and then for 2 hours. Thrombin-treated eluate was then added to the His-Pur™ (Thermo 
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Scientific) column, the flow through collected, and buffered into binding buffer (0.05M Tris-HCl, 
0.05M NaCl, pH 7.4). A 1mL Benzamidine Sepharose 4 Fast Flow (GE Healthcare) column was 
prepared, washed with 5mL H2O, and equilibrated with 5mL binding buffer. Buffered eluate was 
then added to the prepared column and the flow through collected. To make sure all protein was 
eluted from column, an additional 1mL of binding buffer was added to the column and collected. 
This was then buffered into ultrapure H2O and concentrated to 500ul using a 3,000-molecular-
weight(3K)-cutoff centrifugal filter. After filter sterilization, the concentrated protein was further 
concentrated using an Amicon Ultra Ultracel 10K centrifugal filter, centrifuged at 4°C. Aliquots 
of 10ul were prepared and kept at -20°C until needed. Different volumes of a 1:1 mix of λ beta 
and mutagenic oligo, incubated on ice for 10 minutes, were added to 100ul of electrocompetent 
cells. Cells were then electroporated and plated as outlined in the above “Oligonucleotide 
recombineering” section. For trials with the addition of MgCl2, 10ul of oligo was added alongside 
0.4ul of 50mM MgCl2 to one 10ul aliquot of purified λ beta. This was incubated for 10 minutes at 
37°C and then 5 ul of this mixture was added to 100ul of electrocompetent cells.  
 
Statistical analysis  
This section describes the default statistical analyses performed in this body of work. If a particular 
experiment or project required differential statistical analyses than what is described below, it is 
noted in the relevant section within Materials and Methods chapter. All data were assessed for 
normality using the Shapiro-Wilk test. Equality of variance was assessed using the Brown-
Forsythe test. The means of normally distributed data with equal variance were compared by using 
either one-way ANOVA (analysis of variance) with a post hoc Tukey honestly significant 
difference (HSD) test (for comparisons of  > 2 means) or Student’s t test (comparisons of 2 means). 
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The means of normally distributed data with unequal variance were compared using Welch’s t test 
with a post hoc Tukey HSD test (for comparisons of > 2 means). The means of non-normally 
distributed data were compared using a nonparametric Wilcoxon text. All statistical analyses were 
performed using JMP Pro 14.0 software (SAS Institute Inc., Cary, NC, USA). All cytokine data 
from EpiVaginal tissues were log transformed prior to analysis. P values of less than 0.05 were 







Table 3. Bacterial strains used in this study.  
Species Strain Use 
Gardnerella vaginalis 1 ATCC 14018 VLY purification, biofilm assays, phagocytosis 
assays, oligonucleotide recombineering, 
confirmation of opacity variation, aggregation 
assays, opacity variant switch frequency 
Gardnerella leopoldii 5 AMD VLY purification, EpiVaginal growth, 
EpiVaginal cytokines, EpiVaginal cytotoxicity, 
biofilm assays, phagocytosis assays, tad locus 
sequencing, tad locus RT-PCR, oligonucleotide 
recombineering, confirmation of opacity 
variation, aggregation assays, opacity variant 
switch frequency 
Gardnerella piotii 3 GV3 Oligonucleotide recombineering, confirmation of 
opacity variation 
 GV1 Confirmation of opacity variation 
Gardnerella 2 JCP7275 Confirmation of opacity variation 
Gardnerella 8 101 Confirmation of opacity variation 
Gardnerella  UM224 Confirmation of opacity variation 
Gardnerella  UM35 Confirmation of opacity variation 
Escherichia coli  NEB Stable Transformation of plasmid:insert ligations, 
plasmid replication and purification, maintenance 
of  expression vectors 





Table 4. Antibiotics used in this study.  
Name Concentration Use 
Streptomycin 50 µg/mL Maintenance of tissue 
culture cell lines 
Streptomycin 100 µg/mL Selection of oligo. recomb. 
transformants  
Penicillin 50 U/mL Maintenance of tissue 
culture cell lines 
Ampicillin 100 µg/mL Selection of Table 5. 





Table 5. Primers used in this study.  
Name Sequence (5’à 
3’) 





Initial denature: 94°C, 30 sec. 
Cycle #: 35 
----------- 
Denature: 94°C, 30 sec. 
Anneal: 60°C, 30 sec. 
Extend: 72°C, 2 min. 
----------- 








Initial denature: 94°C, 30 sec. 
Cycle #: 35 
----------- 
Denature: 94°C, 30 sec. 
Anneal: 60°C, 30 sec. 
Extend: 72°C, 2 min. 
----------- 








Initial denature: 94°C, 30 sec. 
Cycle #: 35 
----------- 
Denature: 94°C, 30 sec. 
Anneal: 60°C, 30 sec. 
Extend: 72°C, 2 min. 
----------- 








Initial denature: 94°C, 30 sec. 
Cycle #: 35 
----------- 
Denature: 94°C, 30 sec. 
Anneal: 60°C, 30 sec. 
Extend: 72°C, 2 min. 
----------- 








Initial denature: 94°C, 30 sec. 
Cycle #: 35 
----------- 
Denature: 94°C, 30 sec. 
Anneal: 50°C, 30 sec. 
Extend: 68°C, 30 sec. 
----------- 














Initial denature: 94°C, 30 sec. 
Cycle #: 35 
----------- 
Denature: 94°C, 30 sec. 
Anneal: 50°C, 30 sec. 
Extend: 68°C, 30 sec. 
----------- 













Initial denature: 98°C, 30 sec. 
Cycle #: 40 
----------- 
Denature: 98°C, 5 sec. 
Anneal: 58°C, 5 sec. 
Extend: 72°C, 105 sec. 
----------- 
Final extend: 72°C, 60 sec. 
Amplification 










Initial denature: 98°C, 30 sec. 
Cycle #: 40 
----------- 
Denature: 98°C, 5 sec. 
Anneal: 58°C, 5 sec. 
Extend: 72°C, 105 sec. 
----------- 
Final extend: 72°C, 60 sec. 
Amplification 




































































































































NA Sequencing of 
Tad locus 
starting at ~10 
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Initial denature: 94°C, 30 sec. 
Cycle #: 35 
----------- 
Denature: 94°C, 30 sec. 
Anneal: 50°C, 30 sec. 
Extend: 68°C, 30 sec. 
----------- 
Final extend: 68°C, 5 min. 
Amplification 










Initial denature: 94°C, 30 sec. 
Cycle #: 35 
----------- 
Denature: 94°C, 30 sec. 
Anneal: 50°C, 30 sec. 
Extend: 68°C, 30 sec. 
----------- 
Final extend: 68°C, 5 min. 
Amplification 












Initial denature: 94°C, 30 sec. 
Cycle #: 35 
----------- 
Denature: 94°C, 30 sec. 
Anneal: 62°C, 30 sec. 
Extend: 68°C, 30 sec. 
----------- 
Final extend: 68°C, 5 min. 








Initial denature: 94°C, 30 sec. 
Cycle #: 35 
----------- 
Denature: 94°C, 30 sec. 
Anneal: 62°C, 30 sec. 
Extend: 68°C, 30 sec. 
----------- 
Final extend: 68°C, 5 min. 
λ beta cloning 
Gv16sc-FWD AGATCATCAT
GCCCCTTACG 
Initial denature: 95°C, 120 sec. 
Cycle #: 45 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 





Initial denature: 95°C, 120 sec. 





Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 
Melt curve: 65 °C, 30 sec. 
MH7 CTTGCGCAGC
CAGCAAGG 
Initial denature: 95°C, 120 sec. 
Cycle #: 45 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 





Initial denature: 95°C, 120 sec. 
Cycle #: 45 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 





Initial denature: 95°C, 120 sec. 
Cycle #: 45 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 






Initial denature: 95°C, 120 sec. 
Cycle #: 45 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 






Initial denature: 95°C, 120 sec. 






Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 
Melt curve: 65 °C, 30 sec. 
TadDREV ACTTGTTGCAC
GATGCTCTG 
Initial denature: 95°C, 120 sec. 
Cycle #: 45 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 






Initial denature: 95°C, 120 sec. 
Cycle #: 45 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 






Initial denature: 95°C, 120 sec. 
Cycle #: 45 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 









Initial denature: 95°C, 120 sec. 
Cycle #: 45 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 










Initial denature: 95°C, 120 sec. 
Cycle #: 45 
----------- 





Anneal: 53°C, 15 sec. 
Extend: 60°C, 20 sec.         RT 
----------- 
Cycle #: 31 









Initial denature: 95°C, 120 sec. 
Cycle #: 30 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 
Final extend: 72°C, 4 min. 
 
Step 2: 
Initial denature: 95°C, 120 sec. 
Cycle #: 10 
----------- 
Denature: 95°C, 30 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 














Initial denature: 95°C, 120 sec. 
Cycle #: 30 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 
Final extend: 72°C, 4 min. 
 
Step 2: 
Initial denature: 95°C, 120 sec. 
Cycle #: 10 
----------- 
Denature: 95°C, 30 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 










Initial denature: 95°C, 120 sec. 










Denature: 95°C, 15 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 
Final extend: 72°C, 4 min. 
 
Step 2: 
Initial denature: 95°C, 120 sec. 
Cycle #: 10 
----------- 
Denature: 95°C, 30 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 











Initial denature: 95°C, 120 sec. 
Cycle #: 30 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 
Final extend: 72°C, 4 min. 
 
Step 2: 
Initial denature: 95°C, 120 sec. 
Cycle #: 10 
----------- 
Denature: 95°C, 30 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 













Initial denature: 95°C, 120 sec. 
Cycle #: 30 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 









Initial denature: 95°C, 120 sec. 
Cycle #: 10 
----------- 
Denature: 95°C, 30 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 









Initial denature: 95°C, 120 sec. 
Cycle #: 30 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 
Final extend: 72°C, 4 min. 
 
Step 2: 
Initial denature: 95°C, 120 sec. 
Cycle #: 10 
----------- 
Denature: 95°C, 30 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 














Initial denature: 95°C, 120 sec. 
Cycle #: 30 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 
Final extend: 72°C, 4 min. 
 
Step 2: 
Initial denature: 95°C, 120 sec. 
Cycle #: 10 
----------- 
Denature: 95°C, 30 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 















Initial denature: 95°C, 120 sec. 
Cycle #: 30 
----------- 
Denature: 95°C, 15 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 
Final extend: 72°C, 4 min. 
 
Step 2: 
Initial denature: 95°C, 120 sec. 
Cycle #: 10 
----------- 
Denature: 95°C, 30 sec. 
Anneal: 55°C, 30 sec. 
Extend: 72°C, 30 sec. 
----------- 











Table 6. Oligonucleotides used in this study.  









Table 7. Plasmids used in this study. 
Name Antibiotic resistance Use 
pET32XT Ampicillin, 100 µg/mL Recombinant protein 
expression (VLY from AMD 
and 14018 and λ beta) 




Table 8. Cell lines and tissues used in this study.  
Name Cell type  Source Use 
VK2/E6E7 Human vaginal 
keratinocyte 
ATCC VLY cytotoxicity and 
cytokine assays 




MatTek VLY and Gardnerella 
growth, cytotoxicity, 
and cytokine assays 




McVoy lab, VCU VLY cytotoxicity 
assays 
HL-60 CCL-240 Human peripheral 
blood 
promyeloblast 



































Characterization of G. vaginalis and VLY interactions with a stratified, 




Although G. vaginalis is found in both BV-positive and BV-negative women, its 
abundance is significantly greater in those with the disease86–88. Moreover, this abundance 
increases just days prior to the onset of incident BV, suggesting that factors contributing to G. 
vaginalis growth in vivo may be important in the cascade of events leading to the establishment of 
BV81. The Vaginal Human Microbiome Project (VaHMP) was a NIH-funded, VCU-led project 
with the aim of characterizing the structure and composition of the vaginal microbiome in response 
to host and environmental factors5. To do this, participants were asked to contribute samples from 
various body sites, including the vagina, which were subsequently analyzed to generate 16S rRNA 
and metagenomic data for each subject. Patient data including sociodemographic factors, sexual 
and physical activity, diet regime, medication history, and substance use were also recorded. These 
data were previously examined to investigate whether there were any significant associations 
between patient meta-data and Gardnerella abundance154. Interestingly, of all the variables 
examined, the only factor exhibiting a significant association with bacterial abundance was statin 
use. Analysis of 16S rRNA survey profiles from women who were or were not using statins at the 
time of sampling, revealed that women using statins had significantly lower proportions of G. 
vaginalis and higher proportions of Lactobacillus crispatus relative to women not taking statins. 
As statins are most frequently prescribed as cholesterol-lowering drugs, and G. vaginalis produces 
a cholesterol-dependent virulence determinant, vaginolysin (VLY), it was hypothesized that 
inhibition of the toxin via reduced cholesterol levels in vaginal epithelial cell membranes could 
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potentially explain these observed in vivo differences in bacterial abundance116,155. This study went 
on to show statin treatment of vaginal epithelial cell monolayers could indeed reduce VLY-
mediated cytotoxicity. Consequently, this led us to hypothesize that VLY promoted G. vaginalis 
growth within the vaginal epithelium, through pore-formation and subsequent release of epithelial 
cell contents (i.e. glycogen). 
 
Vaginolysin has been the most extensively studied virulence factor of G. vaginalis due to 
its conserved nature within the genus and its associations with bacterial vaginosis156. More than 
half of women with bacterial vaginosis mount a specific IgA response against the toxin, and this 
response is associated with increased levels of vaginal IL-1β and reduced adverse birth 
outcomes94,99,115. In addition, BV isolates of G. vaginalis exhibit increased expression of vly 
compared to non-BV isolates157. And most recently observed, higher concentrations of VLY in 
vivo were associated with women who have a vaginal microbiota deficient in lactobacilli, a clinical 
indicator of BV158. The toxin is characterized as a cholesterol dependent pore-forming cytolysin 
(CDC) because of its sequence similarity to other CDCs and its documented lysis of human 
erythrocytes, epithelial cells, and polymorphonuclear leukocytes112,116. However, whether or not 
VLY concentrations produced in vivo are sufficient to lyse host cells, is questionable. It has been 
shown that concentrations of VLY in the ng/µl range induce membrane blebbing rather than lysis 
in epithelial cell monolayers, and in vivo VLY concentrations are estimated to be in this same 
range118,158.  VLY binding and pore formation are dependent on cell membrane cholesterol121. 
Interactions with the human complement regulatory protein CD59 are thought to potentiate 
binding and contribute to the species selectivity of the toxin159. Various roles for VLY in G. 
vaginalis pathogenesis are plausible, considering the already characterized interactions of VLY 
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with eukaryotic cells as well as the described roles of other cholesterol dependent toxins in 
bacterial pathogenesis; however, a specific function for the toxin has yet to be described.  
 
Various models have been used to characterize G. vaginalis host-pathogen interactions. 
Murine models of G. vaginalis infection demonstrate that vaginal colonization by G. vaginalis is 
possible; however,  bacterial populations in this model are unstable, never achieving significant  
growth, with steady clearance over time137,139,160. Conversely, in a porcine explant model, G. 
vaginalis was able to colonize, grow to clinically relevant densities, and form a dense biofilm. 
Interestingly, the epithelial cells directly covered by the biofilm were non-viable11. Three-
dimensional human epithelium models have been used to study the immune response to G. 
vaginalis, but cytotoxicity was not observed and growth on these models was not measured161,162. 
VLY interaction with epithelial cells has only been studied in the context of monolayer culture 
systems116,118,121. Because of the limitations of these models, we sought to investigate the 
contribution of VLY to Gardnerella growth using a commercially available, human-derived model 
of the vaginal epithelium. Specifically, we investigated bacterial growth, tissue cytotoxicity, and 
tissue cytokine production in order to identify interactions that might contribute to BV 
pathogenesis, using a model that more closely resembles in vivo conditions compared to monolayer 
and non-human models163.   Our findings unexpectedly show pronounced differences in these host-
pathogen interactions in relation to tissue polarity and provide insight into already characterized 








G. vaginalis exhibits increased growth on the apical face of vaginal tissue relative to the 
basolateral face. 
 
To determine whether or not this EpiVaginal model of the vaginal epithelium would be 
adequate to test our hypothesis of the contribution of VLY to G. vaginalis growth, we first 
quantified bacterial growth in coculture with EpiVaginal tissues. To do this, ∼105 CFU/tissue were 
added either apically or basolaterally, and CFU were determined after 16 h of anaerobic incubation. 
Apically inoculated tissues were checked for tissue breaks by quantifying CFU in the basolateral 
medium to ensure that bacteria did not gain access to the basolateral face. Apical EpiVaginal tissue 
inoculation with G. vaginalis consistently yielded 3- to 4-log growth, with the maximum 
concentration reaching 1.1 × 109 CFU/mL (Fig. 1A). The observed growth was not attributable to 
nutritional components of the cell culture medium, as bacterial viability actually decreased in 
medium alone. Interestingly, basolateral inoculation of EpiVaginal tissue on average yielded <2-
log growth, which was significantly lower than growth on the apical side. To further investigate 
the differences in apical versus basolateral growth of G. vaginalis, we performed a kill assay using 
spent medium from either side of the tissue to determine whether differentially secreted 
components in the medium (i.e., antimicrobial peptides or glycogen) might impact bacterial growth 
or survival. There was no observed reduction in survival from bacterial cultures treated with apical 
or basolateral spent tissue medium relative to untreated cultures, but there was an ∼1-log-higher 
concentration of bacteria in wells with apical medium added (Fig. 1B). These results suggest that 
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the EpiVaginal model is a sufficient system in which to investigate bacterial growth in response to 
VLY activity and that the apical vs basolateral sides of the tissue promote quantifiable differences 







Figure 1. G. vaginalis growth is enhanced on the apical side of the vaginal epithelium. (A) A total of ∼105 CFU G. 
vaginalis/mL was added to EpiVaginal tissues (apically or basolaterally) or to medium alone. After 16 h of 
coincubation, both media and homogenized tissues were plated to determine CFU. Log growth was calculated by 
subtracting input from output CFU. (B) Kill assay. Log-phase cultures of G. vaginalis were added to wells and were 
either left untreated or treated with spent medium from the apical or basolateral sides of EpiVaginal tissues. All data 






G. vaginalis mediates greater damage on the basolateral face of tissue. 
 
Because of the observed differences in growth on opposite sides of the epithelial tissue, we 
hypothesized that G. vaginalis would elicit greater cytotoxicity on the apical side of the tissues. 
Cytotoxicity was quantified as lactate dehydrogenase (LDH) release, trypan blue uptake, and 
formazan production. For LDH quantification, values from treated tissues were compared to those 
from untreated and Triton X-100-treated tissues to quantify percent LDH release. The addition 
of G. vaginalis to EpiVaginal tissues did elicit LDH release (Fig. 2A), increased trypan blue uptake 
(Fig. 2C), and reduced formazan production (Fig. 2E). However, LDH release and trypan blue 
uptake were greatest when G. vaginalis was added to the basolateral face (60.4% LDH release and 
80.8% of basolateral cells stained) of the tissue relative to apical exposure (8.3% LDH release and 
29.0% of apical cells stained) (Fig. 2B). Apically added G. vaginalis elicited some trypan blue 
uptake from apical cells, which was significantly different than the trypan blue uptake observed 
for untreated tissue (8.1% of apical cells stained; P = 0.04). We confirmed vly expression by G. 
vaginalis via reverse transcription-PCR (RT-PCR) (Fig. 3) but observed no significant difference 
in vly expression in relation to the side of inoculation. Thus, even though G. vaginalis growth is 







Figure 2. G. vaginalis tissue cytotoxicity is greatest at the basolateral face of the vaginal epithelium. 
EpiVaginal tissues were treated apically or basolaterally with ∼105 CFU G. vaginalis/mL for 16 h. Spent 
medium was used for lactate dehydrogenase (LDH) release assays to quantify cytotoxicity. The tissues were 
then rinsed and stained with trypan blue, MTT, or H&E. (A) Cytotoxicity of G. vaginalis toward apically or 
basolaterally challenged EpiVaginal tissues. The y axis represents the percent LDH release relative to controls. 
These data were not normally distributed but exhibited equal variance. (B) Percentage of trypan blue-stained 
cells within the most apical or basolateral cell layer. No Treatment indicates the apical layer of untreated tissue. 
These data were normally distributed and exhibited unequal variance. (C) Trypan blue-stained tissues. The red 
arrows point to trypan blue-stained cells. (D) H&E-stained tissues. (E) Formazan (MTT)-stained tissues. NT, no 
treatment; GV-A, tissue challenged apically with G. vaginalis; GV-B, tissue challenged basolaterally with G. 






Figure 3. G. vaginalis expresses vly on either side of EpiVaginal tissues. Approximately 109 G. vaginalis AMD in 
PBS was added to tissues or media and incubated anaerobically for 4 hours. RNA was then extracted and quantified 
using RT-PCR. The expression of vly is relative to G. vaginalis 16s rRNA. GV Media is sBHI and Tissue Media is 
VEC-100, both detailed in the methods. Data exhibited a normal distribution and equal variance. * = P ≤ 0.05, ** ≤ 
0.01, *** ≤ 0.001. n ≥ 3. Error bars represent standard deviation. 
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Statin treatment reduces cytotoxicity, but not Gardnerella growth 
 
Results thus far did not support the hypothesis that VLY activity promotes G. vaginalis 
growth within the epithelium. As a final test, we investigated whether statin treatment, which was 
previously shown to reduce VLY-mediated cytotoxicity against vaginal epithelial cell monolayers, 
could reduce G. vaginalis growth in this model. As G. vaginalis cytotoxicity was observed to be 
greatest on the basolateral face, we limited our investigation to this side. Similar to monolayer 
data, statin treatment was able to reduce G. vaginalis-mediated cytotoxicity, measured by LDH 
release, to basolateral epithelial cells (Fig. 4A). However, no reduction in G. vaginalis growth with 
statin treatment was observed (Fig. 4B). Collectively, these data suggest that G. vaginalis growth 








Figure 4. Statin pretreatment does not reduce G. vaginalis growth on EpiVaginal tissues. (A) Cytotoxicity of 
VLY toward basolaterally challenged EpiVaginal tissues with or without statin pretreatment. (B) Log growth of G. 





VLY mediates lactate dehydrogenase release only when exposed to the basolateral face. 
 
We then followed-up on the interesting observation that G. vaginalis cytotoxicity was 
greatest at the basolateral face of the epithelium. To test whether this difference was dependent on 
VLY interactions with the vaginal epithelium, we added supra-physiological (10 μg/mL) levels of 
purified, recombinant VLY to the apical or basolateral face of EpiVaginal tissue in 100 μl 
phosphate-buffered saline (PBS). After 16 h of anaerobic incubation, LDH that had been released 
into the medium was quantified. VLY elicited considerable LDH release from basolaterally 
challenged tissues (25.5% of the positive control) but not from tissues challenged apically (0.85%) 
(Fig. 5A). LDH release was significantly different between the two treatments (P = 0.0013). 
 
 
VLY fails to permeabilize the apical epithelium. 
 
We next sought to determine whether the lack of LDH release following apical VLY 
exposure was due to the inability of VLY to permeabilize the apical cells. To investigate this, a 
trypan blue exclusion assay was performed on tissues at 16 h post-inoculation. The trypan blue-
stained tissues were fixed, embedded, and sectioned. The sections were then either hematoxylin 
and eosin (H&E) stained for gross morphological comparisons of differentially treated tissues or 
deparaffinized and immediately overlaid with mounting medium and a coverslip for visualization 
of trypan blue staining. From these analyses, we observed that untreated and VLY-challenged 
tissues were morphologically quite similar and did not exhibit the extent of damage induced by 
Triton X-100 treatment (Fig. 5D). Furthermore, trypan blue was excluded from untreated or 
apically challenged cells but was taken up by both apical and basolateral cells of Triton X-100-
treated tissues (Fig. 5B). Only the most distal cell layer was stained by trypan blue within 
basolaterally challenged tissues, suggesting that VLY did not penetrate the tissue (Fig. 5B). The 
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quantification of trypan blue-stained cells from each treatment shows that basolateral challenge 
with VLY (54.9%) elicits greater cell permeabilization than apical challenge (5.7%) (P = 0.0002) 
(Fig. 5C). The percentage of trypan blue-stained cells of untreated tissue (8.1%) was not 
significantly different from that of apical VLY-treated tissues. These data suggest that VLY does 
not permeabilize cells when introduced to the apical side of vaginal tissue but permeabilizes cells 









Figure 5. VLY elicits cytotoxic effects on basolateral but not apical vaginal epithelial cells. EpiVaginal tissues 
were treated apically or basolaterally with 10 μg VLY/mL for 16 h. Lactate dehydrogenase released into spent media 
from tissues was quantified as a measure of cytotoxicity. The tissues were then rinsed and stained with either trypan 
blue or H&E. Percent permeability of trypan blue was subsequently calculated as described in Materials and Methods. 
(A) Cytotoxicity of VLY toward apically or basolaterally challenged EpiVaginal tissues. The y axis represents the 
percent LDH release relative to controls. These data exhibited equal variance. (B) Trypan blue-stained tissues. The 
red arrows point to trypan blue-stained cells. (C) Percentage of trypan blue-stained cells within the most apical or 
basolateral cell layer. No Treatment indicates the apical layer of untreated tissue. These data exhibited unequal 
variance. (D) H&E-stained tissues. NT, no treatment; +, positive cytotoxicity control (1.0% Triton X-100); VLY-A, 
tissue challenged apically with VLY; VLY-B, tissue challenged basolaterally with VLY. All data exhibited a normal 





CD59 is more abundant on basolateral cells than on apical cells in the EpiVaginal model of the 
vaginal epithelium. 
 
We hypothesized that the increased sensitivity of basolateral cells to VLY-mediated 
permeabilization could be due to a greater abundance of surface-associated CD59, the VLY 
coreceptor. To test this, we performed immunohistochemistry (IHC) analysis on fixed, paraffin-
embedded tissues and compared anti-CD59 staining on apical cells to that on basolateral cells (Fig. 
6A). Quantification of the intensity of anti-CD59 staining per cell revealed that basolateral cells 
exhibited a significantly higher (3.4-fold) intensity of staining than apical cells (Fig. 6B) 
(P = 0.0004). This suggests that increased VLY-mediated permeabilization of basolateral cells 








Figure 6. CD59 exhibits higher intensity on basolateral cells of EpiVaginal tissues. Shown is 
immunohistochemical staining of untreated EpiVaginal tissue. (A) DAB- and hematoxylin-stained tissue. (B) 
Quantification of average DAB staining intensity per cell. Data exhibited a normal distribution and equal variance. 




Effects of VLY on the cytokine profile are restricted to basolateral exposure. 
 
Although VLY had no cytotoxic effect on apical epithelial cells, we reasoned that VLY 
may have other, non-cytotoxic effects. Reports indicate that VLY can stimulate the expression of 
certain cytokines, including IL-8, from epithelial cells. We investigated whether these VLY-
mediated effects were also influenced by tissue polarity. After 16 h of tissue challenge with VLY 
(10 μg/mL), the concentrations of 27 cytokines were quantified in samples of media from the 
tissues (Fig. 7A). We found that IL-1β and monocyte chemoattractant protein 1 (MCP-1) levels 
were significantly increased in media from VLY-challenged tissues compared to untreated tissues 
but only when VLY was exposed to the basolateral side of the epithelium (Fig. 7B). A small 
increase in the level of RANTES in response to this treatment also achieved statistical significance; 
however, the increase was less than 2-fold. No secreted cytokine level was significantly different 
from those of controls when tissues were challenged apically with VLY. In order to confirm that 
secretion of cytokines was mediated by VLY and not a contaminating protein or endotoxin in the 
protein preparation, we used protein prepared from Escherichia coli containing an empty 
expression vector in VK2 epithelial cell monolayers and quantified cytokine production. The 
concentration of IL-1β was significantly increased upon exposure to VLY, and a similar increase 
was not observed from empty-vector-treated cells (Fig. 8). VLY-treated monolayers also exhibited 
significantly increased MCP-1 concentrations relative to both the untreated and empty-vector-
treated cells. However, when accounting for the increase observed in the empty-vector-treated 
cells, the fold change in the concentration of MCP-1 attributable to VLY, and, therefore, the 
biological relevance, is reduced. These data suggest that the major cytokine induced by VLY is 












Figure 7. VLY-mediated cytokine secretion is restricted to the basolateral face. EpiVaginal tissues were treated 
apically or basolaterally with 10 μg VLY/mL for 16 h. Samples of spent media from the tissues were then analyzed 
by a multiplex cytokine bead array. (A) Mean cytokine concentrations in picograms per milliliter and standard 
deviations (S.D.) for each mean. (B) Cytokines exhibiting significantly different concentrations between different 
treatments. The data from all three cytokines were normally distributed. IL-1β exhibited unequal variance, while MCP-








Figure 8. VK2 monolayers secrete IL-1β and MCP-1 in response to VLY. Vaginal epithelial cell monolayers were 
treated with 1µg VLY or empty vector/mL for 4 hours. Samples of spent media were then analyzed by a multiplex 
cytokine bead array. IL-1β data were not normally distributed. MCP-1 data were normally distributed. All data 




G. vaginalis elicits different cytokine secretion profiles when exposed to the apical versus 
basolateral face of the tissue model. 
 
To investigate whether G. vaginalis-mediated effects (both VLY dependent and VLY 
independent) were also influenced by the polarity of exposure, we exposed the apical and 
basolateral sides of the tissue to live bacteria. Samples of media were collected from either side of 
the tissues 16 h after bacterial inoculation, and cytokine concentrations were quantified (Fig. 
9A and Fig. 10A). When the apical side of the tissues was challenged with G. vaginalis, one of the 
cytokines that was induced upon basolateral VLY exposure, RANTES, was actually suppressed 
14.8-fold (Fig. 9B). Additional cytokines that were significantly downregulated include vascular 
endothelial growth factor (VEGF) (<2-fold), IL-6 (<2-fold), IL-9 (2.5-fold), macrophage 
inflammatory protein 1b (MIP-1b) (3.1-fold), IL-8 (3.3-fold), and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (6.6-fold). IP-10 showed a 53-fold decrease in secretion, 
which trended toward significance (P = 0.038; no significant differences with post hoc analysis). 
Significantly upregulated cytokines were interferon gamma (IFN-γ) (<2-fold), PGDF-bb (<2-
fold), MCP-1 (<2-fold), and the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-
1ra), which exhibited a 5-fold increase compared to untreated controls. Basolateral challenge 
with G. vaginalis, similar to VLY, increased the secretion of IL-1β (3.1-fold) (Fig. 10B). 
Additionally, basolateral treatment significantly increased IL-12, eotaxin, and IL-1ra (5.1-fold) 
secretion and decreased IP-10 secretion 25-fold. The increases in IL-12 and eotaxin secretion were 
less than 2-fold and thus may not be biologically relevant. Thus, cytokine changes that were 
mediated by purified VLY were absent when purified protein or live bacteria were added to the 
apical side of the tissues. Live G. vaginalis bacteria induced IL-1β when exposed to the basolateral 
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face, similar to purified VLY. Live bacteria also induced a number of other cytokines in an 







Figure 9. Apical G. vaginalis tissue challenge dampens tissue secretion of proinflammatory cytokines. 
EpiVaginal tissues were treated apically with ∼105 CFU G. vaginalis/mL for 16 h. Samples of spent media were then 
analyzed by a multiplex cytokine bead array. (A) Mean cytokine concentrations in picograms per milliliter and 
standard deviations for each mean. (B) Cytokines exhibiting significantly different concentrations between untreated 
tissues and tissues treated apically with G. vaginalis. All cytokines except IP-10 exhibited a normal distribution. All 










Figure 10. Basolateral G. vaginalis tissue challenge elicits a different cytokine secretion profile than with apical 
challenge. EpiVaginal tissues were treated basolaterally with ∼105 CFU G. vaginalis/mL for 16 h. (A) Mean cytokine 
concentrations in picograms per milliliter and standard deviations for each mean. (B) Cytokines exhibiting 
significantly different concentrations between untreated tissues and tissues treated basolaterally with G. vaginalis. All 
cytokines exhibited a normal distribution and equal variance. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (n ≥ 3). Error 







G. vaginalis was first implicated in BV almost 70 years ago164. However, its role in the 
etiology and pathogenesis of BV remain poorly described, due in part to the lack of a good animal 
model and to the physiologic over-simplicity of tissue culture monolayer models. In this study, we 
used an organotypic, stratified, polarized model of the human vaginal epithelium to characterize 
the influence of host tissue on bacterial growth and to further characterize G. vaginalis-mediated 
cytotoxicity and cytokine response. We found striking differences in the interaction between 
bacteria and tissue with respect to apical versus basolateral exposure. We speculated that the 
absence of lactate dehydrogenase release following apical VLY challenge could be due to low 
levels of LDH in apical cells. Within the human vaginal epithelium, cells originate from the 
basolateral side, mature, differentiate, and flatten over time, and as apical epithelial cells slough 
off, the deeper layers become progressively closer to the lumenal face. During this process, cells 
that were once actively replicating, become anucleated, devoid of organelles, and packed with 
glycogen27. With this, we postulated that the more apical layers of cells in the tissues simply lacked 
the LDH to be released upon pore formation. Alternatively, it was possible that VLY was unable 
to form pores on apically distributed cells. To test this, we performed MTT reduction and trypan 
blue exclusion assays on VLY-challenged tissues. The MTT reduction assay is a method to 
quantify the proliferative capacity of a cell165. So, cells still capable of proliferating will reduce the 
yellow MTT to a purple formazan product that stains the cell, while damaged cells or fully 
differentiated, non-proliferative cells will remain unstained. The trypan blue exclusion test 
operates under the premise that the dye cannot cross healthy, intact host plasma membranes, but 
can enter and stain cells in which the membrane has lost its integrity166. From our MTT stained 
tissues, we observed that the more apical layers were indeed reduced in their proliferative capacity, 
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while densely stained basolateral layers were actively proliferating. However, results from 
histological analysis of the trypan blue stained tissues indicate that a lack of VLY-mediated 
permeabilization of the apical cells likely caused the lack of LDH release from apically challenged 
tissues.  Furthermore, our results suggest that this lack of VLY-mediated permeabilization of apical 
cells could be due to decreased levels of surface-expressed CD59 (Fig. 6B). It is unclear, however, 
whether CD59 expression in vivo is also greater on more basolateral cell layers. Differences in 
membrane cholesterol content could also be a contributing factor, but that was not tested in this 
study.  
 
While apical VLY challenge failed to permeabilize cells, apical challenge with G. vaginalis 
yielded some permeabilization of cells, although it was much reduced relative to basolateral G. 
vaginalis challenge. A possible explanation for this could be related to bacterial adhesion to 
epithelial cells. When VLY is added alone, the protein is dependent on abundant CD59 to 
potentiate binding and subsequent pore formation. When viable bacterial cells promote adhesion, 
however, the toxin is delivered directly at the host cell surface. This may reduce the dependence 
on CD59.  As long as sufficient cholesterol is present in the cell membrane, local delivery of VLY 
promotes pore formation and permeabilization, regardless of CD59 abundance.  Alternatively, it 
is conceivable that bacterial interaction with epithelial cells may alter epithelial expression of 
factors to promote pore formation. 
 
We observed a significant difference in bacterial growth when the bacteria were inoculated 
apically vs basolaterally. This is likely due in large part to a gravity-mediated increase in contact 
between the bacteria and host cells when the bacteria are added to the apical side. It may also be 
 86 
due, in part, to the differential distribution of glycogen within the vaginal epithelium, with greater 
concentrations locating to the apical face. Polar distribution of glycogen has been documented in 
EpiVaginal tissues163. Gardnerella strains are capable of catabolizing glycogen and proteomic 
analysis of cervicovaginal secretions from women with G. vaginalis-dominated bacterial 
communities detected G. vaginalis specific glycogen degradation proteins, including an alpha-1,4 
glucan phosphorylase47,85. Thus, it’s possible that G. vaginalis uses the glycogen produced by 
vaginal epithelial cells as a nutrient source. If this glycogen utilization occurs in vivo, it would 
describe yet another mechanism by which G. vaginalis is able to compete with commensal 
lactobacilli species. The high conservation of the vly gene suggests that it plays an important role 
for the bacteria, but this role remains undefined. Our results, which demonstrate that growth is 
greater when the bacteria are on the apical face and that VLY fails to function on the apical face, 
as well as the inability of statin-mediated reduction in cytotoxicity to reduce G. vaginalis growth, 
suggest that VLY-mediated pore formation is not necessary for bacterial growth in co-culture with 
vaginal epithelium. Furthermore, it has been hypothesized that VLY and its dependence on human 
CD59 contribute to the species selectivity of the pathogen. If VLY were important for growth on 
the vaginal epithelium, then, it would be expected that this would only occur in human or 
humanized tissues. However, this is not the case, as both G. vaginalis growth and cytotoxicity are 
observed in a porcine model of the vaginal epithelium. It is conceivable that VLY may still 
promote nutrient acquisition in the more competitive in vivo environment and that these nutrients 
come from a source other than the vaginal epithelium (erythrocytes, for example). Another 
possible role is that VLY is required to protect G. vaginalis from host innate immunity by killing 
neutrophils or other cellular host immune components. Without further study, we cannot rule out 
the possibility that VLY exerts effects on apical cells that are unrelated to cell permeabilization.   
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Another major finding of the study was that G. vaginalis elicits differential cytokine 
secretion profiles on the apical and basolateral faces of vaginal tissue. Apical administration of G. 
vaginalis significantly enhanced the secretion of IFN-g, MCP-1, IL-1ra and PDGF-bb and resulted 
in decreased secretion of VEGF, IL-6, IL-8, IL-9, GM-CSF, IP-10, MIP-1b, and RANTES. 
Basolateral tissue inoculation with G. vaginalis, on the other hand, increased the secretion of IL-
1β, IL-12, eotaxin, and IL-1ra but decreased the secretion of only IP-10.  This is the first time 
many of these cytokines have been detected in response to G. vaginalis. A study of monospecies 
co-cultures on epithelial monolayers did detect significant differences in PGDF-bb and IP-10 
secretion, but the levels of PGDF-bb were much smaller compared to this study and IP-10 
increased rather than decreased167.  These discrepancies could be due to a lack of cell polarization 
or stratification and a lack of bacterial growth in the monolayer system. The results from a three 
dimensional tissue model of G. vaginalis infection are in agreement with this study in that no 
significant increase in TNF-a, IL-6, or IL-8 were detected162. These data partly reflect in vivo 
cytokines profiles in BV positive women. In a study of 430 sexually active African women, a BV 
positive status was associated with increased levels of IL-1a, IL-1β, IL-6, IL-12, and IL-8 and 
decreased levels of IP-10 in cervicovaginal lavage samples168. Vaginal lavage samples from 
pregnant women colonized with BV-associated bacteria exhibited increased levels of IL-1β and 
IL-1ra compared to un-colonized women169. Moreover, several other studies have detected an 
increase in IL-1β in BV positive women170–172. IL-1β is the most consistent cytokine marker of 
BV.  Its secretion has been observed in response to other BV-associated pathogens, including 
Atopobium vaginae and Prevotella bivia, where bacterial infection in a 3-D vaginal epithelial cell 
aggregate model showed that these bacteria induced a 4-fold increase in IL-1β secretion, similar 
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to what was detected from G. vaginalis in this study173. Together, these data suggest that G. 
vaginalis could contribute, at least in part, to the immunopathology of BV. Other cytokines 
detected in vivo but not in these studies could potentially be attributed to the other species 
associated with BV. 
 
Interestingly, apically administered G. vaginalis significantly reduced the secretion of 
several pro-inflammatory cytokines (GM-CSF, IP-10, MIP-1b, IL-8, and RANTES) and increased 
the secretion of the anti-inflammatory cytokine IL-1ra. The cytokines suppressed by G. vaginalis 
normally act to recruit, mature, and activate a variety of immune cell types, including neutrophils, 
dendritic cells, macrophages, NK cells, and T-cells174–176. The suppression of these cytokines may 
explain why BV positive women do not exhibit neutrophil influx into the vaginal lumen. In 
addition, although the T-cell response during BV has not been thoroughly investigated, the high 
rate of recurrence suggests that adaptive immunity may be impaired. The suppression of IP-10 and 
RANTES indicate that T-cell recruitment could be diminished by G. vaginalis in vivo and the 
reduction of GM-CSF may interfere with dendritic cell maturation to promote a tolerogenic rather 
than immunogenic response to G. vaginalis177–180. Moreover, despite the increase in IL-1β elicited 
by G. vaginalis, which is important for an effective host response to several bacterial pathogens, 
the increased secretion of IL-1ra may act to inhibit this otherwise proinflammatory response to 
promote bacterial survival and persistence in the host181,182. This is the first study to detect this 
immunosuppressive capacity of G. vaginalis on epithelial cells and has implications for the role of 
G. vaginalis in BV pathogenesis. Perhaps through its immunosuppressive effects on the vaginal 
epithelium, G. vaginalis may support the incorporation of other BV-associated species that may 
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otherwise be detected and eliminated by the host immune system. Further experimentation is 
needed to directly test this hypothesis. 
 
This is the first study investigating the impact of tissue polarity on VLY cytolytic activity. 
Other studies investigating VLY-mediated cytotoxicity or pore formation have utilized monolayer 
systems, non-adherent erythrocytes and polymorphonuclear leukocytes, or cholesterol rich 
liposomes112,113,116,117,120,121. These studies were useful for establishing the cholesterol dependence 
of VLY pore formation and for characterizing the role of CD59 in this process, however, these 
systems lack the structural and functional complexity the toxin is likely to encounter in vivo. This 
study revealed a greater abundance of CD59 on basolateral cells, which may explain, at least in 
part, the greater sensitivity of these cells to VLY. Basolateral and apical epithelial cells could also 
differ in abundance and/or distribution of cholesterol on the surface. The selectivity is somewhat 
surprising, because VLY would be expected to encounter the apical (lumenal) side of the vaginal 
epithelium in vivo. One possibility is that this preference minimizes damage and immune 
activation, allowing for a commensal state to develop and that VLY-mediated damage only occurs 
when there is a breach of the vaginal epithelium, allowing the toxin to reach the basolateral cells. 
Microtrauma induced by sexual intercourse or by other, more invasive bacterial species could 
cause a breach in the epithelium, possibly explaining, in part, the association between sexual 
intercourse and BV onset183–186. Alternatively, VLY may not actually target epithelial cells, but 
rather immune cells, in an effort to thwart immune defenses. Further studies are needed to 
determine the basis for the polar selectivity of the toxin and the physiologic implications. 
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The use of an organotypic model of the vaginal epithelium in this study has enhanced our 
knowledge about host-pathogen interactions that may be relevant to BV pathogenesis in vivo. 
However, we note a few limitations. The EpiVaginal tissues used in this study did not contain 
immune cells such as dendritic cells. Thus, the immune response was that of epithelial cells alone. 
This is both a strength, because we know the cell type from which the cytokines derived, and a 
limitation, because the absence of immune cells does not accurately reflect the complexity of the 
host. Next, these tissue experiments were performed at a pH of 7.2. While this is higher than the 
physiological pH (<4.5) of a healthy vaginal environment, it is also more characteristic of a G. 
vaginalis dominated environment.  Since pH could potentially alter bacterial growth and VLY 
activity11,113,187,  future experiments using these tissues to investigate BV pathogenesis should take 
this into consideration. Finally, G. vaginalis strains can exhibit significant heterogeneity both in 
the virulence factors they express and the degree to which they express them85,101,157. It would have 
been more ideal to investigate the host response to multiple strains to see if our findings are broadly 
applicable to G. vaginalis. Future studies may be aimed at determining the relevance of G. 
vaginalis access to the basolateral face in BV pathogenesis and well as identifying the host and 
bacterial factors that drive the differential apical vs basolateral response to G. vaginalis and VLY. 
It would also be interesting to investigate biofilm formation and multispecies interactions using 

















Species of the genus Gardnerella, formerly grouped together as Gardnerella vaginalis, have 
been considered important etiologic agents in bacterial vaginosis (BV) since its characterization 
in the late 1950s164. However, the specific role(s) of the pathogen and its putative virulence factors 
have been difficult to establish due to the genetic intractability of the organism. Vaginolysin 
(VLY), produced by Gardnerella spp.,  is one such virulence factor suspected to play an important 
role in Gardnerella  colonization and survival within the vaginal mucosa112,116. Like other 
cholesterol dependent cytolysins (CDCs), VLY requires adequate membrane cholesterol levels for 
oligomerization and subsequent pore formation116,121. However, it also exhibits a requirement for 
the human complement receptor, CD59, in that the amount of toxin needed to elicit the same 
amount of cytotoxicity on cells lacking human CD59 is increased by 1000-fold121. Several reports 
indicate that VLY is toxic to a variety of cell types, including erythrocytes, epithelial cells, and 
neutrophils112,113,116. Interestingly, however, we recently reported that the apical face of a polarized 
model of the human vaginal epithelium is resistant to VLY, and our data suggested that this was 
due to the reduced expression of CD59 on that side188. This finding contradicts in vivo evidence 
that suggests that Gardnerella spp. and VLY are pro-inflammatory and contribute to vaginal tissue 
damage during BV94,99,115,158,189. Multiple reports have suggested that both commensal and BV-
associated strains of Gardnerella exist and a recent study using high-resolution bioinformatics to 
enable taxonomic assignment to the subspecies level found that the previous association between 
the Gardnerella genus and preterm birth was attributable to a singular subspecies clade83–85,190,191. 
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Therefore, to reconcile the contradiction between in vivo data and our in vitro findings, we 
hypothesized that species-specific variations in the VLY amino acid sequence may be one factor 
that distinguishes avirulent, commensal strains from more virulent BV-associated strains and 
sought to characterize VLY differences among Gardnerella strains. 
 
Previous efforts to characterize putative Gardnerella virulence determinants focused on 
identifying factors that may be differentially distributed among the distinct Gardnerella clades or 
differentially expressed in BV isolates of Gardnerella relative to isolates from asymptomatic 
women190. These studies showed that in vitro expression and secretion of VLY is variable among 
strains. Specifically, one report found that BV strains expressed two-fold greater vly compared to 
non-BV strains157. Another study found significant differences in the level of VLY secreted from 
Gardnerella clinical isolates101. However, no significant difference in VLY production was 
observed when comparing pairs of different Gardnerella clades133. Beyond these comparisons, 
studies have noted the high VLY amino acid identity shared between small samples of Gardnerella 
strains (90-99%), but there has yet to be a more comprehensive analysis of the level of VLY 
conservation among the now 84 publicly available Gardnerella genomes82,101. Furthermore, VLY 
comparisons between the recently proposed 13 distinct Gardnerella species have yet to be made135. 
Thus, while previous studies focused on differences in vaginolysin regulation between clades and 
BV vs non-BV isolates, we questioned whether VLY amino acid differences between the newly 
proposed species could have functional consequences and possibly distinguish pathogenic vs non-
pathogenic species of Gardnerella. To do this, we first sought to bioinformatically analyze VLY 
amino acid conservation within the publicly available Gardnerella genome sequences. After 
identifying conserved differences that could distinguish distinct VLY types, we tested whether a 
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selection of these types differentially interacted with vaginal epithelial cells, focusing on 
cytotoxicity and cytokine production. Finally, using metagenomic data from a cohort of women 
from the Vaginal Human Microbiome Project, we investigated whether these different VLY types 
exhibited any significant associations with patient symptoms or in vivo Gardnerella abundance5. 
Our findings suggest that amino acid differences alter VLY interactions with vaginal keratinocytes, 
which may potentiate differences in BV immunopathology in vivo. These differences may 
determine whether or not a productive immune response is mounted and may explain why some 




Conserved amino acid differences distinguish five vaginolysin types 
 
Whole sequence alignment of 84 publicly available VLY sequences showed that the 
percent identity between any two pair of sequences ranged from 90.48-100.0%. The average 
percent identity for all strains was 96.97%. With this alignment, we noticed that domain 4, 
containing the undecapeptide, CD59, and loop regions conserved in CDCs, was particularly 
enriched in conserved amino acid substitutions. When we re-aligned the sequences using only the 
undecapeptide and CD59 regions, five distinct vaginolysin types were apparent (Figs. 11 and 12). 
These types were first distinguished by the sequences comprising the CD59 region, and then 
further sub-grouped based on sequence differences in the undecapeptide region. Type 1 VLY 
contained aspartate and serine in positions 4 and 6 of the CD59 region, respectively. Type 1A was 
characterized by valine at positions -1 and 6 of the undecapeptide region while type 1B had valine 
and alanine and type 1C had glutamine and valine at these positions. The CD59 region of type 2 
VLY contained asparagine and threonine at positions 4 and 6. The undecapeptide region of this 
type was characterized by glutamate at position -1 and valine at position 6. As there was no 
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variability in this region, type 2 was not further sub-classified. Finally, type 3 VLY was 
characterized by asparagine and serine within the CD59 region and valine and leucine at positions 
within the undecapeptide region. Types 1A and 1B appeared to be the most common types among 
the available sequences with 45.2% and 32.1% of analyzed strains classified as these VLY types, 
respectively. The other types were more rare; 17 of 84 strains were classified as Type 2 VLY while 
types 1C and 3 had only a single representative among all of the available strains. In sum, this 
survey of VLY amino acid sequences from Gardnerella spp. isolates reveals heterogeneity within 
the regions of the toxin known to interact with host cells.  Vaginolysin types were delineated based 







Figure 11. Alignment of VLY undecapeptide and CD59 regions reveals distinct VLY types. This alignment was 
generated using the undecapeptide and CD59 regions of VLY amino acid sequences extracted from 84 Gardnerella 
spp. genome sequences available on NCBI. Amino acids shaded in grey are conserved. Colored amino acids are 
divergent.  
41V          VEKTGLAWEPWRTVYDRSD 
55152        VEKTGLAWEPWRTVYDRSD 
1400E        VEKTGLAWEPWRTVYDRSD 
JCP8108      VEKTGLAWEPWRTVYDRSD 
NR010        VEKTGLAWEPWRTVYDRSD 
23_12        VEKTGLAWEPWRTVYDRSD 
UMB0233      VEKTGLAWEPWRTVYDRSD 
315_A        VEKTGLAWEPWRTVYDRSD 
JCP8151B     VEKTGLAWEPWRTVYDRSD 
JCP7719      VEKTGLAWEPWRTVYDRSD 
UMB0830      VEKTGLAWEPWRTVYDRSD 
UMB0032B     VEKTGLAWEPWRTVYDRSD 
UMB0032A     VEKTGLAWEPWRTVYDRSD 
N101         VEKTGLAWEPWRTVYDRSD 
N95          VEKTGLAWEPWRTVYDRSD 
N153         VEKTGLAWEPWRTVYDRSD 
1500E        VEKTGLAWEPWRTVYDRSD 
UMB1686      VEKTGLAWEPWRTVYDRSD 
101          VEKTGLAWEPWRTVYDRSD 
00703Dmash   VEKTGLAWEPWRTVYDRSD 
KA00225      VEKTGLAWEPWRTVYDRSD 
75712        VEKTGLAWEPWRTVYDRSD 
18_4         VEKTGLAWEPWRTVYDRSD 
UMB0061      VEKTGLAWEPWRTVYDRSD 
NR039        VEKTGLAWEPWRTVYDRSD 
PSS_7772B    QEKTGLVWEPWRTVYDRSD 
CMW7778B     VEKTGLLWEPWRTVYNRSD 
 
UGent09.01    EEKTGLVWEPWRTVYNRTD 
409_05       EEKTGLVWEPWRTVYNRTD 
GV37         EEKTGLVWEPWRTVYNRTD 
UMB0170      EEKTGLVWEPWRTVYNRTD 
UMB0264      EEKTGLVWEPWRTVYNRTD 
GS10234      EEKTGLVWEPWRTVYNRTD 
GS9838_1     EEKTGLVWEPWRTVYNRTD 
AMD          EEKTGLVWEPWRTVYNRTD 
6420B        EEKTGLVWEPWRTVYNRTD 
UMB0912      EEKTGLVWEPWRTVYNRTD 
UMB0913      EEKTGLVWEPWRTVYNRTD 
UGent06.41   EEKTGLVWEPWRTVYNRTD 
UGent09.48   EEKTGLVWEPWRTVYNRTD 
43586        EEKTGLVWEPWRTVYNRTD 
UMB0682      EEKTGLVWEPWRTVYNRTD 
UMB1642      EEKTGLVWEPWRTVYNRTD 
N72          EEKTGLVWEPWRTVYNRTD 
00703Bmash   VEKTGLVWEPWRTVYDRSD 
UGent25.49   VEKTGLVWEPWRTVYDRSD 
JCP8017B     VEKTGLVWEPWRTVYDRSD 
JCP8017A     VEKTGLVWEPWRTVYDRSD 
6119V5       VEKTGLVWEPWRTVYDRSD 
N160         VEKTGLVWEPWRTVYDRSD 
GED7275B     VEKTGLVWEPWRTVYDRSD 
NR038        VEKTGLVWEPWRTVYDRSD 
JCP7672      VEKTGLVWEPWRTVYDRSD 
0288E        VEKTGLVWEPWRTVYDRSD 
JCP7276      VEKTGLVWEPWRTVYDRSD 
NR001        VEKTGLVWEPWRTVYDRSD 
00703C2mash   VEKTGLVWEPWRTVYDRSD 
JCP7659      VEKTGLVWEPWRTVYDRSD 
N144         VEKTGLVWEPWRTVYDRSD 
UMB0386      VEKTGLVWEPWRTVYDRSD 
UMB0298      VEKTGLVWEPWRTVYDRSD 
ATCC14019    VEKTGLVWEPWRTVYDRSD 
FDAARGOS_568   VEKTGLVWEPWRTVYDRSD 
UGent09.07   VEKTGLVWEPWRTVYDRSD 
ATCC49145    VEKTGLVWEPWRTVYDRSD 
FDAARGOS_296   VEKTGLVWEPWRTVYDRSD 
3549624      VEKTGLVWEPWRTVYDRSD 
NCTC10287    VEKTGLVWEPWRTVYDRSD 
DSM_4944     VEKTGLVWEPWRTVYDRSD 
14018c       VEKTGLVWEPWRTVYDRSD 
WP023        VEKTGLVWEPWRTVYDRSD 
GH015        VEKTGLVWEPWRTVYDRSD 
DNF01149     VEKTGLVWEPWRTVYDRSD 
UMB0768      VEKTGLVWEPWRTVYDRSD 
UMB0770      VEKTGLVWEPWRTVYDRSD 
UMB0775      VEKTGLVWEPWRTVYDRSD 
14019_MetR   VEKTGLVWEPWRTVYDRSD 
JCM11026     VEKTGLVWEPWRTVYDRSD 
284V         VEKTGLVWEPWRTVYDRSD 
HMP9231      VEKTGLVWEPWRTVYDRSD 
ATCC14018    VEKTGLVWEPWRTVYDRSD 
NR037        VEKTGLAWEPWRTVYDRSD 
JCP8481B     VEKTGLAWEPWRTVYDRSD 




Figure 12. Five VLY types are distinguishable among Gardnerella strains. VLY type classification based on 
undecapeptide and CD59 region sequences of 84 Gardnerella spp. strains. Percent values are the number of strains 





Some VLY types are restricted to select Gardnerella species 
 
Next, to determine whether these different versions of the toxin are restricted to specific 
Gardnerella species, we phylogenetically mapped each available strain using whole genome 
sequences, grouped them into one of the 13 proposed Gardnerella species, and marked the VLY 
type that each strain encoded (Fig. 13)135. Type 1 VLY was found in all species except for species 
5 (G. leopoldii), 6 (G. swidsinskii), 11 and 12. G. leopoldii and G. swidsinskii exclusively harbored 
the type 2 toxin. And, surprisingly, while group 4 had a single representative strain with the type 
1 VLY, the toxin was absent from the remaining 9 strains in this group. A few other strains from 
groups 1-3 were also missing VLY. Thus, it appears that certain vaginolysin types are indeed 





Figure 13. Some VLY types are restricted to select Gardnerella clades and species. Distribution of VLY types 
amongst Gardnerella clades and species. This tree was generated by alignment of Gardnerella strain whole genome 
sequences and then retrieved from NCBI’s Genome Tree report, Rectangle Cladogram layout. Clade and species 
assignments were made based on the schemes reported in Ahmed et. al 2012 and Vaneechoutte et. al 2019, 
respectively129,135.  
 





















































































































































Cytokine secretion profiles of VK2 cells challenged with type 1A and type 2 VLY are similar 
 
While there appeared to be 5 distinct VLY types based on sequence differences, we 
suspected that some differences had greater potential to alter protein function than others. For 
example, the amino acids distinguishing type 1A and 1B toxins are of the same amino acid class 
(nonpolar aliphatic) and we therefore anticipated that they would be phenotypically similar. Type 
2 VLY, on the other hand, is distinguished from type 1 VLY by a change in a polar, uncharged 
asparagine residue in the CD59 region to a negatively charged aspartate residue. It also has a 
negatively charged glutamate residue upstream of the undecapeptide region that is replaced with a 
nonpolar, aliphatic valine in type 1A and type 1B VLY. While type 1C and type 3 toxins exhibited 
sequence differences that could potentially impart functional diversity, their rarity amongst 
available Gardnerella strains prompted us to limit our in vitro analyses to type 1A and type 2 
toxins. We hypothesized that differences in these proteins could result in differential interactions 
with vaginal epithelial cells and focused our analyses on the cytokine response and cytotoxicity. 
To test our hypothesis, we recombinantly produced and purified VLY from strains harboring type 
1A (G. vaginalis ATCC 14018) or type 2 (G. leopoldii AMD) toxins. We verified that endotoxin 
levels in preparations were low and then added equal amounts (1 µg/mL) of either toxin to VK2-
E6E7 cell monolayers, verified by analyzing appropriately diluted toxin preparations by 
denaturing PAGE (Fig. 14).  
 
To assess differences in cytokine production amongst differentially challenged cells, spent 
media samples were collected after 19 hours of co-incubation and concentrations of a panel of 27 
different cytokine were determined. The secretion of several cytokines was similarly altered upon 
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VK2 cell exposure to either VLY type (Fig. 15). The cytokines with potentially biologically 
relevant increases (≥ 2-fold) in secretion upon VLY exposure include IL-2 (3.1-fold), IL-4 (6.6-
fold), IL-5(13-fold), IL-13 (2.9-fold), MIP-1a (2.1-fold), and GM-CSF (5.6-fold). VEGF was the 
only cytokine with reduced concentrations in spent medium following VLY exposure (6.7-fold). 
Conversely, the concentrations of many cytokines were significantly different when VK2 cells 
were challenged with either VLY type (Fig. 16). Although, only two cytokines exhibited 
biologically relevant differences. VK2 cells challenged with type 1A VLY secreted 2.6-fold 
greater IL-1ra but 4.4-fold less IL-8 than cells challenged with type 2 VLY. Thus, both VLY types 
elicit similar cytokine secretion profiles from VK2 cell monolayers, but there are some differences 








Figure 14. VLY concentrations are the same. SDS-PAGE gel showing that the given dilutions of VLY from G. 






Figure 15. VLY types similarly alter the secretion of several cytokines. VK2-E6E7 monolayers were treated with 
<1 μg VLY/mL for 19 h. Samples of spent media from the cells were then analyzed by a multiplex cytokine bead 
array. Mean cytokine concentrations (in picograms per milliliter) exhibiting significantly different concentrations 
between untreated and VLY treated cells are shown. White numbers inside the bars represent the fold change in 
cytokine secretion relative to untreated and empty vector controls.  Error bars represent standard deviations. * = P ≤ 








Figure 16. VLY types stimulate differential secretion of select cytokines. VK2-E6E7 monolayers were treated with 
<1 μg VLY/mL for 19 h. Samples of spent media from the cells were then analyzed by a multiplex cytokine bead 
array. Mean cytokine concentrations (in picograms per milliliter) exhibiting significantly different concentrations 
between type 2 and type 1A VLY are shown. White numbers inside the bars represent the fold increase in cytokine 
secretion relative to the other VLY type. Bars without numbers have fold changes of < 2.  Error bars represent standard 
deviations. * = P ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001 (n ≥ 3). Empty vector control was included to account for any 






Type 1A VLY exhibits greater cytotoxicity on cells with reduced CD59  
 
Next, to quantify differences in cytotoxicity, we similarly added equal concentrations (1 
µg/mL) of either toxin to VK2-E6E7 cell monolayers and stained cells with trypan blue after 30 
minutes of VLY exposure. When toxins were added to cells cultured for 4 days post-seeding, there 
appeared to be no difference in cytotoxicity between the two VLY types (Fig. 18, top). However, 
when the toxins were added to cells cultured for 7-days post-seeding, the difference in cytotoxicity 
was readily apparent (Fig. 17). Type 1A VLY-treated cell monolayers exhibited 90.3% trypan blue 
staining while type 2 VLY-treated cells only exhibited 53.0% (p < 0.0001). We reasoned that, 
similar to senescent cells on the apical side of vaginal epithelial organoids, which were found 
previously to express less CD59188, that senescent VK2 cells might also produce less CD59, 
suggesting that the two VLY types differed in their interactions with CD59, which consequently 
resulted in the observed differences in cytotoxicity. To test this, we treated 4-day cells with anti-
CD59 antibody for one hour prior to VLY challenge and then assessed cytotoxicity with trypan 
blue staining. While anti-CD59 pre-treatment reduced cytotoxicity in both type 1A and type 2 
VLY-challenged cells (Fig. 18), the reduction in cytotoxicity was significantly greater (p = 0.0021) 
in type 2 VLY-challenged cells. These results suggest that type 1A VLY may have a higher affinity 
for CD59 than type 2 VLY, and thus under conditions where CD59 is reduced, type 1A elicits 





Figure 17. Type 1A VLY elicits greater cytotoxicity VK2-E6E7 monolayers were treated with 1 μg VLY/mL 7 days 
post seeding, for 30 minutes. Cells were then rinsed, stained with trypan blue, and imaged. A) Images of trypan blue 
stained cells. B) Percent cytotoxicity. Percent cytotoxicity was determined by dividing the number of blue stained 








Figure 18. Anti-CD59 pre-treatment has a greater impact on type 2 VLY cytotoxicity VK2-E6E7 monolayers (4 
days post seeding) with and without pretreatment (0.2 µg/mL anti-CD59 antibody for one hour) were challenged with 
1 μg VLY/mL, for 30 minutes. Cells were then rinsed, stained with trypan blue, and imaged. A) Images of trypan blue 
stained cells. B) Percent reduction in cytotoxicity. Percent cytotoxicity was determined by dividing the number of 
blue stained cells by the total number of cells. To calculate the percent reduction in cytotoxicity, percent cytotoxicity 
in pretreated cells was subtracted from the percent cytotoxicity in non-pretreated cells. Error bars represent standard 






Cohort 1 study participants are simultaneously colonized by several Gardnerella species 
 
To investigate whether these observed in vitro differences could also potentiate in vivo 
differences, we analyzed metagenomic data from a cohort of 62 BV-positive women from the 
Vaginal Human Microbiome Project (Cohort 1). Because our in vitro data suggest that differences 
in toxin function are potentially attributable to differences in the interaction with CD59, our 
analyses of in vivo data included type 3 VLY, which has a CD59 region distinct from both type 1 
and 2 VLYs. We also grouped type 1A-C together, as their CD59 regions were the same. Since 
each functional vaginolysin type is restricted to select Gardnerella species, we began our analyses 
by investigating the distribution of each Gardnerella species within our cohort, using cpn60 
universal target sequences to resolve distinct species136. Interestingly, we observed that a majority 
of our participants were simultaneously colonized by multiple Gardnerella species (Fig. 19). Most 
women (90.2%) had 3 or more species present at the time of sampling. The average number of 






Figure 19. Cohort 1 participants are simultaneously colonized by multiple Gardnerella spp. cpn60 reads were 
used to distinguish each Gardnerella species and its relative abundance within the total Gardnerella population of 
each sample. Each species is numbered according to the scheme reported in Vaneechoutte et. al 2019, and, where 








Type 1 is the dominant VLY type of Cohort 1 subjects 
  
We next assessed whether the three vaginolysin types were differentially distributed among 
our Cohort 1 participants. To do this, we summed the number of reads of each type across all 
samples and divided by the total number of all vaginolysin type reads from all samples. Type 1 
vaginolysin represented 49.5% of the total vly reads while type 2 represented 39.9% and type 3 
only 10.7% (Fig. 20). In comparing Gardnerella species distribution to vaginolysin distribution, 
there was generally agreement between the species and the vaginolysin type dominating the 
sample. For example, in a sample with 64.8% type 1, 23.5% type 2, and 11.6% type 3 vaginolysin-
producing Gardnerella, 56.4% of the vly reads are from type 1 VLY, 28.3% are from type 2, and 









Figure 20. VLY types exhibit unequal distribution in Cohort 1. Percent of total vly reads for a given VLY type. 






Figure 21. Relative abundance of Gardnerella species and VLY type are concordant in Cohort 1 samples. (Left) 
Percent of the Gardnerella population in a sample belonging to a species known to secrete a given VLY type, 





Vaginal symptom frequency is increased in women with a majority of type 1 VLY  
 
Overall, 67% of Cohort 1 subjects reported at least one vaginal symptom (itching, odor, or 
discharge) (Fig. 22). Using vly read numbers, we next identified the dominant VLY type of each 
sample in Cohort 1 and assessed whether women experiencing symptoms were more frequently 
dominated by a specific type. If a similar number of reads were observed for two or more toxin 
types in a sample, that sample was classified as being dominated by both types. Of the women 
who reported any of the three vaginal symptoms, a greater proportion had type 1 as the dominant 
VLY type in all cases (Fig. 23). While 57.1% and 42.9% of women experiencing vaginal itching 
had type 1 or 3 VLY as the dominant type, respectively, only 14.3% had type 2 as the dominant 
type (p=0.09). Sixty eight percent of women reporting vaginal odor were dominated by type 1 
VLY while only 24.0% were dominated by type 2 and 12.0% dominated by type 3 (p < 0.001). 
And 68.6% of women with vaginal discharge had type 1 as the dominant VLY, with 25.7% 
dominated by type 2 VLY and 14.3% by type 3 (p < 0.001). Thus, there does seem to be an increase 






Figure 22. A majority of Cohort 1 subjects experienced at least 1 vaginal symptom. Percent of subjects reporting 
vaginal symptoms. Subjects reporting “No” for each of itching, odor, or discharge were counted as “No symptoms”. 










Figure 23. Cohort 1 subjects with type 1 VLY more frequently experience vaginal symptoms. Proportion of 
Cohort 1 women experiencing symptoms in each VLY type group. Significant differences in proportions among the 




Cohort 1 subjects in the type 2 VLY group have a significantly increased median relative 
Gardnerella abundance  
 
We then grouped participants by their dominant VLY type and determined whether there 
were differences in bacterial abundance between each group in Cohort 1. CLARKs was used to 
classify taxa from metagenomic reads and to determine the relative abundance of the taxa 
comprising the vaginal community profile in each subject. Participants in the type 1 vaginolysin 
group exhibited a median relative Gardnerella abundance of 24.1%, while those in the type 2 
vaginolysin group exhibited a significantly increased Gardnerella abundance of 62.0% (p=0.0077) 
(Fig. 24). Subjects in the type 3 VLY group exhibited the lowest Gardnerella median relative 
abundance at 12.9% (p=0.03).  Thus, there does seem to be a relationship between VLY type and 







Figure 24.  Cohort 1 subjects with type 2 VLY exhibit increased Gardnerella relative abundance. Median relative 







Type 2 is the dominant VLY type of Cohort 1 subjects 
 
Because of the small sample size in the previous data set, we sought to give more power to 
the observed associations between VLY type, symptoms, and taxa abundance. To do this, we used 
a different, larger data set from the Vaginal Human Microbiome Project that consisted of 733 
healthy and BV-positive women (Cohort 2).  Although this data set did not include metagenomic 
data, we used cpn60 read data to extrapolate the dominant VLY type of each sample. We began 
our analyses by determining whether the three vaginolysin types were similarly distributed among 
our Cohort 2 participants (Fig. 25). In contrast to Cohort 1, Type 1 vaginolysin represented only 
31% of the total reads while type 2 represented 61%, making type 2 the dominant VLY type in 
Cohort 2 subjects. Surprisingly, only one sample in this cohort had any type 3 vly reads and no 
sample in this cohort was dominated by type 3 VLY. However, 2.8% of women were colonized 
only by Gardnerella strains lacking the vly gene and VLY-null Gardnerella made up 8% of the 






Figure 25. VLY types exhibit unequal distribution in Cohort 2. Percent of total vly reads for a given VLY type. 





Vaginal symptom frequency is similar in Cohort 2 women, regardless of VLY type or BV status 
 
The overall symptom frequency in Cohort 2 was 35%, understandably less than Cohort 1 
considering that Cohort 2 includes BV-positive and healthy women (Fig. 26). When only looking 
at BV-positive samples, symptom frequency increases to 53%, which is still less than the 67% 
frequency observed in Cohort 1 (Fig. 26). Analysis of symptom frequency among women 
dominated by each VLY type revealed no significant differences (Fig. 27). We next assessed 
whether there was any significant association between VLY type abundance (number of reads) 
and symptom frequency using logistic regression. No significant association was observed for any 
VLY type. We then questioned whether our previous findings may be limited to BV positive 
women, as Cohort 1 consisted only of BV positive women. However, even after excluding healthy 
women from our analyses, we still did not detect any significant association between VLY type 
and symptoms, either by looking at symptom frequency or by logistic regression, suggesting that 
the finding in Cohort 1 could have been a false discovery due to the smaller sample size and lower 









Figure 26. A majority of BV-positive Cohort 2 subjects experienced at least 1 vaginal symptom. Percent of 
subjects reporting vaginal symptoms. Subjects reporting “No” for each of itching, odor, or discharge were counted as 
“No symptoms”. Subjects with “NA” or “NS” were not counted. “Symptoms” represents the percent of subjects 








Figure 27. Symptom frequency is similar in Cohort 2 subjects, irrespective of VLY type. A) Proportion of Cohort 
2 women experiencing symptoms in each VLY type group. Significant differences in proportions among the three 





Figure 28. Symptom frequency is similar in BV-positive Cohort 2 subjects, irrespective of VLY type. A) 
Proportion of BV-positive Cohort 2 women experiencing symptoms in each VLY type group. Significant differences 





BV-positive Cohort 2 subjects in the type 2 VLY group have a significantly increased median 
relative Gardnerella abundance  
 
Finally, we used 16S read data alongside the cpn60 read data to determine if the abundance 
of any vaginally relevant taxa increased or decreased depending on VLY type. Using the entire 
762 sample data set, we identified only one significant difference in taxa abundance by VLY type. 
Lactobacillus iners abundance was significant increased in women dominated by type 1 VLY 
compared to women dominated by type 2 VLY (p= 0.0060) (Fig. 29A). There was no significant 
difference in Gardnerella relative abundance between the two VLY types (Fig. 29B). However, 
when we excluded healthy women from the analysis, relative Gardnerella abundance was 
increased by roughly two-fold in women dominated by type 2 VLY, similar to what we observed 
in Cohort 1 (Fig. 30) (p = 0.0002). In sum, the increased relative Gardnerella abundance observed 
in type 2 VLY dominant, BV-positive Cohort 1 subjects was also observed in type 2 VLY 







Figure 29. Cohort 2 subjects with type 1 VLY exhibit increased L. iners relative abundance. Median relative 







Figure 30. BV-positive Cohort 2 subjects with type 2 VLY exhibit increased Gardnerella relative abundance. 
Median relative abundance in each VLY type group in BV-positive Cohort 2 subjects. “x” marks the mean relative 






In this study, we compared VLY amino acid sequences across the 84 publicly available 
Gardnerella genome sequences. Through comparisons focusing on the conserved undecapeptide 
and CD59 regions, we were able to distinguish 5 distinct VLY types that were differentially 
distributed among the 13 recognized Gardnerella species. While types 1A-C were found in 
Vaneechoutte et. al species groups 1-3, 7-10, and 13, VLY type 2 was only found in species groups 
5 and 6. These distributions are consistent with a 2012 study that performed a comparative analysis 
of 17 Gardnerella isolates129.  The analysis of VLY amino acid sequences of these 17 isolates 
provided evidence that VLY from clades 1 (species groups 1 and 2), 2 (species group 3), and 3 
(species groups 8-10) engaged in recombination between clades while clade 4 (species groups 5 
and 6) retained a unique identity. Our study builds upon this by introducing VLY type 3 as an 
additional candidate VLY with a unique identity. It was only identified in a single strain 
representing species group 12, which does not fall into one of the four previously described clades. 
Inspection of the undecapeptide and CD59 regions indicate characteristics of both type 1 and type 
2 VLYs. While only ~1% of the publicly available strains we analyzed make this version of the 
toxin, 15% of women from Cohort 1 had at least 25% of Gardnerella reads coming from this 
species group. Interestingly, all of these samples exhibited less than 20% relative Gardnerella 
abundance. Thus, this VLY type warrants more investigation and should be isolated and 
functionally compared to the other two predominant VLY types. 
 
Alignment of Gardnerella strains based on whole genome sequences and subsequent 
mapping of species group and VLY type revealed that ~22% of analyzed strains were devoid of 
vly. While the existence of Gardnerella strains lacking the vaginolysin gene have been noted 
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previously, we noticed that species group 4 was particularly enriched in vly deficient strains and 
that species group 11, represented by a single strain, was also vly deficient133,157,192. When we 
looked at samples containing a large percentage (at least 25%) of either of these two species groups 
among the total Gardnerella population, we observed a wide range (9.5-65%) of relative 
Gardnerella abundance within the total bacterial population of each sample. We also noticed that 
out of all 62 samples of Cohort 1, only one woman was colonized by a single Gardnerella species 
group. All other samples contained more than one species, to suggest that the lack of VLY 
production from some species can likely be compensated by another, co-colonizing, VLY-
producing species. Therefore, although several vly null strains of Gardnerella exist and are 
abundant during BV, this in itself is not suggestive of the inessentiality of the putative virulence 
factor. Furthermore, what is interesting to consider, in light of this finding that multiple 
Gardnerella species coexist in a single host, is the interdependence that may be at play so that 
infection with multiple, distinct species is the norm. Future research should be directed at defining 
the contributions that disparate Gardnerella species make to promote community success within 
the vaginal mucosa.  
 
To determine whether these observed sequence differences could alter VLY protein 
function, we performed in vitro assays using recombinantly produced toxins of the two most 
common divergent VLY types, type 1A and type 2.  Vaginal epithelial cell monolayers were more 
greatly damaged by the type 1A VLY, but only when CD59 levels were reduced. These results 
were suggestive of an increased affinity for CD59 in type 1A VLY relative to type 2 VLY. Our 
findings contradict a 2012 study that compared the hemolytic activity of five Gardnerella strains 
with divergent VLY sequences101. This study found that the diversity of the VLY sequences did 
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not affect the hemolytic activity of VLY. However, as our findings suggest, differences in 
cytotoxicity would only be expected where surface expression of CD59 is limited. CD59 is 
abundant on erythrocyte and leukocyte membranes and may be significantly increased in these 
cells relative to vaginal epithelial cells, considering the large difference in the concentration of 
VLY toxin necessary for cell lysis193.  Our experiments with 4- and 7-day vaginal keratinocyte 
monolayers may suggest that CD59 decreases with the age of vaginal epithelial cells, which is in 
agreement with the fact that the peripheral cells on vaginal epithelia are senescent. This suggests 
that in vivo, superficial epithelial cells that are exposed to VLY may be somewhat resistant to its 
effects, and even more so to the type 2 version of the toxin. 
 
The cytokines altered in response to either toxin under the same reduced CD59 conditions 
were, for the most part, similar. There were some significant differences in cytokine quantities 
between differentially challenged cells, likely due to differences in the amount of cell death 
induced by either toxin (i.e. more death from type 1A challenged cells, resulting in reduced 
cytokine secretion). We recently reported that in a stratified, polarized model of the human vaginal 
epithelium, VLY type 2 cytotoxicity was limited to the basolateral side. Apical (lumenal) cells 
were resistant (impermeable) to the toxin188. These apical cells also exhibited reduced surface 
expression of CD59 relative to basolateral cells. With this, we hypothesized that the observed 
differences in cytotoxicity between type 1A and type 2 toxins could potentiate important 
differences in the interaction with the host epithelium in vivo. Specifically, type 1A, with a putative 
increased affinity for CD59, would be more damaging to the lumenal (apical) side of the vaginal 
mucosa which Gardnerella spp. directly interact with in vivo. Because of the reduced CD59 
expression on this side, type 2 VLY would elicit much less damage, if any. As a consequence, type 
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1A VLY may induce a pro-inflammatory response manifesting in overall tissue inflammation and 
related host symptoms (itching, odor, or discharge) whereas type 2 VLY may effectively promote 
immune evasion. Essentially, we would expect women colonized by Gardnerella spp. producing 
type 1 toxin to more frequently report symptoms and women colonized by type 2 producing 
Gardnerella to exhibit increased Gardnerella abundance. 
 
We first investigated this hypothesis using a cohort of BV-positive women from the 
Vaginal Human Microbiome project for which metagenomic data was available (Cohort 1). A 
majority of samples were simultaneously colonized by multiple Gardnerella species, and thereby 
contained multiple VLY types. However, based on vly read data, we were able to determine the 
“dominant” VLY type for each sample. When we looked at women experiencing any of the 3 
reported symptoms, these women more frequently had type 1 as the dominant VLY type compared 
to types 2 and 3. We then grouped the samples by dominant VLY type and looked at the relative 
abundance of various taxa. Relative Gardnerella abundance was greatest in women with type 2 
VLY as the dominant VLY type, with a median abundance 2 to 4-fold greater compared to women 
with type 1 or 3 as the dominant VLY type. While the data from this cohort of women supported 
our hypothesis, we wanted to see if our findings would replicate in a larger data set that included 
healthy women in addition to BV-positive women. Because data from the small cohort indicated 
that cpn60 and vly read data were in agreement, even though we didn’t have metagenomic data for 
the larger data set, we extrapolated vly abundance from cpn60 read data. This was achieved by 
using the custom cpn60 database made for this study. Since cpn60 sequences are able to classify 
Gardnerella at the strain level, and each strain produces a specific VLY type, each cpn60 read was 
assigned to a specific VLY type. When we analyzed the data set as a whole for differences in 
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symptom frequency and taxa abundance, our initial findings did not replicate. However, when we 
analyzed only BV-positive women, we again saw that women with type 2 VLY as the dominant 
toxin type exhibited a relative Gardnerella abundance 2-fold greater than women with type 1 VLY. 
There was still no difference in symptom frequency. We considered whether the differences in the 
findings between the two data sets could be due to differences in the study populations. While a 
more thorough comparison of the cohorts is warranted, one readily apparent difference was that 
type 1 was the dominant VLY type in Cohort 1, while type 2 was the dominant type in Cohort 2. 
Perhaps not unrelated, Cohort 1 subjects exhibited an increase in the overall frequency of 
symptoms relative to BV-positive Cohort 2 subjects (67% vs 53%). In addition, we found that BV-
positive Cohort 2 subjects were characterized by a significantly increased L. crispatus relative 
abundance (data not shown). This is interesting considering that a recent study observed that L. 
crispatus was able to repress vly expression194. Thus, even though type 1 VLY-producing bacteria 
are there, there may be reduced vly expression in the larger data set due to increased L. crispatus. 
Despite these discrepancies and their causes, however, our findings suggest that the differences in 
VLY phenotype may only be relevant during BV.  
 
Results from both our in vitro and in vivo data are reminiscent of the findings from studies 
investigating the recently discovered candidalysin (CLY) toxin produced by the mucosal 
opportunistic pathogen, Candida albicans. Discovered in 2010, this toxin has been shown to elicit 
cell death through pore formation, activate innate epithelial immune responses, and promote the 
release of alarmins and antimicrobial peptides from epithelial cells195–197. In multiple mucosal 
infection models, it is critical for infection, as mutant strains lacking the toxin were avirulent198. 
Specifically within the vaginal mucosa, it was found to drive epithelial cell signaling, the 
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recruitment of neutrophils, and ultimately the immunopathology characteristic of vaginal 
candidiasis199.  
 
Of particular interest is the finding that different C. albicans strains elicited differing levels 
of LDH release from epithelial tissue, and this difference was accompanied by differing levels of 
neutrophil recruitment, tissue inflammation, host symptoms (weight loss), and either persistence 
or clearance of the pathogen in a murine oral infection model200. Strains of C. albicans that were 
more cytotoxic towards the epithelial tissue elicited greater neutrophil infiltration into the tissue, 
an increased pro-inflammatory response, increased weight loss, and reduced fungal burden. Less 
cytotoxic strains, on the other hand, elicited low levels of inflammation, little, if any, neutrophil 
recruitment, significantly less weight loss, and increased fungal burden. For comparison, while all 
strains were inoculated with ~ 106 C. albicans cells, high-cytotoxicity strains were reduced to 102 
cells per gram of tissue by day 3 post-infection whereas low-cytotoxicity strains were maintained 
at 106 cells per gram of tissues at least up to 7 days and at lower but detectable concentrations up 
to 4 weeks post infection. The authors of this study hypothesized that CLY played a role in these 
observed strain differences, as it is the only described LDH-inducing toxin produced by C. 
albicans. However, while strains did differ in toxin gene expression, they did not correlate with 
the degree of LDH release. Strain differences in the toxin sequence (nucleotide or amino acid) 
were not investigated.  
 
Although the polymicrobial nature of BV and the simultaneous presence of multiple 
Gardnerella strains and VLY types in vivo likely contribute to a more complex dynamic than that 
transpiring during a C. albicans infection, it is interesting to consider whether something similar 
 132 
may be occurring with the different VLY-type secreting strains of Gardnerella. Regarding our 
initial question of whether VLY type could distinguish commensal and pathogenic strains of 
Gardnerella, our data suggest that the answer is no. This is because the differences in symptom 
frequency and abundance were only observed in BV-positive women. It is possible that VLY type 
is irrelevant in healthy women because Gardnerella and therefore VLY is maintained at a low 
concentrations by the beneficial lactobacilli. However, under conditions promoting Gardnerella 
proliferation (i.e. BV), increased VLY concentrations could lead to damage of host cells, 
depending on the VLY type. Thus, we postulate that VLY type may impact BV immunopathology, 
which could potentially impact BV persistence or recurrence or influence the likelihood of adverse 
sequelae.  Type 1 VLY, by inducing damage to the epithelium, could drive an immune response 
that ultimately leads to its removal, but also results in tissue damage that increases the likelihood 
of adverse sequelae. Type 2 VLY, on the other hand, may promote bacterial persistence in the 
absence of damage. These interactions may be influenced by other host and bacterial factors at 
play. For example, hosts with greater basolateral epithelial cell exposure, due to increased 
superficial cell shedding, may elicit an immune response to type 2 VLY, as these proliferating 
cells are sensitive to both type 1 and type 2 VLY. Gardnerella strains producing sialidase may 
persist despite the induction of an immune response, as there is evidence to suggest that this 
enzyme cleaves host IgA produced in response to Gardnerella. Furthermore, the presence and 
abundance of other BV-associated organisms and their virulence factors could influence the 
immune response, bacterial persistence, and likelihood of adverse outcomes.  
 
To build upon this work and to continue to test the hypothesis that different VLY types affect 
BV immunopathology, there are several remaining questions to address. First, our in vitro data 
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suggest that VLY types differ in their interactions with CD59 on epithelial cells. While we think 
this is driven by differences in affinities for the surface receptor, affinity was not directly measured. 
Surface plasmon resonance should be employed to quantify the affinity of each VLY type for 
CD59. Additionally, cholesterol-dependent pore forming toxins are ubiquitously produced by a 
wide variety of organisms. These toxins exhibit differences in the cholesterol concentration 
required for pore formation and oligomerization as well as different pH optima. For example, a 
study comparing inerolysin (INY) produced by L. iners and VLY (type 1A) found that INY can 
bind cells with lower membrane cholesterol content and has an acidic pH optimum123. VLY, on 
the other hand, requires more than double the cholesterol content and exhibits a neutral pH 
optimum. The other VLY types should be similarly studied to see if they exhibit any differences 
other than affinity for CD59. Next, EpiVaginal tissues should be used to investigate whether 
different VLY types promote the release of various alarmins and cytokines and subsequent 
neutrophil recruitment. While in this work we quantified cytokine production from VLY treated 
VK2 cell monolayers, these cells are phenotypically more similar to the basolateral cells of 
EpiVaginal tissue. Our previous study of type 2 VLY on these tissues revealed that the cytokine 
response of apically challenged cells to VLY is distinct from the response of basolateral cells. 
Furthermore, type 2 VLY did not elicit any pro-inflammatory cytokine production from the apical 
side. We predict that EpiVaginal tissues challenged apically with type 1 VLY would secrete pro-
inflammatory cytokines and alarmins, which would signal to recruit neutrophils inoculated into 
the medium underlying the basolateral cell layer into the exudate overlaying the apical cells. 
Finally, in vivo studies quantifying protective antibody production, adverse outcomes, and BV 
resolution and recurrence in women with different dominant VLY types will be essential for 
resolving the role of VLY in BV immunopathology. Previous studies of anti-VLY antibody 
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production during BV found that more than half of women make anti-VLY during BV which was 
protective against adverse pregnancy outcomes. We anticipate that women with type 1 VLY as the 
dominant type will have greater anti-VLY production, but that the protective effects may depend 
also on the production of sialidase, which is hypothesized to cleave anti-VLY IgA. As various 
stimuli can regulate the expression and secretion of virulence determinants in vivo, it would also 
be worthwhile to more directly quantify vly expression and protein concentrations to more 













Characterization of a putative phase-variable opacity phenotype conserved 




Bacteria produce a variety of external appendages that allow them to interact with their 
environment, including proteinaceous polymeric structures called pili201. These surface organelles 
are assembled via multiprotein complexes localized to bacterial membranes and facilitate adhesion 
to surfaces, some forms of motility, and DNA uptake, among other functions202,203. For many 
urogenital pathogens, pilus production is associated with virulence, as these pili-dependent 
functions promote survival and adaptation in the host. For example, uropathogenic strains of 
Escherichia coli (UPEC), the etiological agent in a large percentage of urinary tract infections 
(UTI), use pili to adhere to urinary tract epithelial cells and to invade bladder epithelial cells204,205. 
In Neisseria gonorrhoeae, the causative agent of the sexually transmitted infection, gonorrhea, pili 
appear to have numerous functions. Pilus-producing variants are able to attach to human epithelial 
cells and resist phagocytosis by neutrophils206. In addition, mutants deficient in pilus production 
are impaired in twitching motility and natural transformation207. Furthermore,  pili produced by 
Gram-positive Group B streptococcus (GBS) facilitate attachment and invasion of cervical 
epithelial cells and reduce internalization and killing by macrophages208,209. Thus, pili are virulence 
determinants commonly used by diverse urogenital pathogens and aid in colonization of host 
tissue, dissemination, and evasion of the immune response.  
 
Various classes of pili can be distinguished based on the pathway used for assembly. For 
example, type IV is a ubiquitous class of pili characterized by the dynamic nature of its assembly, 
wherein pilin subunits cyclically polymerize and depolymerize to promote both extension and 
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retraction of the pilus210,211. Type IV pili can be further subdivided into type IVa and type IVb, 
based on the length and amino acid composition of the pilin subunit. Type IVb pilins are typically 
longer and more heterogeneous compared to type IVa pilins212. Tight adhesion (Tad) pili are 
representatives of the type IVb class and are found in both Gram-negative and Gram-positive 
bacteria as well as Archea213,214. Tad loci encode major (flp) and minor (tadE) pilin subunits, 
integral membrane proteins that form the secretion apparatus for the pilin subunits (tadB and tadC), 
an ATPase that energizes the transfer of pilin subunits from the cell interior (tadA), a prepilin 
peptidase that processes pilin subunits prior to integration into the pilus (tadV), and a factor thought 
to direct localization of the Tad machinery to the cell poles (tadZ)213,215–218. In the Tad loci of 
Gram-negative bacteria, genes that facilitate outer membrane secretion (rcpA, rcpB, and rcpC) are 
also included219,220. Autoaggregation, biofilm formation, surface colonization, and natural 
competence are some of the functions ascribed to Tad pili in various organisms213,221–224.  
 
While the ability to perform these pilus-dependent functions certainly benefits 
microorganisms, the pilus can be targeted by adaptive immune defenses, which may give non-
piliated bacteria an advantage. Additionally, under certain conditions, it may be advantageous for 
bacteria to move from one site to another, and non-piliated bacteria may be better equipped to exit 
the community. Consequently, bacteria employ various mechanisms to regulate the production of 
their pili.  By one such mechanism, called phase variation, bacteria reversibly switch the 
production of a certain factor “ON” or “OFF225.” There are several ways to achieve this, but two 
of the most common mechanisms involve slipped strand mispairing and site-specific inversion. In 
slip strand mispairing, paired DNA segments are separated during DNA repair or replication, and 
upon subsequent re-annealing, mispair with a segment upstream or downstream of the correct 
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pairing location. This is facilitated by short repetitive sequences, either homo- or hetero-polymeric 
tracts of nucleotides, within or upstream of a gene, ultimately altering the reading frame and 
leading to altered transcription or translation of a gene or locus.  Alternatively, site-specific 
inversion is facilitated by a pair of short, often imperfect, inverted repeats that flank a region of 
DNA to be inverted. Inversion typically requires a specific recombinase and, depending on the 
orientation, can promote or inhibit transcription by altering the location of promoters or other 
important regulatory elements. Phase variation of pili is a common strategy used by both urogenital 
and non-urogenital pathogens, including UPEC, Proteus mirabilis, Bordetella pertussis, 
Salmonella typhimurium, and Haemophilus influenzae226–230. Variance in colony morphology is 
often an indicator of a phase variable phenotype and has been used to distinguish pilus-producing 
and pilus-deficient strains in a variety of bacterial species231–233. This ability to “flip” a molecular 
switch is thought to help bacteria to both respond rapidly to their changing environment and to 
also escape recognition by the host immune response225.  
 
Gardnerella spp. are Gram-positive urogenital tract pathogens234. A wealth of evidence 
suggests that Gardnerella play a key role in the establishment of bacterial vaginosis, a disease with 
multiple adverse outcomes that ultimately reduces the barrier integrity of the vaginal epithelium 
and increases the susceptibility to other urogenital pathogens46,47,128,235,236. Gardnerella spp. have 
also been implicated in recurrent urinary tract infections60,237. Multiple reports show evidence of 
pilus production in Gardnerella spp., however, evidence of the genetic determinants driving 
Gardnerella pilus formation is still lacking109–111. Other studies of Gardnerella virulence show 
that they are able to auto-aggregate, adhere to cervical and vaginal epithelial cells, and form a 
dense biofilm82,107. Moreover, although competence and DNA uptake in Gardnerella spp. have yet 
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to be observed directly, Gardnerella spp. genomes encode competence promoting proteins and 
show evidence of substantial horizontal gene transfer85,129. These virulence mechanisms are 
thought to contribute to Gardnerella spp. pathogenicity and host adaptation and are hypothesized 
to be pilus-driven, as they are in other pathogens.  However, it has been difficult to directly test 
this given that the genes responsible for pilus production are unknown and methods to perform 
directed mutagenesis in Gardnerella spp. have not yet been developed.  
 
In this study we describe an opacity colony phenotype that appears to be conserved among 
various Gardnerella species.  We investigate the contribution of pilus production mediated by a 
Tad locus homologue to this phenotype. Opacity appears to be phase variable, which allowed for 
the ability to distinguish and purify opaque and translucent colony variants in the absence of the 
ability to genetically manipulate the organism. In vitro assays performed with both variants 
demonstrate that Gardnerella opacity contributes to dense auto-aggregation and biofilm 
formation. Despite the lack of evidence for pilus production and the involvement of the Tad locus, 
these results suggest that phase variable Gardnerella opacity could promote survival and immune 
evasion in vivo and thus should be further explored to assess its potential as a target in the 





Gardnerella spp exhibit opacity colony variants that are potentially phase variable 
 
During routine passage of Gardnerella leopoldii AMD on solid medium supplemented 
with FBS, we observed the presence of two distinct colony morphologies (Fig. 31). The first 
morphotype, “opaque” (op), consisted of round, raised, white colonies. The “translucent” (t) 
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morphotype consisted of similarly shaped colonies that were more gray-colored and transparent. 
We tested whether this observation was unique to G. leopoldii or applicable to a variety of 
Gardnerella species and strains. All tested strains exhibited the presence of both colony 
morphologies (Table 8). Interestingly, we observed that the passage of purified, single colonies of 
the translucent variant consistently yielded a small fraction of opaque variant colonies (Table 9). 
Similarly, albeit, less frequently (~1-5 in every 3500 colonies), we also observed that opaque 
colonies could give rise to translucent colonies. This observation led us to hypothesize that opacity 
(putatively attributed to differential pilus production) in Gardnerella was phase variable. However, 
under the conditions of standard laboratory passage and in most experimental conditions, there is 








Figure 31. Gardnerella colony variants. Small images were taken with a phone camera. Larger images were taken 










Table 8.  Various Gardnerella species exhibit both colony opacity phenotypes. The presence of both phenotypes 
was confirmed by streaking strains onto sBHI agar plates supplemented with 10% FBS. Only four of the proposed 
thirteen Gardnerella species have been given a species name designation. The remaining nine are only recognized by 
their number. The strains with both unknown species and species number have not been sequenced to determine which 
species number they belong to. Strain GV1 is a clade 1 classified strain. Clade 1 spans Vaneechoutte species numbers 
1 and 2. 
  
Strain Species Vaneechoutte 














UM35 Unknown Unknown ✔ ✔
UM224 Unknown Unknown ✔ ✔
101 Unnamed 8 ✔ ✔
JCP7275 Unnamed 2 ✔ ✔
GV1 Unknown 1 or 2 ✔ ✔






Table 9. Translucent opacity phenotype can switch during routine passage. Switch frequency of G. vaginalis 
ATCC 14018 opacity variants. C = colony; S = solid medium; L = liquid medium; + FBS = medium supplemented 
with 10% FBS; X1 = single passage; X3 = 3 passages. These are results from a single experiment. While the same 





Method C→S+FBS C→L C→L+FBS L→L X1 L→L X3
Original 
variant
Opaque 0 0 0 0 0
Translucent 2 7.5 0 20.1 34.1
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Opacity and pilus production 
 
Because of similar observations of distinct colony morphologies attributable to pili in other 
bacterial species, we hypothesized that the observed difference in Gardnerella colony morphology 
was the result of differences in the production of pili. To test this, we sought to perform 
transmission electron microscopy (TEM) on both variants. Unfortunately, TEM imaging of the 
variants was interrupted by the shutdowns resulting from the COVID-19 pandemic so we have a 
few images of opaque bacteria but not translucent bacteria. In Figure 32, short appendages that 
cover the surface of opaque bacteria are visible, and these could be pili. However, the results from 






Figure 32. Opaque variant cultures contain cells with surface structures resembling pili and fimbriae. TEM 





Opacity variants exhibit differential resistance to antibiotics and lactic acid 
 
We next questioned whether these two variants exhibited any other phenotypic differences 
beyond opacity. To test this, we challenged cells with various inhibitory compounds they are likely 
to encounter in vivo (antibiotics, lactic acid, and hydrogen peroxide), quantified bacterial density 
at a range of concentrations, and calculated the minimum inhibitory concentration required to 
reduce the density by 50% (MIC50). For strain AMD, the translucent variant exhibited a slightly 
increased resistance to both antibiotics tested, with higher MIC50 values compared to the opaque 
variant (Strep. p = 0.0050; Met. p = 0.029). For strain 14018, on the other hand, the opaque variant 
MIC50 for streptomycin was nearly 2-fold greater than that of the translucent variant (p = 0.0001), 
yet the opaque variant MIC50 for metronidazole was nearly 4-fold less than that of the translucent 
variant (p = 0.0028)(Table 10). The opaque variant appeared to be more resistant to lactic acid, as 
both strains exhibited higher MIC50 values for their opaque variants relative to their translucent 
variants (AMD p = 0.052; 14018 p = 0.018) (Table 11). Surprisingly, both strains and variants 
were quite resistant to hydrogen peroxide, as even the highest (supra-physiologic) concentration 
used (25mM) only reduced density to 95% (Fig. 33). Finally, we observed that translucent variant 





Table 10. Opacity variants exhibit differential resistance to antibiotics. MIC50 of select antibiotics against opacity 





AMD op 1.49 ± 0.03 64.57 ± 1.9
AMD t 1.71 ± 0.05 79.06 ± 5.2
14018 op 4.45 ± 0.09 3.77 ± 0.05





Table 11. Opaque variants are more resistant to lactic acid. MIC50 of lactic acid against opacity variants. MIC = 




AMD op 0.33  ± 0.006
AMD t 0.28  ± 0.033
14018 op 0.42 ± 0.008





Figure 33. Gardnerella strains exhibit resistance to supraphysiological levels of hydrogen peroxide. Relative 
density of opacity variant cultures exposed to 25mM hydrogen peroxide. Density is relative to wells without any 





Opacity enhances biofilm formation  
 
Gardnerella spp. produce biofilms in vitro and in vivo. Because we suspected that the 
opacity phenotype was due to the production of Tad pili, and these pili also mediate biofilm 
formation in other organisms, we hypothesized that opacity could contribute to biofilm formation 
in Gardnerella. We quantified biofilm formation by inoculating growth medium in 96-well plates 
with overnight cultures of opaque or translucent variants. After 24 hours of anaerobic incubation, 
we removed the media and stained the attached biofilm with safranin. Because translucent variants 
exhibited slower growth kinetics relative to opaque variants, we normalized our biofilm readings 
against the amount of bacterial growth. This biofilm value was 2-fold greater for opaque variants 
relative to translucent variants (Fig. 34). Because of the observed phenotype switching, we plated 
the input inoculum as well as output bacteria residing in the medium (planktonic) and comprising 
the biofilm to determine the percent of each variant in each population. While variant phenotype 
was stable for strain AMD, both planktonic and biofilm bacteria of the translucent variant of strain 






Figure 34. Opaque variants produce more biofilm. The percent of each variant in the input inoculum for biofilm 
assays (top). Biofilm production normalized to growth (middle). Growth was calculated by diving the output OD600 
by the input OD600. The percent of each variant as planktonic bacteria and within the biofilm of wells (bottom).  *** 




Opacity promotes non-surface attached bacterial aggregation  
 
In addition to biofilm formation, other bacteria expressing Tad pili are able to form 
bacterial aggregates in suspension. We wanted to investigate whether the different variants 
aggregated under various conditions, hypothesizing that opaque, potentially pilus-producing 
variants would exhibit an enhanced aggregation phenotype relative to translucent variants. While 
both variants exhibited small (2-10 cells) clusters under a variety of conditions, the addition of 
FBS to nutrient deplete (IMDM) medium stimulated the production of large (> 20 µm), densely 
packed aggregates from the opaque variants (Fig. 35, left). These aggregates began to form within 
5 minutes post exposure to the aforementioned medium. The translucent variant, on the other hand, 
was only able to form loosely associated aggregates (Fig. 35, right).  The introduction of 
antibiotics alone also stimulated the production of these dense aggregates and the addition of 
sodium citrate to nutrient deplete, FBS-supplemented medium further enhanced their size (Figure 
36). Physical disturbance (i.e. sonication) was sufficient to break up aggregates, however, it is 
worth noting that while 30 seconds at the lowest setting yielded single cells in strain AMD, 
aggregates of 5-20 cells persisted in strain 14018. Prolonged sonication (> 30 seconds) abolished 
aggregate formation in response to FBS. Similarly, when lactic acid, proteinase K, or DNase were 
added under conditions normally promoting aggregate formation, aggregate formation was 
prevented or reduced.  Surprisingly, heat inactivation of bacteria did not eliminate the ability to 
form dense aggregates. In sum, these results suggest that while opacity contributes to Gardnerella 
dense aggregate formation, there are also other environmental factors that may regulate their size 
or structure. Moreover, there are several differences between the two tested Gardnerella strains 
regarding what promotes and inhibits aggregate formation. This suggests that aggregate formation, 
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Figure 35. Opaque variants form large, dense bacterial aggregates in suspension. Bacterial cultures were washed 
in PBS then resuspended in IMDM supplemented with 10% FBS. After 90 minutes of incubation, suspensions were 
fixed onto slides and Giemsa stained. Top images were taken on an inverted EVOS® XL Core imaging system digital 
microscope at 10X magnification. Bottom images were taken with a phone camera using a light microscope at 100X 






Figure 36. Various environmental factors regulate aggregate formation and size. Gardnerella aggregation in 
suspension after 90 minutes of exposure to the listed compounds and media. Images were taken on an inverted EVOS® 









AMD op AMD t 14018 op 14018 t 
IMDM (Baseline clumping) + + +++ +
IMDM + FBS +++ + ++++ +
IMDM + FBS(HI) + ++ ++++ +++
SBHI + + + +--
SBHI +FBS + + + +--
SBHI + glucose + - + +
SBHI + glucose + FBS - + - +
IMDM + Fibronectin + - ++++ +
IMDM + EDTA + + ++++ +
IMDM + Hyaluronic acid + + ++++ +
IMDM + BSA ++ + ++++ +
IMDM + Collagen +-- + ++++ ++
IMDM + Elastin + + +++ +
IMDM + Mucin + - +++ +
IMDM + Lactic acid + + +++++ ++
IMDM + Streptomycin +++ + ++++ +
IMDM + H2O2 + - +++ +
IMDM + Sodium citrate (SC) + - +++ +
IMDM + FBS + SC ++++ ++++ ++++++ +
IMDM + FBS + EDTA ++ + ++++ +
IMDM + FBS + H2O2 ++ + ++++ +
IMDM + FBS + Lactic acid + + ++ +
IMDM + FBS + Trypsin 
EDTA +++ + +++++ +
IMDM + FBS + Proteinase K - - ++ ++
IMDM + FBS + DNase ++ +-- +++ -
IMDM + FBS + TritonX100 ++ + ++++ +
IMDM + FBS + HI bacteria +++ + +++ +--




Opacity-driven bacterial aggregation does not enhance bacterial survival of opsonophagocytosis 
 
We reasoned that the size of these non-surface attached bacterial aggregates could 
potentially impede phagocytosis and thus enhance bacterial survival of the immune response (Fig. 
37).  To test this, overnight cultures of opaque or translucent variants were added to differentiated 
HL-60 cells and bacterial survival of phagocytosis was quantified by sonicating HL-60s and 
plating viable bacteria. In contrast to our hypothesis, we observed increased survival from 
translucent variants, despite increased aggregate numbers and size in opaque variant samples (Fig. 
38). Curiously, results from experiments with strain ATCC 14018 were highly variable. And 
although aggregate formation was observed from this strain under conditions similar to those used 
in phagocytosis assays (IMDM with serum), no aggregates were observed when the bacteria were 







Figure 37. Bacterial aggregates are much larger than neutrophils. Methanol fixed, Giemsa stained suspensions of 







Figure 38. Translucent variants exhibit greater survival of neutrophil challenge.  The percent survival of each 
AMD variant after 90 minutes of exposure to differentiated HL-60 cells and human serum (top). Images of bacteria 
and HL-60 cell suspensions(bottom). After 45 minutes of incubation, suspensions were fixed onto slides and Giemsa 
stained to determine aggregation score. Images were taken on an inverted EVOS® XL Core imaging system digital 






Figure 39. Variants of strain ATCC 14018 do not aggregate in the presence of neutrophils Images of bacteria 
and HL-60 cell suspensions. After 45 minutes of incubation, suspensions were fixed onto slides and Giemsa stained. 





Opacity and the tight adhesion (Tad) locus  
 
Evidence of pilus production in Gardnerella spp. was published in the 1980s. However, 
the genes driving pilus production remain undefined. Because we suspected that opacity was due 
to pilus production, we screened the available genomes of strains exhibiting both colony variants 
for conserved putative pilus machinery. A fully populated tight adhesion (Tad) locus was present 
in all strains (Table 12). The Tad locus was also identified in nearly 100 additional strains, 
representing all 13 recognized Gardnerella spp.  (data not shown). A detailed diagram of the Tad 
locus in G. leopoldii AMD is presented in Figure 40. The organization of the Tad locus in 
Gardnerella spp. is consistent with that observed in other Gram-positive organisms; it is 
particularly reminiscent of the locus described for Bifidobacterium breve223. The flp gene was 
originally annotated as tadG. It was only after plugging in its amino acid sequence to PilFind (v1.0) 
that it was identified as a pilin (flp)238.	A TadV recognition motif (GXXXXEY/F), important for 
pilin processing, was also identified in the TadG-annotated peptides in both AMD and 14018, 
further supporting their re-annotation as Flp proteins216,223. This motif is also present in the un-
annotated peptide upstream of Flp, in both AMD and 14018, suggesting it may be a minor or 
pseudo-pilin. The tadV gene is located outside of the Tad locus.  
 
Inspection of the G. leopoldii AMD Tad locus revealed numerous elements associated with 
phase variation in other phase-variable bacteria, including direct tandem repeats (DTR), poly-
nucleotide tracts, and inverted repeats. We hypothesized that if Gardnerella opacity were driven 
by the Tad locus, opaque and translucent colonies would exhibit sequence differences within the 
Tad locus at these sequence elements. We initially suspected that the imperfect, DTRs in the tadZ 
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gene of the published AMD sequence were driving phase variation and, consequently, the switch 
between opaque and translucent colony variants (Fig. 41A). To test this, we designed primers 
against the published AMD sequence to amplify a 465 bp region encompassing the DTR and 
hypothesized that this region would be different sizes in opaque and translucent variants. We used 
these primers to perform colony PCR on opaque and translucent colonies as well as colonies that 
were originally translucent but switched to opaque and colonies that were originally opaque but 
switched to translucent. However, a gel of the PCR reactions revealed a band of the same size for 
each variant, suggesting that the DTR size was unchanged in opaque and translucent colonies. 
Furthermore, when the PCR products for each variant were sequenced, there were no sequence 
differences among variants. We next hypothesized that an inverted repeat, rather than the direct 
tandem repeats, were driving phase variation of the Tad locus. We identified an 18-nt imperfect, 
inverted repeat flanking the noncoding region upstream of tadZ and 120-bp into tadB (Fig. 41B). 
We predicted that in the published sequence orientation, where IR1 is upstream of tadZ, the Tad 
locus is in the “ON” phase, driving pilus production and giving rise to opaque colonies. Upon 
inversion, IR1 would be found within tadB, and the Tad locus would be in the “OFF” phase, giving 
rise to translucent colonies. However, PCR amplification with multiple primers, product digest, 
and ultimately sequencing revealed no sequence differences between variants in this region. This 
lack of success in identifying differences in targeted regions of the Tad locus led us to sequence 
the locus in its entirety as well as approximately 1500 base pairs upstream. DNA for PCR and 
subsequent sequencing was isolated from both liquid-grown cultures and colonies. Again, 
however, no sequence differences were detected between variants.  
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Without any differences within the 7kb region that was sequenced, we considered two 
scenarios. In the first, the Tad locus was not responsible for opacity. In the second, the locus was 
responsible for opacity, but expression was turned “ON” or “OFF” by a phase variable regulator 
residing outside the locus. In this second scenario, although there are no sequence differences 
between the Tad loci of opaque and translucent variants, expression of the locus should be 
increased in opaque variants. To test this, we performed RT-PCR using primers designed against 
various points within the locus (tadZ, tadC, tadD, and flp), with RNA isolated from both liquid 
cultures and colonies. Relative expression values were normalized against 16s values. We 
observed no significant differences in expression between opaque and translucent variants (Fig. 







Figure 40. Gardnerella genomes contain all of the essential components of a Gram-positive Tad locus. Schematic 
of Tad locus organization in G. leopoldii AMD. The identifier above represents the locus tag in the reference sequence: 







Table 12. Gardnerella strains exhibiting both opacity phenotypes encode a complete Tad locus. Strains were 
checked for proteins with significant shared amino acid identity to those in strain AMD. Operon = whether all genes, 




















Figure 42. Tad locus expression is the same in both opacity variants. Relative expression of Tad locus genes 








     In this work, we describe an opacity colony phenotype that is conserved among different 
Gardnerella species. We sought to characterize this phenotype, hypothesizing that it was a 
consequence of pilus production driven by the tight adhesion locus machinery. Our results indicate 
that opaque variants exhibit significantly enhanced bacterial aggregation, both in suspension and 
when surface attached (biofilm). Curiously, opacity alone was not sufficient to drive dense 
aggregate formation in suspension.  Both strains tested required suspension in a more nutrient-
deficient medium (i.e. Gardnerella cannot grow in this medium) and strain AMD also required the 
addition of serum. It is unclear whether these conditions simulate the “host” environment, put 
stress on bacterial cells, or both. However, considering that the introduction of antibiotics alone 
(AMD), or lactic acid alone (ATCC 14018) increased aggregate formation, we speculate that dense 
aggregate formation in suspension is a stress response. Furthermore, because the large aggregates 
begin to form within 5 minutes of exposure to stimulatory conditions, and heat inactivation of the 
bacteria does not impact the ability to aggregate, we suspect that dense aggregation is mediated by 
something that is pre-formed in opaque variants. As proteinase K treatment prevents aggregation, 
this suggests that the primary mediator of dense aggregation is proteinaceous in nature.  
 
While our attempts to detect differential pilus production between variants were inconclusive, 
our data contradict the hypothesis that an ON/OFF switch within the Tad locus regulates the 
variation between opaque and translucent colonies. Both the targeted sequencing of regions with 
potentially phase variable elements and the subsequent untargeted sequencing of the entire locus 
failed to reveal any significant nucleotide differences between variants that would mediate an 
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“ON” versus “OFF” state of the locus. Furthermore, analysis of Tad locus transcript levels 
indicates that locus expression is similar in both variants under the conditions tested. The 
conservation of the Tad locus across over 100 Gardnerella isolates suggests it serves an important 
function for the organism. In the closely related Bifidobacterium breve, it was shown that a Tad 
pilus was an essential and conserved host-colonization factor223. While this was in an intestinal 
infection model, gut and vaginal isolates of B. breve are indistinguishable, suggesting that the pilus 
is also present in vaginal isolates and may similarly contribute to vaginal colonization239.  It is still 
possible that the Tad locus contributes to pilus production in Gardnerella. Reports of Gardnerella 
pilus production describe the loss of piliation following repeated laboratory passage110. As the 
strains tested in this study have been passaged innumerable times, it is possible that the piliation 
phenotype has been lost. Thus, to investigate whether or not the Tad locus is responsible for 
Gardnerella pilus production, the use fresh isolates may be warranted. Alternatively, it is possible 
that the Tad locus in Gardnerella contributes to the secretion of a proteinaceous extracellular 
coating, as it does in Vibrio vulnificus221. Such a coating has been described for Gardnerella240. In 
sum, although the Tad locus in Gardnerella does not appear to be involved in the opacity 
phenotype, the locus and its contribution to Gardnerella host-pathogen interaction deserves further 
investigation.  
 
While we have not yet ruled out the possibility of pili contributing to colony opacity in 
Gardnerella,  it is possible that differential expression of surface proteins or differences in 
polysaccharide or capsule production mediate opacity, similar to what is observed in other bacteria 
241–244. It is also possible that this phase variable phenotypic change could be dependent on the 
switching ON/OFF of a global regulator that controls the expression of a number of genes. In 
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Streptococcus pneumoniae, colony opacity is driven by differential epigenetic gene regulation as 
a result of a six-phase genetic rearrangement of a restriction modification system to produce 
methylases with alternate specificities and thus clones with distinct methylation patterns243. In any 
case, we still suspect that whatever generates or regulates colony opacity is subject to phase 
variation. If confirmed, this would be the first report of phase variation in Gardnerella. This 
observation may also aid in the identification of the genes responsible for opacity and help 
demonstrate causality without the ability to generate isogenic mutants due to the genetic 
intractability of Gardnerella spp.  
 
 During our characterization of the putative phase variability of opacity, we observed a switch 
bias in vitro towards opacity, meaning that the frequency of switching from a translucent variant 
to an opaque variant was much higher than the frequency of switching from an opaque variant to 
a translucent variant under standard culture conditions. This bias is further enhanced during liquid 
growth and increases with passage number. We are unsure of the mechanism underlying opacity 
switch bias. However, the increased frequency of opaque variants during liquid growth and with 
passage number could be due to the observed differences in liquid growth kinetics, as opaque 
variants typically exhibit faster growth kinetics relative to translucent variants. This may also 
explain differences in switch frequency between strains. Strain ATCC 14018 exhibits an increased 
switch frequency relative to strain AMD; strain ATCC 14018 also exhibits faster growth kinetics 
relative to strain AMD.  
 
In our initial characterization of variant differences, we investigated resistance to antibiotics 
and compounds likely to be encountered in the vaginal environment, i.e. lactic acid and hydrogen 
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peroxide. The increased sensitivity of opaque variants to metronidazole can potentially be 
explained by their enhanced growth kinetics. As the bactericidal action of this antibiotic depends 
first on its reduction under anaerobic conditions, faster growing cells may reduce a greater amount 
of antibiotic. In contrast, the opaque variants were more resistant to lactic acid relative to the 
translucent variants. If opacity variants are indeed distinguished by increased surface expression 
of a compound, this could protect the cell against lactic acid, similar to how surface 
polysaccharides were found to enhance E. coli resistance to organic acids245.  
 
We investigated our hypothesis of dense aggregate protection by quantifying variant survival 
of phagocytosis. We first developed a neutrophil-like model of phagocytosis using differentiated 
HL-60 cells and normal human serum to promote bacterial opsonization. Opaque variants formed 
dense aggregates that were much larger than the phagocytes. However, contrary to our hypothesis, 
opaque samples in which large dense aggregates were formed exhibited reduced survival of 
neutrophil challenge relative to translucent variants.  Findings by multiple groups show that 
neutrophils are only able to engulf particles and bacterial aggregates up to 10 µm in diameter, 
which is approximately the size of neutrophils themselves246,247. Thus, we do not think this is 
difference is due to increased opaque variant uptake relative to translucent variant uptake. Instead, 
and due to our hypothesis of dense aggregate formation as a stress response, we suspect that 
bacterial cells within these dense aggregates may be in an altered metabolic state, existing as viable 
but not culturable (VBNC) or persister cells. As a consequence, because opaque variants form 
more and larger aggregates than do translucent variants in phagocytosis assays, less culturable 
bacterial cells emerge from opaque samples following co-incubation with neutrophils. Therefore, 
to test our hypothesis that dense aggregate formation is protective against host defenses, a more 
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sensitive method for distinguishing viable (irrespective of cultivability) and non-viable cells, such 
as vital dye staining followed by fluorescence microscopy or flow cytometry, must be employed. 
Alternatively, even if aggregates are not engulfed, neutrophil extracellular traps (NETs) could be 
effective at breaking up clumps or killing bacterial cells within them. This could be why strain 
14018 samples lacked aggregates when neutrophils were added. NET formation may also augment 
host tissue damage. A study investigating the relationship between pathogen size and neutrophil 
function found that large pathogens, including large bacterial aggregates, promoted the formation 
of  NETs rather than productive phagocytosis or pathogen avoidance248. While NETs can be 
beneficial in some circumstances, there is increasing evidence to suggest that NET formation is 
more harmful than helpful in the context of many mucosal bacterial infections, particularly those 
involving biofilms249.  
 
Under a majority of conditions tested, translucent variants do not form dense aggregates in 
suspension. However, we observed some smaller aggregate formation from AMD translucent 
variants in phagocytosis assays as well as ample aggregation upon the addition of serum and 
sodium citrate to IMDM. Furthermore, aggregates were seen from ATCC 14018 translucent 
variants when in IMDM supplemented with heat inactivated FBS. Because of the observed switch 
bias towards opacity, this could be mediated by a subset of opaque variants within the translucent 
population. Alternatively, this may suggest that opacity is not simply “ON” or “OFF”. Opacity in 
opaque variants may be constitutively “ON,” or require much less of a stimulus relative to 
translucent variants. In either case, a genetic distinction between opaque and translucent variants 
is still expected.  
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In conclusion, our data collectively suggest that the opacity phenotype in Gardnerella, which 
contributes to bacterial aggregation, may promote survival and immune evasion in vivo, and this 
phenotype, therefore, warrants further investigation. Whole genome sequencing was recently 
employed to aid in the identification of genetic factors responsible for opacity and to provide clues 
as to the mechanism of putative phase variation. Results from sequencing the whole genomes of 
both opaque and translucent variants in two different Gardnerella strains identified several 
potential “hits”. Multiple variations in the genes of cell wall-anchored proteins were detected and, 
interestingly, many of the noted variations reside within poly-guanine tracks. After verification of 
the presence of these identified variants via Sanger sequencing, candidates will be tested for 
differences in gene expression or protein production. Beyond identification of the genetic and 
downstream factors driving the opacity phenotype, it would be worthwhile to quantify the 
predominance of each variant in vivo and to test whether certain environmental factors alter the 
observed switch bias. Investigating switch frequency under a variety of conditions would help us 
understand if the observed switch bias may be due to intrinsic rather than environmental 
conditions. For example, if phase shift always favors opacity, regardless of environment, it could 
be due to reduced affinity of a regulatory element for the DNA substrate in one orientation (“ON”) 
compared to the other  (“OFF”) 250. EpiVaginal tissues would be a good environment more closely 
approximating in vivo conditions in which to compare variants with respect to switch frequency, 
growth, biofilm and aggregate formation, and survival of stressors (antibiotics, lactic acid, and 
neutrophils). However, the phase variability of the opacity phenotype has the potential to introduce 
significant variability into experiments, especially if the variant distribution in the input inoculum 
cannot be controlled or predicted (i.e. liquid cultures inoculated with translucent colony variants 
give rise to a variable percentage of opaque variants). In this instance, it may be better to work 
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with bacteria grown on solid medium rather than in liquid cultures. Alternatively, the ability to 
phase lock variants would reduce experimental variability. This may be possible once the genetic 
determinants for opacity are identified and the efficiency of Gardnerella transformation using the 
oligonucleotide recombineering method detailed in the following chapter is significantly 











Comparing isogenic mutants is the gold standard for characterizing the functions of 
virulence factors in pathogenic organisms. Both random and site-specific mutagenesis approaches 
are available for generating these mutants. Random mutagenesis is advantageous for reverse 
genetic approaches to identify novel virulence attributes. Furthermore, classical random 
mutagenesis techniques, including the use of UV or chemical mutagens, are still valuable today as 
they are broadly applicable to a wide range of organisms and allow for the manipulation of 
organisms that are otherwise genetically intractable. One pitfall of these techniques, however, is 
that identifying mutants and ensuring that mutants are truly isogenic is often a cumbersome, time-
consuming task. More sophisticated mechanisms of random mutagenesis, such as transposon 
mutagenesis, can be highly efficient and more restrictive in the number of mutations generated per 
genome. However, not all organisms are amenable to manipulation with common transposon 
systems (N. gonorrhoeae and Tn5, for example) and a significant time-investment to identify the 
best transposon system for your organism may also be necessary251.  
 
In site-directed mutagenesis, a specific mutation is introduced at a specific location in the 
bacterial chromosome or on extrachromosomal plasmids. This is frequently mediated by some 
form of homologous recombination, where homologous DNA segments are exchanged. With the 
appropriate design, mutations can be introduced into a specific region by flanking the mutation 
with DNA sequences that match the sequence at the location where you want to insert the mutation. 
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One major setback of site directed mutagenesis is that getting some bacterial species to take up 
and incorporate the exogenous DNA required for mutagenesis is rather difficult. Limited bacterial 
competence, restriction-modification systems, and a lack of a host-adapted plasmid all have the 
potential to impede site directed mutagenesis in a given organism. Moreover, systems designed 
for other, even closely related organisms, aren’t always easily adaptable for use in your organism 
of choice.   
 
Oligonucleotide recombineering is a ubiquitous homology-based mechanism for directed 
mutagenesis that is independent of RecA activity. It is specific, non-hypermutagenic, and is 
capable of generating point mutations, deletions, and small insertions. Studies show that the 
efficiency of this mechanism of recombination is significantly limited by single-stranded 
exonuclease activity252. Consequently, when this activity is reduced, either by using exonuclease 
null mutant strains or by saturating nucleases with excess single stranded DNA substrates, 
recombination efficiency is comparable to that achieved with RecA-dependent methods (~3 x 10-
6)252,253 This method of directed mutagenesis has been performed in various bacterial species, 
including Escherichia coli, Legionella pneumophila, Pseudomonas syringae, Salmonella 
typhimurium, Shigella flexneri, Lactobacillus reuteri, Lactococcus lactis, and Mycobacterium 
tuberculosis253–257.  
 
In these systems, several factors important for transformation efficiency were identified. 
As already mentioned, the ability to subvert single stranded restriction endonucleases is crucial, as 
recA mutants, only able to perform RecA-independent recombination, exhibit near complete 
recombination deficiency in a wild-type background258. Some groups have impaired the restriction 
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system by working in backgrounds lacking one or all known single-stranded nucleases, while other 
groups found that simply adding high (5 ug) concentrations of the mutant oligo is sufficient to 
overcome the inhibitory effect on recombination255. Electroporation is the typical mechanism used 
to deliver the oligo into host cells. When preparing electrocompetent cells, growing bacteria in 
rich media and harvesting the cells during the early log phase of growth have been shown to 
significantly increase the efficiency of recombination253. Furthermore, the recovery time allowed 
to the cells following electroporation should be sufficient to promote at least one replication cycle, 
particularly if mutants will be subsequently selected and the wild type (sensitive) allele is dominant 
to the mutant (resistant) allele253,255. This is because recombination occurs only on one strand and 
cells selected immediately after recombination will be heterologous and unable to survive 
selection.  
 
Beyond this, multiple aspects of the oligonucleotide design can significantly impact 
efficiency. First, the oligo, apart from the mutagenic region, should match the lagging strand of 
the chromosome, as oligos designed to match the leading strand exhibit reduced efficiency up to 
10,000-fold257. Furthermore, the mutagenic region of the oligo should be flanked on each side by 
at least 10-nucleotides of sequence homologous to the desired site of recombination255. However, 
increasing the total oligonucleotide length, and consequently, the number of homologous 
nucleotides, can increase efficiency up to 3-log, with maximum efficiency achieved with oligos of 
50-70 nucleotides253. Next, oligos must be able to stably anneal to the chromosome. One study 
empirically determined that this stable annealing is achieved when oligos are designed to have a 
Tm of at least 62°C255. Finally, the oligo must be designed so that the aberrant pairing of mutagenic 
nucleotides with the chromosome is minimally recognized by the methyl-directed mismatch repair 
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(MMR) system of the cell. Evasion of the MMR system, at least in E. coli, can be achieved by 1) 
including a C-C mismatch 6 base pairs away from the desired change on the oligo; 2) generating 
at least four adjacent mismatches; 3) placing mismatches at four or more consecutive wobble 
positions; 4) generating a deletion rather than a substitution253,255.  
 
If all of these aforementioned techniques are used, the maximum recombination efficiency 
that can be achieved in the absence of any exogenous recombinase activity is ~10-1000 
transformants per 108 viable cells. Practically speaking, this limits the types of mutations to those 
with selectable phenotypes or phenotypes that can be enriched under certain growth conditions.  
However, this efficiency can be further enhanced by the addition of single strand DNA 
recombinases, such as the phage λ Beta or RecT, typically introduced to the bacterial cell via 
transduction or via a plasmid259–261. In L. reuteri and L. lactis, the use of RecT allowed for the 
generation of recombinants at frequencies ranging between 0.4 and 19.0%256. These frequencies 
allow for the identification of mutants without any selection and increase the feasibility of using 
oligonucleotide recombineering to generate isogenic mutants that will aid in the characterization 
of putative virulence factors.  
 
The lack of methods for genetic manipulation in Gardnerella has significantly hindered 
the characterization of putative virulence factors and limited our ability to define a role for the 
putative pathogen in BV pathogenesis. In this work, we sought to develop a method for directed 
mutagenesis in Gardnerella spp. We elected to design an approach using oligonucleotide 
recombineering due to both its ability to direct chromosomal mutations in the absence of any 
exogenous functions and the previous success in using this system in both Gram-positive and 
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anaerobic organisms. To do this, we designed a mutagenic oligonucleotide that would introduce a 
two-nucleotide substitution in the rpsL gene, effectively mutating K43 to R to impart streptomycin 
resistance and the ability to select for recombinants. We then altered a variety of parameters to 
determine which were important for optimizing transformation efficiency. Using these optimized 
methods, we were able to transform 3 strains of Gardnerella representing 3 different species. This 
is the first report of directed mutagenesis in Gardnerella and represents a significant advance in 
the field. However, continued optimization is necessary to further improve transformation 





Method development strategy and baseline efficiency 
 
As a starting point, we wanted to establish the electroporation parameters that would produce 
a sufficient balance between cell death and survival. We reasoned that the conditions promoting 
ample pore formation for DNA delivery would also yield increased bacterial death. However, with 
too much cell death, DNA uptake would be irrelevant. Using the pre-programmed settings for 
bacteria (Table 13), we measured G. vaginalis ATCC 14018 survival after exposure to each 
setting. The “Agr” setting had the greatest impact on survival (Table 14).  
 
Active growth is a requirement for successful transformation in other bacteria using 
oligonucleotide recombineering. We generated a growth curve for Gardnerella strains to 
determine the OD600 of early log phase growth and thus the OD600 at which we should harvest cells 
for electrocompetence. An OD600 value below 0.5 was determined to be within the “early log” 
phase of growth (Fig. 43). Cells harvested at a value ~0.35 show a majority of the cell population 
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to be dividing (Fig. 44A). After cell harvesting, we prepared the cells for electrocompetence using 
a standard protocol developed for Staphylococcus aureus involving multiple washes of the cells in 
ice cold 10% glycerol. The original culture is concentrated 100-fold and dispensed in 100ul 
aliquots yielding approximately 2x108 cells per aliquot.  
 
Due to the genome of G. vaginalis ATCC 14018 being unclosed, we were unable to distinguish 
which of the DNA strands were “leading” and “lagging.” So, when designing mutagenic 
oligonucleotides (oligos), we designed them against both strands of a 44-nucleotide region within 
the rpsL gene and arbitrarily labeled them “lead” and “lag”. In principle, these oligos, if 
incorporated, should change codon 43 from “AAG” to “CGG,” which would result in the 
production of arginine instead of lysine. This amino acid change should impart streptomycin 
resistance and the ability to select for transformants.  
 
To aliquots of electrocompetent cells, 10ug of either oligo was added. After a 10-minute 
incubation on ice, cells were either immediately plated to determine spontaneous background 
streptomycin resistance or electroporated using the “Agr” protocol. Immediately following 
electroporation, recovery medium (sBHI) was added and the cells were incubated anaerobically 
for sufficient time to allow at least one replication cycle to occur (~16 hours). Cells were then 
plated on medium with and without streptomycin to determine the transformation efficiency (# of 
streptomycin resistant colonies/ all colonies). This initial protocol yielded several streptomycin 
resistant colonies following electroporation with either oligo, with the lag oligo producing slightly 
more (Table 15). There were no colonies on streptomycin plates to which un-electroporated 
bacteria had been added, suggesting that all streptomycin resistant colonies were indeed 
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transformants and that background resistance to streptomycin was negligible. Sequencing 
confirmed that resistant colonies possessed the intended mutations in the rpsL gene. Based on these 
results, the approximate baseline transformation efficiency in G. vaginalis ATCC 14018 using 







Table 13. Pre-programmed settings of Bio-Rad MicroPulserTM. Adapted from MicroPulserTM Electroporation 










EC1 1.8 1 -
EC2 2.5 1 -
EC3 3.0 1 -
StA 1.8 1 2.5





Table 14. Viable cell numbers before and after electroporation. “lawn” = no single colonies; “TNTC” =single 
colonies, but too numerous to count. OD600 at cell harvest was 0.795. *These electroporation conditions were 











- - - 5.7 x 108
EC1 lawn lawn -
EC2* lawn lawn -
EC3* lawn lawn -
StA lawn lawn -





Figure 43. Gardnerella spp. growth curve. Anaerobic growth in sBHI plus 5% human serum at a starting inoculum 






















Figure 44. Gram stain of Gardnerella electrocompetent cell preparations. A) G. vaginalis ATCC 14018 opaque 






Table 15. Baseline transformation efficiency in G. vaginalis ATCC 14018 using oligonucleotide recombineering. 
The number of streptomycin recombinants per 108 viable cells produced by transformation with a 44 nt oligo, carrying 
the rpsLK43R, designed to match one strand of the genome or the other and arbitrarily labeled “lead” or “lag.” These 











Parameters impacting efficiency 
 
With a successful proof of principle experiment and a baseline transformation efficiency, we 
next sought to alter a variety of parameters to determine their impact on transformation efficiency 
(Table 16). Single changes were made to the baseline protocol and the number of recombinants 
were compared. The greatest reduction in transformants was observed when cells were either 
electroporated at room temperature rather than at ~4°C or only allowed to recover for 4 hours; no 
streptomycin resistant colonies were observed under these conditions. Harvesting bacterial cells at 
an OD600 of 0.5 resulted in a 4-fold reduction in the number transformants. Changing the 
electroporation program from Agr to StA or EC1 produced half the number of streptomycin 
resistant colonies. Using frozen and thawed cells, rather than freshly prepared cells, and the 
addition of sucrose to the wash medium reduced efficiency by one third. Increasing the oligo 
concentration had no impact on the number of recombinants.  
 
Having recently identified opaque and translucent colony variants in several different 
Gardnerella strains, we questioned whether transformation efficiency significantly differed 
between different strains, or variants of the same strain (Table 17). Opaque variants of G. piotii 
GV3 exhibited the highest efficiency. Strain AMD was the most difficult to transform, requiring 
sonication to get any transformants. Sequencing of DNA from streptomycin resistant colonies 
showed that all strains only incorporated the “intended” mutations (Fig. 45). As the mutagenic 
oligo was designed against the 14018 rpsL sequence, and this sequence is somewhat divergent in 
AMD, the oligo contained a few additional nucleotide differences beyond the “AAG” to “CGG” 
encoded to alter codon 43. These additional differences were not incorporated.  
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The maximum efficiency we were able to achieve in the absence of exogenous enzymes was 
866 transformants per 108 cells. We next attempted to increase this efficiency via the addition of 
the single stranded DNA recombinase, Beta from bacteriophage λ. Since a system for recombinant 
expression in Gardnerella is unavailable, we elected to load recombinantly produced beta into 
Gardnerella cells via electroporation. Purified beta was added 1:1 to the rpsL mutagenic oligo and 
increasing quantities of this mixture were added to aliquots of electrocompetent cells subsequently 
electroporated with the “Agr” protocol. The addition of Beta did not substantially increase 
efficiency, and higher concentrations of protein appeared to negatively impact bacterial viability.  
(Table 18). The addition of MgCl2, previously shown to be essential for λ beta binding of DNA, 






Table 16. Impact of altering transformation parameters on recombination frequency. Baseline conditions 
included: G. vaginalis ATCC 14018; 10µg rpsLmutlag oligo; OD600 at harvest ~0.35; Agr electroporation protocol; 
electrocompetent cell preparation on ice; ice-cold cuvette; freshly prepared electrocompetent cells (no freeze/thaw); 
10% glycerol in H2O electroporation medium (no sucrose); 16-hour recovery. “RT” = room temperature. “+ sucrose” 


















Table 17. Difference in recombination efficiency among Gardnerella species and opacity variants.  
Baseline conditions included: 10µg rpsLmutlag oligo; OD600 at harvest ~0.35; Agr electroporation protocol; 
electrocompetent cell preparation on ice; ice-cold cuvette; frozen/thawed cells; 10% glycerol in H2O electroporation 
medium (no sucrose); 16-hour recovery. * indicates that electrocompetent cells were sonicated after the addition of 




























Figure 45. Region of Gardnerella rpsL to be mutated. Lowercase, bolded letters represent “intentional” mismatches 
to impart streptomycin resistance in both AMD and ATCC 14018. Red bolded letters represent sequence differences 
in AMD relative to the ATCC 14018. Lowercase blue letters represent “unintentional” mismatches between the 







Table 18. Impact of λ beta on recombination efficiency. Baseline conditions included: 10µg rpsLmutlag oligo; 
OD600 at harvest ~0.35; Agr electroporation protocol; electrocompetent cell preparation on ice; ice-cold cuvette; 
frozen/thawed cells; 10% glycerol in H2O electroporation medium (no sucrose); 16-hour recovery. The volume in the 
λ beta column is the amount of 1:1 rpsLmutlag oligo (10 µg/ µl): λ beta (0.94 mg/mL) added to 100 µl of 

















In this work we successfully developed a protocol for DNA uptake and subsequent 
oligonucleotide-guided recombination for use in Gardnerella spp. This is the first report of any 
type of site-directed mutagenesis in Gardnerella. Oligonucleotide recombineering has been 
utilized for directed mutagenesis in other prokaryotes, including Gram-positive organisms. Our 
maximum efficiency of transformation using this system, 866 recombinants / 108 cells, is 
approximately 50 times higher than that reported for E. coli, but similar to that of S. flexneri and 
S. typhimurium255. Regarding oligo concentration, 10 ug was sufficient for recombination in 
Gardnerella, although lower concentrations were not tested.  Reports of recombineering in Gram-
negative organisms indicate that 0.1-5 ug oligo is sufficient, while 100ug is required for Gram-
positive Lactobacillus and Lactococcus species253–256. This requirement for a higher oligo 
concentration may be due to a thicker layer of peptidoglycan. While Gram-negative bacteria only 
have a cell wall 2-7nm thick (5-10% peptidoglycan by weight), Gram-positive organisms contain 
a cell wall 20-80 nm in thickness, made up predominantly of peptidoglycan (50-90% by weight). 
Gardnerella is paradoxically enclosed by a thin, 8-12 nm cell wall comprised of only 20% 
peptidoglycan263,264. This may explain why the oligo concentration requirements of Gardnerella 
are more similar to Gram-negative bacteria, despite being definitively Gram-positive.  
 
Similar to other studies, important parameters for high efficiency transformation included 
growth phase (as measured by optical density) and recovery time. In addition, we found that 
increasing cuvette temperature significantly reduced efficiency. We also investigated whether 
Gardnerella strains and opacity variants exhibited differences in their transformation efficiencies. 
The greatest transformation efficiency was observed in G. piotii strain GV3. Interestingly, the 
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opaque variant in G. vaginalis ATCC 14018 exhibited a two-fold greater efficiency compared to 
the translucent variant. This may be attributable to the production of competence-promoting pili, 
as pilus production is suspected to distinguish the two variants. G. leopoldii strain AMD had a 
markedly reduced efficiency relative to the other two Gardnerella species. This could be for two 
reasons. First, electrocompetent cell preparations between the strains are phenotypically different. 
While strain ATCC 14018 and GV3 cell preparations consist predominantly of single cells, strain 
AMD exhibits substantial cell aggregation (Fig. 46B). These large (hundreds of cells), dense 
aggregates may impede delivery of the oligo into cells and may explain why recombinants were 
obtained only after sonication. This difference in recombination efficiency could also be due to 
differences in oligo annealing thermodynamics between the two strains. The mutagenic oligo was 
designed using the rpsL gene sequence of ATCC 14018 and thus the only differences between the 
oligo and the homologous region of the genome are the two intentional base pair differences. The 
homologous region in strain AMD, on the other hand, has 4 total base pair differences compared 
to the oligo: the two intentional differences and two SNPs divergent from the ATCC 14018 
sequence. Thus, the Tm for strain AMD may be suboptimal.  
 
We also observed that strain AMD only incorporated the “intentional” mutations into its 
genome. The nucleotides divergent from ATCC 14018 remained unchanged, suggesting that these 
mismatches were repaired by mismatch repair machinery. The repair of only some mismatches 
can potentially be explained by the differing efficiencies with which different base pair mismatches 
are repaired. In E. coli, G:T and A:C mismatches are repaired with high efficiency while C:T 
mismatches are repaired with low efficiency265. Both of the unintentional sequence differences in 
AMD yield mismatches that are repaired with high frequency (G:T and A:C). Of the two 
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intentional mismatches, one is repaired with high efficiency (G:T) and the other with low 
efficiency (C:T). It is possible that the consecutive nature of the intentional mismatches prevented 
repair of the high repair efficiency mismatch, as has been shown in E. coli253. It is also conceivable 
that differences in neighboring base composition enhanced repair efficiency of the unintentional 
mismatches266. As a recent study indicates, mismatch repair specificity is highly variable among 
bacterial species267. Thus, the rules that govern mismatch repair in E. coli could be substantially 
different than those in Gardnerella. It would be interesting to use this protocol for oligo-guided 
recombination to further characterize the mismatch repair system in Gardnerella and see how it 
compares to better characterized model organisms.  
 
Although we acknowledge that the current efficiency of the system precludes the facile 
isolation of non-selectable mutants, there are still multiple scenarios in which it may be of use 
without the need to increase efficiency. For example, our protocol could be used to generate a 
library of Gardnerella spp. with differing antibiotic resistance profiles that could then be competed 
on our EpiVaginal model to characterize inter- and intra- species interactions important for growth 
and survival. This would be particularly useful considering that reports by our group and others 
indicate that multiple Gardnerella species are simultaneously present during BV136. Our protocol 
could also be useful for generating mutants whose growth can be enriched relative to non-mutants 
under specific conditions or mutants for which a customized method of selection could be 
developed. For example, antibiotic-loaded erythrocytes embedded in agar could be used to select 
for loss of function vaginolysin mutants268. As a mix of mutant and wild type cells are added to 
the agar, wild type cells secreting VLY will release the antibiotic encapsulated in the erythrocytes 
and die upon exposure whereas mutant cells not secreting VLY will not be exposed to the antibiotic 
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and grow to sufficient numbers to yield visible colonies. This method is in development in our lab 
but further optimization is required. Specifically, more work is required to determine whether a 
sufficient amount of antibiotic is being loaded into the erythrocytes and the optimum density of 
loaded erythrocytes in the agar. Finally, a method to perform high throughput screening of mutants 
while maintaining cell viability would allow us to use our method at its current efficiency to 
generate mutations in both coding and non-coding regions of the genome and subsequently isolate 
cells with a given mutation. Such a method, live fluorescence in situ hybridization followed by 
fluorescence-activated cell sorting (live-FISH FACS), was recently developed to sort specific 
taxonomic groups of bacteria from natural bacterial communities and subsequently culture 
them269. Fluorescent probes could be designed to distinguish wild type and mutant Gardnerella 
cells which can then be sorted with FACS and plated to obtain viable mutants. This would, of 
course, require substantial optimization.  
 
Increasing recombination frequency to levels typically achieved with the addition of a single 
stranded recombinase (up to 50%) would expand the mutagenic potential of Gardnerella and 
would substantially accelerate the identification and characterization of important virulence 
factors. Our attempts to increase recombination frequency via the electroporation of purified, 
recombinant λ beta alongside the mutagenic oligonucleotide have yet to be successful. However, 
there are various aspects of the protocol that must be more exhaustively evaluated before we can 
definitively say that this method does not work. Specifically, it is currently unknown whether or 
not DNA binding and Beta oligomerization are occurring. It is also unknown if the protein is being 
delivered efficiently inside of cells. Furthermore, the ratio of oligo to protein and oligo length may 
need to be optimized257,260,270.  Alternatively, a recombinase from a more closely related organism 
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may be required. Datta et. al cloned in recombinase homologues from both Gram-positive and 
Gram-negative bacteria into E.coli and measured oligo recombination efficiency271. Recombinases 
from Gram-positives had a 2-4 log decrease in transformation efficiency relative to λ beta. This 
decreased efficiency wasn’t improved when using a plasmid that should alleviate the codon-bias, 
suggesting that, for whatever reason, Gram-positive recombinases don’t work as well in Gram-
negative bacteria. Thus, a recombinase from a Gram-positive bacterium may potentially function 
better in Gardnerella. Regardless, we know that our protocol is successful at delivering DNA 
inside Gardnerella. Knowing this, it may be worthwhile to attempt plasmid delivery, if not to 
perform recombination, at least to express a functional recombinase. A plasmid was recently 
developed to produce heterologous proteins in Bifidobacterium bifidum272. As Bifidobacterium 
species are closely related to Gardnerella, this might serve as a logical starting point. Furthermore, 
as an excess of single stranded oligo is used to saturate single stranded restriction enzymes during 
our method to increase efficiency, decoy double stranded substrates might similarly be added to 











Conclusions and future perspectives  
 
The overall aim of these collective works was to characterize putative Gardnerella 
virulence factors in order to better understand how members of this genus interact with the human 
host, with the long-term goal of understanding how these interactions contribute to the 
development of bacterial vaginosis (BV). Our studies focused on vaginolysin (VLY), a 
cholesterol-dependent pore-forming toxin, and an opacity phenotype suspected to be driven by 
pili. We hypothesized that VLY played a role in Gardnerella nutrient acquisition, targeting the 
vaginal epithelium as a source of nutrients, and that opacity promoted immune evasion. To test 
these hypotheses, we developed novel Gardnerella infection models. In using these models, we 
observed several previously uncharacterized features of the two virulence determinants in addition 
to previously undescribed features of Gardnerella spp. as a whole.  
 
In order to test our hypothesis that VLY played a role in nutrient acquisition, we reasoned 
that we would need a model of the vaginal epithelium on which Gardnerella would grow. Due to 
the lack of Gardnerella growth, we ruled out the use of previously developed murine models. 
Because of the proposed species specificity of VLY, we also ruled out the use of the previously 
characterized porcine explant model, even though Gardnerella growth was observed in this model. 
After failure in getting Gardnerella to grow on human VK2-E6E7 monolayers, we moved to a 
commercially available, stratified, polarized, three-dimensional model of the human vaginal 
epithelium derived from primary tissues. In this model, Gardnerella grew to in vivo densities; 
however, multiple measured parameters suggested that VLY did not contribute to Gardnerella 
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growth in this model.  Despite the lack of support for our nutrient acquisition hypothesis, this 
EpiVaginal model unexpectedly identified multiple polarity-dependent interactions between 
Gardnerella and the vaginal epithelium. 
 
 First, spent medium from the apical side of the tissue supported a 1-log increase in 
Gardnerella growth relative to medium from the basolateral side. Gardnerella tissue growth was 
also increased on the apical side compared to the basolateral side. These results suggest that the 
apical side of the tissue produces a nutritional component that is either more accessible or more 
abundant than it is on the basolateral side. We suspect this nutritional component is glycogen. 
Degradation of starch and glycogen was recently observed in G. leopoldii in vitro273. If its 
utilization by Gardnerella spp. occurs in vivo, it would describe yet another mechanism by which 
Gardnerella is able to compete with commensal lactobacilli species. Second, when we added live 
bacteria to the apical or basolateral sides of the EpiVaginal tissues, we observed that apical 
challenge suppressed the secretion of several pro-inflammatory cytokines. We hypothesize that 
this cytokine suppression may explain why some BV positive women do not exhibit neutrophil 
influx into the vaginal lumen and could potentially promote the incorporation of other BV-
associated species that may otherwise be detected and eliminated by the host immune system.  
 
Lastly, we found that VLY-mediated permeabilization of epithelial cells was restricted to 
the basolateral face of the tissue, potentially due to increased surface expression of CD59 on that 
side. Several groups have attributed the reduced barrier integrity of the vaginal epithelium 
observed during BV to VLY. However, that seemed unlikely given that Gardnerella is 
predominantly found at the apical (lumenal) side in vivo; it is not a particularly invasive organism; 
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and, as suggested by our results, the apical side is fairly resistant to VLY cytotoxicity. These results 
led us to hypothesize that in vivo VLY-mediated damage to the vaginal epithelium may only occur 
after Gardnerella is given access to the more basolateral cells via apical damage or exfoliation 
induced by other BV-associated species. However, early studies focusing on VLY characterization 
suggested that the toxin, in the context of BV, impacted birth outcomes. Specifically, BV-positive 
women able to mount an anti-VLY IgA response had reduced adverse birth outcomes relative to 
those who did not mount an anti-VLY response. Additionally, more recent in vivo studies have 
observed associations between Gardnerella abundance and preterm birth, Gardnerella abundance 
and increased vaginal VLY concentrations, increased VLY concentrations and increased IL-1ß, 
and increased IL-1ß and preterm birth. Collectively, these in vivo data suggest that G. vaginalis 
and VLY are pro-inflammatory within the vaginal epithelium, which seemingly contradicted our 
EpiVaginal findings. In considering these contradictions, and in light of reports suggesting that 
both commensal and pathogenic strains of Gardnerella exist, we questioned whether different 
species of Gardnerella differentially interacted with the epithelium. As a pilot experiment, we 
compared EpiVaginal cytotoxicity when G. vaginalis strain ATCC 14018 or G. leopoldii strain 
AMD were added. Interestingly, G. vaginalis elicited greater cytotoxicity from the apical side of 
the tissue compared to G. leopoldii. We subsequently questioned whether this difference in 
cytotoxicity could be due to differences in VLY.  
 
An alignment of VLY from the two species revealed several amino acid differences between 
the two versions of the toxin. We then performed an alignment of 84 publicly available VLY 
sequences from different Gardnerella species and this showed that mutations within the 
undecapeptide and CD59 regions of the protein sequences were well-conserved and could be used 
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to classify distinct VLY-types. Type 1 (strain 14018-like) VLY was characterized by DRS amino 
acids within the CD59 region whereas Type 2 (strain AMD-like) VLY was characterized by NRT 
amino acids. Type 1 VLY was then sub-classified into Type 1A, 1B, 1C, or 1D based on the 
differences in the amino acids within the undecapeptide region. A phylogenetic map of all 
compared strains marked with their VLY-type indicated that some VLY types were restricted to 
certain Gardnerella species. Specifically, Type 2 VLY was only found in G. leopoldii and G. 
swidsinskii. We hypothesized that differences in VLY could alter Gardnerella species virulence.  
 
To begin to test this hypothesis, we recombinantly produced representatives from the Type 1A 
and Type 2 VLY toxins and compared their interactions with vaginal epithelial cells. When the 
same amount of toxin was added to VK2 cell monolayers, Type 1A VLY elicited more 
cytotoxicity, as measured by trypan blue staining, than Type 2. However, this difference was only 
observed on more mature cells (7 days post seeding). When the toxins were compared on less 
mature cells (4 days post seeding), no significant difference was noted. We hypothesized that that 
the more mature, 7-day cells had reduced expression of CD59 relative to 4-day cells, as more 
senescent apical cells exhibit reduced CD59 on EpiVaginal tissues, suggesting that when CD59 is 
limiting, Type 2 VLY cytotoxicity is impaired. This finding was recapitulated when cells were 
pre-treated with anti-CD59; Type 2 VLY cytotoxicity was more greatly reduced than that of Type 
1A VLY. Collectively, these data suggest that Type1A VLY exhibits an increased affinity for 
CD59 compared to Type 2 VLY. This may explain the initial observation of increased cytotoxicity 
on the apical side of EpiVaginal tissue challenged with G. vaginalis ATCC 14018.  However, an 
experiment using surface plasmon resonance would be needed to more directly measure and 
compare the affinity of each VLY type for CD59.  
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We next questioned whether these amino acid differences in VLY could impact in vivo 
Gardnerella abundance or symptoms. We reasoned that if Type 2 VLY had a lower affinity for 
CD59, this would reduce its cytotoxicity within the vaginal epithelium, potentially allowing it to 
grow to higher densities. Type 1 VLY, on the other hand, with its increased affinity for CD59 
would potentially elicit greater damage to the epithelium, which may stimulate an immune 
response manifesting in patient symptoms. To investigate this, we analyzed data from two cohorts 
of subjects enrolled in the Human Vaginal Microbiome Project. In cohort 1, we used vly read data 
of 62 BV-positive subjects to determine the dominant VLY type in each sample and 16S 
sequencing data to determine the relative abundance of vaginally relevant species. We then 
grouped subjects by their dominant VLY type and then compared the frequencies of symptoms 
and Gardnerella abundance in each group.  In this cohort, women with Type 1 VLY as the 
dominant type experienced increased symptom frequency whereas women with Type 2 VLY 
exhibited increased Gardnerella spp. abundance. The second cohort was comprised of 762 BV-
positive and healthy subjects. While we did not have vly read data for this cohort, we used cpn60 
read data to extrapolate VLY type abundance. In initial comparisons of all 733 subjects, we didn’t 
observe any difference in symptoms or Gardnerella abundance between women dominated by 
either toxin. However, when we only analyzed BV-positive subjects, our finding of increased 
Gardnerella spp. abundance in women dominated by Type 2 VLY replicated.  No differences in 
symptom frequency between VLY type groups were noted in BV-positive Cohort 2 subjects. 
However, it was interesting that cohorts 1 and 2 as a whole were dominated by different VLY 
types and experienced symptoms with frequencies fitting with our hypothesis. Specifically, cohort 
1 was dominated by Type 1 VLY and 67% of subjects experienced at least 1 symptom, while 
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cohort 2 was dominated by Type 2 VLY and only 53% of BV-positive subjects experienced 
symptoms.  
 
These findings suggested that differences in VLY may only be relevant during BV. We further 
postulated that VLY type may impact BV immunopathology, which could potentially impact BV 
persistence or recurrence or influence the likelihood of adverse sequelae.  Type 1 VLY, by 
inducing damage to the epithelium, could drive an immune response that ultimately leads to its 
removal, but also results in tissue damage that increases the likelihood of adverse sequelae. Type 
2 VLY, on the other hand, may promote bacterial persistence in the absence of damage. Beyond 
damaging the vaginal epithelium, VLY may help overcome nutritional immunity in vivo by 
promoting nutrient acquisition from non-epithelial host cells (i.e. erythrocytes) or may serve to 
protect against the immune response by lysing host immune cells. However, further studies are 
needed to test these hypotheses and thus the role of VLY in Gardnerella virulence is still unknown. 
 
In preliminary experiments aiming to test the hypothesis that VLY protected Gardnerella 
against immune cells (data not shown), we first developed an opsonophagocytosis infection model 
using differentiated neutrophil-like HL-60 cells and human serum. We co-incubated immune cells 
and Gardnerella together for 75 minutes and then quantified bacterial survival by plating to count 
CFUs. In this assay, we observed that a VLY positive strain exhibited 100% survival, while a non-
isogenic VLY null strain exhibited significantly reduced survival. While this seemingly supported 
our hypothesis, a closer look at the cells to confirm that bacteria were actually being engulfed 
revealed that the two strains differed in their formation of large, dense bacterial aggregates. The 
VLY positive strain formed very large aggregates several times the size of the neutrophil-like cells, 
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and the VLY null strain did not. We reasoned that the survival advantage conferred to the VLY 
positive strain via aggregate formation likely outweighed the advantage of VLY secretion, and 
thus abandoned further testing our immune protection hypothesis to explore the basis of aggregate 
formation.  
 
A variety of conditions were tested to define what factors promoted and inhibited aggregate 
formation. In all Gardnerella strains tested, we were able to distinguish at least two colony variants 
on solid medium supplemented with FBS. Opaque variants consistently produced large bacterial 
aggregates, while translucent variants did not. Interestingly, subculture of translucent variants on 
either solid or liquid medium frequently gave rise to opaque variants. And less frequently, opaque 
variants gave rise to translucent variants. Collectively, the results suggested that Gardnerella 
aggregation was mediated by a pilus susceptible to some form of phase or antigenic variation. 
While Gardnerella pilus production was noted by several publications in the 1980s, the genetic 
basis for pilus biogenesis remained undefined. Due to its conservation among Gardnerella isolates, 
we hypothesized that a tight adhesion locus homologue was responsible for pilus production. We 
then reasoned that if the tight adhesion locus were responsible for pilus production, its sequence 
would differ between opaque and translucent variants of Gardnerella. Upon sequencing and 
analysis of Tad locus transcription, however, no differences between opaque and translucent 
variants were noted. Attempts to visualize pilus production via TEM were interrupted, so whether 
or not differential pilus production is responsible for variation in opacity is still to be determined. 
Recent results from whole genome sequencing implicate various cell wall-anchored proteins. The 
contribution of these candidate proteins to opacity is currently being explored.  
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In the absence of the ability to generate isogenic mutants, we were able to isolate and compete 
these variants in a variety of assays to show that opaque variants exhibited increased biofilm 
formation and aggregation in suspension. Surprisingly, the formation of large aggregates in 
suspension resulted in reduced survival of neutrophil challenge, as determined by plating viable 
bacteria on solid medium. This finding led us to hypothesize that aggregate formation in 
suspension was a stress response pushing bacterial cells into an altered metabolic state precluding 
their growth on typical culture media, such as that of a persister cell or a viable but unculturable 
phenotype. A different mechanism for assaying bacterial viability must be employed to determine 
whether the bacteria in these aggregates are indeed viable and thus whether protection is conferred. 
Regardless, these results collectively led us to hypothesize that opacity in Gardnerella is a novel, 
putatively phase variable virulence factor important for immune evasion in vivo and thus should 
be explored further.  
 
Finally, we sought to develop a method for directed mutagenesis in Gardnerella, which, prior 
to this work, had yet to be accomplished. We focused our efforts on a RecA-independent 
oligonucleotide recombineering-based method because of its simplicity (i.e. lack of exogenous 
factors needed) and its proven success in other genetically intractable organisms. This method 
introduces mutations via single stranded oligonucleotides that exhibit ~10-40 base pairs of 
homology to the desired site of mutation. As a proof-of-principle, we designed an oligo that would 
introduce a two-nucleotide substitution in the rpsL gene, effectively mutating the lysine at codon 
43 to an arginine. This mutation would impart streptomycin resistance and allow us to select for 
recombinants. This method proved successful in three different Gardnerella species. Attempts to 
further optimize transformation efficiency and to introduce mutations in vly and the Tad locus 
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revealed that this system of recombination in Gardnerella is similar to the RecA-independent 
recombination systems characterized in other organisms. Namely, the maximum transformation 
efficiency achieved with this system does not allow for the facile identification of mutants without 
a mechanism for selection. Thus, while the ability to perform directed mutagenesis in Gardnerella 
is certainly an advance for the field, further work is needed to either develop mechanisms to enrich 
for non-selectable mutants or to introduce exogenous factors that significantly enhance 
transformation efficiency, such as a single-stranded recombinase.  
 
Continuing to build upon the information derived from these collected works has the potential 
to improve BV prevention and treatment outcomes. For example, if further characterization of the 
distinct VLY types and their interactions with the host supports our hypothesis that type 1 VLY 
elicits immune activation, this version of the toxin could potentially be developed as a toxoid 
vaccine. If the toxoid is not effective at altogether preventing BV, it may at least have the potential 
to reduce the frequency of adverse birth outcomes, as women who naturally generate antibodies 
against the toxin seem to be protected. If this version of the VLY toxin is also the factor that 
potentiates the development of symptoms, the localized administration of statins or soluble CD59 
could reduce symptom burden. As Gardnerella spp. appear to have developed multiple 
mechanisms to evade the host immune response, and bacteria are continually evolving to better 
adapt to their environment, it is likely that simply targeting VLY is not the be-all and end-all 
solution for BV treatment. Further characterization of other virulence determinants is warranted. 
Additional optimization of the system we developed for oligonucleotide recombination will allow 
for the generation of isogenic mutants that can be used to better characterize previously identified, 
putative virulence determinants as well as important factors that have yet to be discovered. The 
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opacity phenotype characterized here is an example of one such factor. The diversity in opacity 
within the Gardnerella population, introduced by phase variation, may ensure that a subset of 
bacteria persists after a given treatment. With more detailed characterization using isogenic 
mutants, a method of treatment effective against both variants, or a dual treatment method, could 
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